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The glyoxalase system is the major pathway for metabolism of the reactive 
dicarbonyl metabolites, methylglyoxal (MG) in human cells. It is comprised of 
two enzymes, glyoxalase 1 (Glo1) and glyoxalase 2 (Glo2). These enzymes 
catalyse the metabolism of MG into D-lactate via intermediate called S-D-
lactoylglutathione. MG is produced in glycolysis as a by-product by the trace-
level degradation of triosephosphate glycolytic intermediates. The main 
physiological function of Glo1 is cytoprotective, suppressing the steady-state 
concentration of MG to low tolerable levels. Cytotoxicity of MG is linked to its 
reaction with cell protein and DNA, leading to activation of apoptosis. 
Overexpression of Glo1 in tumour cells is a mediator of multidrug resistance in 
cancer chemotherapy and cell permeable inhibitors of Glo1 have anticancer 
activity, suggesting that cytotoxicity of MG may have a key role in cancer 
chemotherapy. The host research suggested that increased Glo1 expression is 
permissive of high glycolytic rate and growth of many tumours. My project 
emerged from this to study evidence of Glo1 expression as a negative survival 
factor in cancer therapy and the proteomic mechanism of cytotoxicity of MG to 
human tumour cells.  
I accessed databases of gene expression in the public domain: KM Plotter 
– gene expression with links to breast cancer patient survival; and Cancer Cell 
Line Encyclopaedia (CCLE) – gene expression of human tumour cell lines. 
assessement between the association of Glo1 expression in cancer patients to 
effectiveness of treatment (progression free survival) and in human tumour cell 
lines to other gene expression were performed. Also investigated proteomic 
changes during MG-induced cytotoxicity in human HEK293 in vitro.  
Key findings were: Glo1 is a negative survival factor in breast cancer – 
hazard ratio 1.37 (1.22 – 1.53), logrank P = 2.8 x 10-8 (n = 3951); applicable for 
all treatments, genotypes, intrinsic subtypes and stages of breast cancers. In 
human tumour cell lines, Glo1 expression correlated positively with GLO1 copy 
number and with genes enriched in spliceosome, RNA transport, and cell cycle 
and DNA replication pathways, and negatively with apoptosis adaptor TRADD. 




pathway was activated and proteins of the ribosome, spliceosome, RNA transport, 
proteasome, respiratory electron transport, ATP formation by chemiosmotic 
coupling and gluconeogenesis were decreased.  
It is conclude that Glo1 impacts negatively on breast cancer survival and is 
a potential target for improved cancer therapy with Glo1 inhibitors where 
associated MG-induced cytotoxicity involves impairment of multiple processes, 
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1.1 The glyoxalase system 
The glyoxalase system is known as the major enzymatic defence against 
glycation by methylglyoxal (MG) in the physiological systems – Figure 1. 
 
Figure 1. The glyoxalase system.    
 Adapted from (Xue et al., 2011) 
 
1.1.1 Definition and function of the glyoxalase system 
The glyoxalase system consists of two enzymes, glyoxalase 1 (Glo1) and 
glyoxalase 2 (Glo2). The main function of this system is to catalyse the 
metabolism of MG to D-lactate through the intermediate called S-D-
lactoylglutathione. This defence system is found in the cytosol of all mammalian 
cells (Xue et al., 2011). It is also found in bacteria, plants, animal, fungi and 
protocista. The process of the detoxification by the glyoxalase system can occur 
into two consecutive reactions. There is an initial non-enzymatic reaction of MG 
(CH3COCHO) with GSH to for the hemithioacetal adduct, CH3COCH(OH)-SG. 
Glo1 catalyses isomerisation of the hemithioacetal to S-D-lactoylglutathione, 
CH3CH(OH)CO-SG. 
CH3COCHO + GSH ⇌ CH3COCH(OH)-SG → CH3CH(OH)CO-SG 
The KM for the methylglyoxal-glutathione hemithioacetal and Glo1 in 
human is approximately 71-130 µM and the kcat is 7-11 x 10
4 min-1.  The second 




catalysed by Glo2. The GSH consumed in the Glo1 is reformed by the action of 
Glo2 (Xue et al., 2011) – Figure 1. 
CH3CH(OH)CO-SG + H2O → CH3CH(OH)CO2- + H+ + GSH 
The main physiological substrate for Glo1 is MG. In events where Glo1 is 
supressed in situ – as occurs by decrease of cellular GSH, the concentration of 
MG is increased. This also occurs in the presence of the cell permeable Glo1 
inhibitors (Thornalley, 1998, Thornalley, 1993a, Abordo et al., 1999). There are 
other substrates for Glo1 such as glyoxal, hydroxypyruvaldehyde HOCH2COCHO 
and 4,5-doxovalerate H-COCOCH2CH2CO2
- (Thornalley et al., 1996, Thornalley, 
1993a, Thornalley, 1998, Abordo et al., 1999). Glo1 activity metabolises these 
reactive α-oxoaldehydes and thereby inhibits α-oxoaldehyde-mediated glycation 
reaction (Shinohara et al., 1998). Thus, Glo1 is considered as one of the main anti-
glycation defence enzymes (Thornalley, 2003b, Thornalley, 2003a). 
 
1.1.2  Historical development of glyoxalase system 
 In the last century, scientists discovered the activity of the glyoxalase 
system. It was initially known that the glyoxalase system is responsible for the 
conversion of MG to lactate (Dakin and Dudley, 1913, Neuberg, 1913a). L-
Lactate is the main metabolite involved in the metabolism of glucose through 
glycolysis but the product of the metabolism of MG by the glyoxalase pathway is 
D-lactate (Thornalley, 1990). The presence of the glyoxalase in all organisms 
studied suggested that this enzymatic system has a vital role in cell function 
(Gowland-Hopkins and Morgan, 1945). In 1951, Racker discovered that the 
metabolism of MG by the glyoxalase system forms D-lactate and occurred via S-
D-Lactoylglutathione in two successive steps (Racker, 1951). The first discovery 
to show that MG and related aldehydes react with arginine residues was in 1977. 
However, the physiological importance of this reaction was not fully understood 
(Takahashi, 1977a). 
In the last century, there was a several studies exploring the links between 
cancer and the glyoxalase system. Szent-Gyorgyi first showed that the conflict of 
MG and Glo1 in controlled cell growth and how it could be exploited for cancer 




retarding substance and in contrast Glo1 acts as the opposite to this growth 
inhibition. Many other growth factors were discovered and this led to the 
weakness of this hypothesis. Increased levels of MG concentration were toxic to 
tumour cells. Vince and Wadd proposed that Glo1 inhibitors may be effective 
anticancer agents. Glo1 inhibitors act by increasing the accumulation of the 
endogenous MG (Vince and Wadd, 1969). The historical development and the 
link between the glyoxalase system and cancer treatment and development will be 
discussed further in this chapter below. 
In 1970s to 1990s, scientists were able to purify glyoxalase enzymes and 
identified its molecular, kinetics mechanistic and structural characteristics. 
Mannervik and colleagues had an important contribution for mammalian and 
microbial Glo1, with a notable contribution of other scientists: Norton, Kimura, 
Principato Uotila, Thornalley and Vander Jagt (Uotila, 1973, Marmstal and 
Mannervik, 1979, Schimandle and Vander Jagt, 1979, Landro et al., 1992, Allen 
and Thornalley, 1993, Cameron et al., 1997, Cameron et al., 1999, Cordell et al., 
2004). Kompf and co-worker first identified the genetic polymorphism of the 
human GLO1 gene and tracked inheritance patterns by detecting the related 
allozymes in gel electrophoresis, usually measured in red blood cells (Kompf et 
al., 1975). 
The physiological source of the MG metabolised in the glyoxalase 
pathway remained unclear. Philips and Thornalley first studied the non-enzymatic 
degradation of triosephosphates to form MG. This study observed a minor leakage 
ca. 0.05% - 0.1% glucotriose flux from the Embden-Meyerhof pathway leading to 
the formation of MG in physiological systems (Phillips and Thornalley, 1993a). 
This low percentage flux of glucotriose represents ca. 3 mmol of MG formation in 
healthy human subjects per day (Rabbani et al., 2016b). MG has a high reactivity 
rate with DNA and proteins. Therefore the glyoxalase system plays a vital role to 
keep MG concentration at low tolerable level (Thornalley, 2003b). 
In 2003, Thornalley and his colleagues found that MG-derived AGEs were 
one of the major endogenous types of protein damage in vivo. This is based on the 
relatively high steady-state levels of MG-derived glycation adducts and the high 




2006, Redon et al. found that GLO1 gene was located in one of the copy number 
variation (CNV) regions and constructed a CNV map of the human genome 
(Redon et al., 2006). In 2008 Zender et al. found that Glo1 is a tumour suppressor 
protein by investigating, in a genome-wide scan, genes with tumour suppressor 
activity (Zender et al., 2008). 
Thornalley and his colleagues found that MG-derived DNA 
imidazopurinone adducts are one of the major quantitative adducts of DNA 
damage linked to DNA instability in vivo (Santarius et al., 2010). Cahan et al. 
showed that the non-transcribed region of the GLO1 gene is an important site of 
the CNV in the mouse genome giving an increase to ca. 4-fold changes the 
expression of Glo1 (Cahan et al., 2009). 
In 2012, Thornalley and co-worker found the presence of regulatory 
antioxidant response element (ARE) in exon-1 of the mammalian GLO1 gene. 
Transcription factor Nrf2 increases the basal and inducible expression of Glo1. 
Thus, they concluded that there is stress-responsive increase of Glo1 expression 
when MG concentration increased (Xue et al., 2012). In 2016 Xue et al. optimized 
a small dietary molecule bioactive formation for activation of Nrf2-mediated 
ARE-linked expression of Glo1 (Xue et al., 2016). This optimum induction of 
Glo1 expression was achieved by a combination of trans-resveratrol and 
hesperetin (tRES-HESP) combined therapy. This combination therapy was well-
tolerated and in overweight and obese human subjects it increased Glo1 
expression and activity in peripheral white blood cells (PBMC), decreased plasma 
concentration of MG, improved dysglycaemia and corrected insulin resistance. 
tRES-HESP also decreased in vascular inflammation - including decrease of 
cyclo-oxygenase-2 (COX2) or prostaglandin synthetase-2 (PTGS2). This has 
given the chance to develop a Glo1 inducer therapy for metabolic and vascular 
complications of obesity and diabetes (Xue et al., 2016) – and potentially also 
chemoprevention of cancer through the tumour suppressor activity of Glo1 







1.1.3 Glyoxalase 1 
1.1.3.1 Molecular properties 
Glo1 protein of human subjects is a dimer of identical subunits in 
homozygotes or very similar subunits in heterozygotes held together by non-
covalent bonding interactions. The molecular mass of Glo1 in human is 42 kDa by 
sequence, subunit mass of 23 kDa when measured by denaturing polyacrylamide 
gel electrophoresis and 46 kDa when determined by gel filtration. The isoelectric 
point pI of Glo1 is 4.8 - 5.1. Glo1 protein consists of polypeptide chains of 184 
amino acid chains with one prosthetic Zn2+ ion per subunit (Thornalley, 2003b, 
Birkenmeier et al., 2010). The structure around the prosthetic Zn2+ ion of human 
Glo1 consists of two equivalent subunits which come from each domain Glu-99A, 
Gln-33A, His126B, Glu172B and two water molecules in octahedral 
configuration. In each monomer, there are two domains originating from a gene 
duplication and swapping of 3D domain in the N-and C-terminal domains. One 
domain has 124-183 residues while the other domain consists of 31-104 residues; 
20 amino acid residues and long N-region link these domains together. Each of 
the domain there are βαβββ-motif and mixed β-sheet. In the event of dimerization 
of the subunit, a β-parallel structure is formed which contain an active site. The 
individual monomers lack the enzymatic activity (Cameron et al., 1997). 
The activity of Glo1 is present in all human tissues. There is ca. 0.2 µg 
Glo1 per gram protein in human tissues or ca. 1/5000th of total protein. There is 
ca. 2-fold increase of abundance of Glo1 protein in foetal compared to adult 
tissues (Larsen et al., 1985). In human fibroblasts, Glo1 was in the top 13% of 
proteins by abundance. Cytoprotective proteins such as Glo1 are typically found 





Figure 2. Structure of human glyoxalase 1. Solid ribbon representations of the 
crystal structure of human glyoxalase I (Cameron et al., 1997). 
 
1.1.3.2 Kinetic characteristics  
The main enzymatic role of Glo1 is to catalyse the isomerisation of the 
hemiathioacetal formed form the non-enzymatic reaction of GSH and MG to S-D-
lactoylglutathione (Thornalley, 2003b). The steady-state concentration of MG and 
related glycation reactions are thereby decreased in cells and tissue in vivo. Glo1 
has a wide specificity for α-oxoaldehydes: for instance, MG (CH3COCHO), 
glyoxal (CHO)2, 4,5-dioxvaleric acid HO2C(CH2)2COCHO and other acyclic 
glyoxal derivatives. As the hydrophobicity of the side chain of the glyoxal 
derivative substrate increases the KM and kcat values decrease. 
 
1.1.3.3 Regulation of expression 
The GLO1 gene in human subjects has regulatory elements: insulin 
response element, metal response element, E2F4 and AP-2 alpha and an 
antioxidant response element (ARE) (Rabbani et al., 2014). Glo1 expression is 
increased by activation of transcription factor Nrf2 and its binding to the 
functional ARE. Transcriptional control of Glo1 by Nrf2 gives a stress responsive 




decreased due to the activation of the receptor for advanced glycation end 
products (RAGE), although the mechanism of this response is unknown (Reiniger 
et al., 2010, Zeng et al., 2012) – although RAGE-activated  inflammatory 
mechanisms countering Nrf2 regulation of Glo1 expression is a likely mechanism. 
Another factor which may cause Glo1 expression to be decreased comes from the 
activation of hypoxia inducible factor1 alpha (Zhang et al., 2012). 
Once Glo1 polypeptide subunits are translated, the N-terminal Met is 
removed and acetylation reaction is takes place leading to the blockage of the 
remaining N-terminal Ala. Between the 19-20 cysteine residues there is a vicinal 
disulphate bridge and a mixed disulfide glutathione with cysteine-139. Cysteine-
139 may also form an intra-molecular disulfide with cysteine-61. The activity of 
Glo1 is strongly inhibited by glutathionylation on C139 but not affected by the 
oxidation state of C19/C20 and the N-acetylation (Birkenmeier et al., 2010). The 
post-translational modification of Glo1 can lead to multiple forms of differing pI. 
Glo1 may also be S-nitrosylated by reaction with nitric oxide on cysteine-139. 
The presence of C19 and C20 are vital in the reaction of S-nitrosylation which 
take place on the acidic α form of Glo1 (de Hemptinne et al., 2007). The NO-
responsive form of Glo1 is the basic, reduced form of Glo1 without 
intramolecular disulfide bonding. Glo1 is a substrate for calcium, calmodulin-
dependent protein kinase II and is phosphorylated at Thr-107 preferentially but 
not exclusively on the basic, reduced and NO-responsive form (de Hemptinne et 
al., 2007, de Hemptinne et al., 2009). 
 A genome wide study conducted by Selbach and co-workers quantified the 
Glo1 expression in NIH3T3 mouse fibroblast (Schwanhausser et al., 2011). The 
number of copies per cell of mRNA and protein were 22 (transcriptome median 
17) and 584,000 (proteome median), respectively. The half-lives of mRNA and 
protein of Glo1 were 7.8 h (transcriptome median 9 h) and 179 h (proteome 
median 46 h), respectively. The rate of transcription (molecules proteins per cell 
per h) was 750 (genome wide translation median ca 117). This suggested that 
Glo1 has protein abundance ca. 10-fold and half-life 4-fold higher than median 
values. This relatively high level of protein suggested that Glo1 is a highly 




proteins abundance, Glo1 is detected in the top 13% of protein. Glo1 is 677 of 
5028 proteins detected by abundance. Glo1 has a similar abundance to that of 
glycolytic enzymes such as transketolase. 
 There are few studies exploring the link between the levels of transcripts 
and the protein levels they encode in mammals. For example, genetic approach by 
using the natural variation to agitate both proteins and transcript level in inbred 
strain of mice. The study showed that mRNA of Glo1 is strongly correlated with 
Glo1 protein (r=0.87), among the quantification of 7,185 most heritable 
transcripts and proteins (Ghazalpour et al., 2011). In the post-transcriptional 
mechanisms, the conversion of mRNA Glo1 to Glo1 proteins is relatively 
constant, the half live of Glo1 may vary in good health state.  Glo1 appears to 
have slight increase in proteolysis on activation of autophagy (Kristensen et al., 
2008). 
1.1.3.4 Genetics and polymorphism 
Glo1 subunits are encoded by the gene of GLO1. GLO1 is on chromosome 
6, nearby the locus of Human leukocyte Antigen-D Related (HLA-DR). GLO1 
genes contains 27,250bp with six exons. The genetic locus is 6.21.2: 28751,680 - 
38778,9300 (Tripodis et al., 1998, Thornalley, 1991). In the GLO1 gene there are 
two alleles; GLO11 and GLO12. The two alleles are in heterozygous inherited 
autosomally in a co-dominant system (Thornalley, 1991). The emergence of 
GLO11 allele is due to mutation whereas GLO12 allele is considered to be the 
ancestral allele. The differences between the two alleles is due to the mutation 
point in cDNA at position 332 (Thornalley, 2003b). 
GLO1 genotypes are: GLO1 (1-1), GLO1 (1-2) and GLO1 (2-2). Mutation 
occurs in C419A leads to this common polymorphism which takes place in the 
coding region resulting to an amino acids residues polymorphism Ala111Glu 
(A111E) (Degaffe et al., 2007). The related allozymes may be resolved by non-
denaturing gel electrophoreses and ion exchange chromatography due to the 
differences in molecular charge and shape densities (Kim et al., 1995). Studies 
have shown that in human populations, the GLO11 allele has the highest 
frequency in native tribes in Alaska with allele frequency 0.67 - 0.85. This 




towards Africa, Middle East and India.  The lowest allele frequency of GLO11 is 
found to be in Far East and Oceania 0 - 0.16 (Thornalley, 1991). 
 














Figure 3. The catalytic mechanism of the glyoxalase I. 
The catalytic mechanism of Glo1 consists of shielded proton transfer from 
C-1 to C-2 to the hemithioacetal to form an ene-diol intermediate and rapid 
ketonization to the thioester product (Thornalley, 2003b). Two stereoisomers of 
the hemithioacetal, R-and S-substrate diastereoisomers, are formed in the pre-
equilibrium of MG reaction with GSH spontaneously. Both are accepted by Glo1. 
Once they are bound to the active site, an interaction between diastereoisomers 
with different catalytic bases: the S-diastereoisomer interacts with the conjugate 
base of Glu-172 and the R-diastereoisomer interacts with the conjugate base of 
Glu-99. It is likely that re-protonation occurs via the conjugate acid form of Glu-







1.1.4 Glyoxalase 2  












Figure 4. The structure of the human glyoxalase2. C terminus (blue)-N-
terminus (red). Metal ions and coordination showed by balls and sticks. (Cameron 
et al., 1999). 
In human subjects, Glo2 protein is a monomeric enzyme consisting of two 
main isoforms: mitochondrial Glo2 with molecular mass 33,806 Da and pI 8.3; 
and cytosolic Glo2 29,200 Da (Xue et al., 2011). In cytosolic Glo2, there are two 
domains: N-terminal domain comprises of 1-173 amino acids and C-terminal 
consist of 174-260 residues with secondary structure of five alpha-helices (Cordell 
et al., 2004). Glo2 in human subjects has an Fe(II)Zn(II) centre where the Fe(II) 
has minimal effect on the catalytic activity. The structure of Glo2 comprises 
metallo-β-lactamase-like and α-helical domain. The Fe(II)Zn(II) centre of the 
active site lies with a substrate-binding site in the 2-domain interface. A 
hydroxide ion coordinated to the Zn (II) ion is the base catalyst for the enzymatic 
reaction (Cameron et al., 1999). 
The hydrolysis of S-D-lactoylglutathione to GSH and D-lactate is 
catalysed by Glo2. The Km value of Glo2 is 146 µM and kcat value is 726 s
-1 (Xue 
et al., 2011). Glo2 is known to be an efficient enzyme, as indicated by the kcat / Km 




(Cameron et al., 1999). Glo2 isolated from human liver had a broad optimum 
activity range between pH 6.8 - 7.5. 
1.1.4.2 Regulation of expression 
In human subjects, Glo2 is up-regulated at the transcriptional level by p63 
and p73 transcription factors of the family of p53 which are involved in 
development. Glo2 expression is decreased in p53 knockout mice. In the intron1 
of Glo2 gene HAGH there is a p53 response element which is activated when 
bound by p63 and p73. It was found that Glo2 is increased only in cytosol. Cells 
with Glo2 deficiency were hypersensitive to MG-induced apoptosis and DNA 
damage-induced apoptosis (Rabbani et al., 2014). 
 The function of Glo2 in the mitochondria is unclear. This is related to the 
lack of Glo1 targeting in mitochondria. However, Glo2 might be involved in GSH 
delivery into mitochondria with the aid of S-D-lactoylglutathione. This notion 
appears to be unlikely and this is due to the fact that GSH and S-D-
lactoylglutathione had similar kinetics uptake of the mitochondrial and the 
concentration of the cytosolic S-D-lactoylglutathione is ca. <1% of GSH. 
Furthermore, other GSH derivatives can be hydrolysed by Glo2 such as S-acetyl-
GSH and S-succinyl-GSH. Moreover, recent studies proposed that there is a 
significance non-enzymatic acetyl and succinyl transfer from acetyl-CoA and 
succinyl-CoA in mitochondria and this likely to be acceptor as mitochondrial 
GSH. Thus, Glo2 may maintain GSH by the repair of endogenous acylation where 
a high level of acetyl-CoA and succinyl-CoA in mitochondrial necessitate 
targeting of Glo2 to this part. Reviewed in- (Rabbani et al., 2014b). 
1.1.4.3 Genetics and polymorphism 
The human gene of Glo2 is HAGH (hydroxyacylglutathione hydrolase) 
(Thornalley, 1990). It is located on chromosome 16p13.3 (Xue et al., 2011). Two 
genotypes are known for HAGH: HAGH1 and HAGH2 (Thornalley, 1990, Allen 
et al., 1993a). The single gene that gives rise to two distinct mRNA species 
transcribed from 9 and 10 exons, respectively. The 9-exon-derived transcript 
encodes for both mitochondrial matrix targeted and cytosolic Glo2 whereas the 10 





1.1.4.4 Mechanism of action 
 
Figure 5. Catalytic mechanism of human glyoxalase 2.  
Glo2 has a wide specificity for glutathione thiol ester, S-2-
hydroxylacylglutathione derivatives (Xue et al., 2011).The glutathione moiety is 
closely bound to the protein via cysteine and glycine residues. The -glutamyl is 
not interacting with the Glo2 protein (Xue et al., 2011). However, the same 
ligands are involved in hydrogen-bonding and interaction with the protein as in 
Glo1. The three basic residues close to the carboxyl group of glycine are: Lys-
143, Lys-252 and Arg-249.  Lys-252 and Arg-249 participate in the formation of 
-helix of the second domain between the ranges of the hydrogen bonding 
interaction with protein. Asp-253 carboxylate and Cys-141carbonyl oxygen has a 











1.1.5.1 Molecular characteristics, assay and physiological concentration  
MG is a reactive metabolite formed by the trace-level degradation of 
triosephosphate glycolytic intermediates, glyceraldehyde-3-phosphate (GA3P) 
and dihydroxyacetonephosphate (DHAP), and is a by-product of glycolysis 
(Rabbani and Thornalley, 2012c). In the past, reliable estimation of MG 
concentration was challenging (Rabbani and Thornalley, 2014c). MG content in 
tissues and plasma have sometimes been overestimated by >1000-fold (Rabbani 
and Thornalley, 2014c). For example, published estimates of MG concentration in 
human plasma are in the range 123 nM to 407 µM by different analytical methods 
estimates (Beisswenger et al., 1999, Scheijen and Schalkwijk, 2014). Another 
example is MG concentration of mouse brain in the range 1.5 µM (Kurz et al., 
2011) to 174 µM (Hambsch et al., 2010). Assays with reliable, interference-free 
methodologies suggest the lower estimates are the closest to the true values. 
MG formation during pre-analytic processing of sample has been one of 
the causes of MG overestimation problem (Thornalley et al., 1999, Baba et al., 
2009, McLellan et al., 1992a). During sample preparation, MG can be formed by 
degradation of glycated protein, monosaccharides and other samples component 
and derivatizing agent. This can be avoided during sample preparation. MG 
formation during pre-analytic processing of sample is enhanced by heating, high 
pH and peroxidase activity.   
MG is present in aqueous solution under physiological conditions in three 
forms: the unhydrated form CH3COCHO, the monohydrate CH3COCH(OH)2 and 
the dehydrate form CH3C(OH)2CH(OH)2 which under physiological conditions 
represent ca. 1%, 70% and 29% of total MG, respectively (McLellan and 
Thornalley, 1992b, Nemet et al., 2004). MG also has the ability to bind reversibly 
to peptides and proteins, mainly to cysteine residues of GSH and proteins. MG 
assays measure the total of free MG, MG hydrates and MG reversibly bound to 
proteins. MG is detached from proteins and dehydration of all hydrated forms 






1.1.5.2 Physiological formation of methylglyoxal 
MG is produced mainly by trace-level of the degradation of GA3P and 
DHAP (Phillips and Thornalley, 1993b). Other minor sources of formation of MG 
are: formation from acetone in the metabolism of ketones bodies and 
aminoacetone in the catabolism of threonine (Rabbani et al., 2016a, Thornalley, 
2003b). Past studies have shown that MG synthase can form MG in bacteria 
enzymatically but there was no evidence for MG formation enzymatically from 
triosephosphates in mammalian cells (Phillips and Thornalley, 1993b).  
MG detoxification level by the pathway of the glyoxalase system depends 
mainly on the formation of GSH hemithioacetal. As discussed previously, MG 
can be in present in three forms: unhydrated α-oxoaldehyde, monohydrated and 
unhydrated forms at pH 7. The unhydrated MG has the ability to react reversibly 
with GSH to produce the hemithioacetal (Rabbani et al., 2016a, Thornalley, 
2003b). The major abundant solution species of MG is MG-GSH hemithioacetal 
in cells and in situ. Therefore, Glo1 achieve a high catalytic activity (Rabbani et 
al., 2016b). Moreover, cellular protein thiols react with MG and the concentration 
is typically ca. 4-fold higher than concentration of GSH in cells. It is thought that 
protein thiols are depot storage sites of MG during excessive MG formation 
periods. Another factor affecting the formation of MG is the glyceraldehyde-3-
phosphate dehydrogenase (GADPH). GADPH can affect the rate of MG 
formation by influencing the concentrations of triosephosphates in cells (Rabbani 

















Figure 6. Schematic representation of the major protein AGEs (A) MG-H1 
and Major DNA AGEs  MGdG (B) produced by methylgyloxal 
MG has the ability to react with nucleotides, proteins and basic 
phospholipids to form advanced glycation endproducts (AGEs) (Rabbani et al., 
2016a). The reaction of MG with proteins leads to the formation of 
hydroimidazolone adducts derived from arginine residues. MG-H1 is known to be 
the most abundant and functionally important AGEs in physiological system 
(Rabbani and Thornalley, 2012a). There are other minors MG-derived AGEs such 
as Nε(1-carboxyethyl)lysine (CEL), MG derived lysine dimer cross-link (MOLD), 
arginine-lysine-derived crosslinks MODIC and argpyrimidine. (Rabbani and 
Thornalley, 2012a). Multiple factors can influences proteins content of AGE: 
exposure time to MG, chemical stability of the glycation adducts, MG 
concentrations, protein turnover, DNA and phospholipid modification and 
intrinsic reactivity of the protein (Rabbani et al., 2016b). 
The main nucleotide-derived AGEs formed from dicarbonyls are 
imidazopurinones, GdG and MGdG. The content level of MGdG in the DNA is 
higher when compared to the DNA oxidative damage adduct, 8-
hydroxydeoxyguanosine. From glyoxal, the AGEs formed are 3(2′-deoxyribosyl)-
6,7-dihydro-6,7-dihydroxyimidazo[2,3-b]purin-9(8)one (GdG) and N2-
(carboxymethyl)deoxyguanosine (CMdG). However, from MG the AGEs formed 
are 3-(2′-deoxyribosyl)-6,7-dihydro-6,7-dihydroxy-6-methylimidazo-[2, 3-
b]purine9(8)one (MGdG) and N2-(1-carboxyethyl)-deoxyguanosine (CEdG). 





are stable in the double stranded (dsDNA) and single stranded DNA (ssDNA). 
Formation of CEdG is related to DNA depurination (Thornalley, 2003c, 
Thornalley, 2008). Increases in mutation frequency, cytotoxicity and DNA strands 
break are linked to increased GdG and MGdG formation (Thornalley et al., 2010). 
Basic phospholipids can react with MG. Phospholipid glycation affects membrane 
interaction which leads to membrane fluidity (Pun and Murphy, 2012). Glycation 
of phospholipids can elevate lipid peroxidation which leads to increase oxidative 
damage (Pun and Murphy, 2012). 
 
1.1.5.4 Dicarbonyl stress 
Dicarbonyl stress is defined as the abnormal accumulation of α-
oxoaldehyde metabolites leading to an increased DNA and protein modifications 
resulting in cell and tissue dysfunction. The cell and tissue dysfunction are 
implicated in aging and disease (Rabbani and Thornalley, 2014b). There are 
several examples: such as the elevation of MG-protein modification in ageing 
human lens, elevation of plasma and tissue concentration of MG in diabetes, the 
increased level of MG, glyoxal, 3-DG concentration and other dicarbonyls in 
renal failure (Rabbani and Thornalley, 2015). The cause of the dicarbonyl stress is 
the imbalance between the formation of dicarbonyl metabolites and the enzymatic 
metabolism of these metabolites; and also increased exposure to dicarbonyl 
metabolites from exogenous sources (Xue et al., 2012). Normal levels of MG, 
glyoxal and 3-DG range between 50 – 150 nM in human plasma and 1 – 4 µM in 
plant and mammalian cells. During the increase of dicarbonyl concentration, 
dicarbonyl stress arises which leads to an impaired health and disease (Rabbani 
and Thornalley, 2015). 
 
1.1.5.5 Clinical importance of dicarbonyl stress  
Glycation adducts with proteins, nucleotides and reactive dicarbonyls have 
an implication clinically in ageing, disease and number of pathological process. 
For example, diabetes, neurodegenerative disease and tumorigenesis and multi-






S-D-Lactoylglutathione is the physiological intermediate of metabolism of 
MG by the glyoxalase system. The formation of this intermediate comes from the 
hemithioacetal adduct of MG and GSH in a reaction catalysed by Glo1. Followed 
by the hydrolysis of S-D-lactoylglutathione to GSH and D-lactate in a reactions 
catalysed by Glo2 (McLellan et al., 1993). 
MeCOCHO + GSH ⇌ MeCOCH(OH)-SG     Glyoxalase 1       
MeCH(OH)CO-SG 
 The formation of S-D-lactoylglutathione occurs in the cytosol of cells and 
it cannot readily cross the cellular membrane. Nevertheless, S-D-
lactoylglutathione can leak slowly from cells by the GSH conjugate transporter. 
When in the extracellular compartment, γ-glutamyltransferase present on the 
external surface of cellular membrane plasma cleaves S-D-lactoylglutathione to S-
D-lactoylcysteinylglycine. There is then a spontaneous rearrangement of S-D-
lactoylcysteinylglycine to N-D-lactoylcysteinylglycine (Tate, 1975) and cleavage 
of this by dipeptidase forms N-D-lactoylcysteine. 
 Thornalley and his co-worker made remarkable studies on the biological 
properties of S-D-lactoylglutathione added to cells in culture (Thornalley and 
Tisdale, 1988). They have shown that S-D-lactoylglutathione promote 
cytotoxicity and growth arrest in human cell leukaemia in vitro (Thornalley and 
Tisdale, 1988). In human neutrophils, S-D-lactoylglutathione influenced the 
stimulus-activated granule secretion: at low concentration (2 - 5µM), it 
potentiated secretion; and during high concentration (100 µM – 5 mM), it 
inhibited secretion (Thornalley, 1990). It is found that the above effect is 
enhanced by N-D-lactoylcysteine which gets in the cells by passive diffusion as it 
has unionised solution species known.  N-D-Lactoylcysteine is an inhibitor of 
dihydro-orotase of the de novo pyrimidine synthesis pathway. The ability to 
inhibit pyrimidine synthesis accounted for the anticancer activity of S-D-
lactoylglutathione and granule secretion effects through the effect of metabolic 
channelling of pyrimidine metabolites into nucleotide conjugates enhancing for 
degranulation via cell signalling (Edwards et al., 1993, Edwards and Thornalley, 





The main stereoisomer of lactate made in human intermediary 
metabolisms is L-lactate (Drury and Wick, 1965). D-Lactate is another 
enantiomer which mainly ca. 1 - 5% of the concentration of L-lactate in plasma. 
Exogenous sources of D-lactate can be found in high concentration in fermented 
food such as yogurt, pickles and sauerkraut. Moreover, D-lactate is absorbed from 
the microbial fermentation in the gut (Hove, 1998, Mortensen et al., 1991, 
Ewaschuk et al., 2005, de Vrese and Barth, 1991). The endogenous formation of 
D-lactate occurs by the glyoxalase system pathway and it is metabolised by 2–
hydroxyacid dehydrogenase to pyruvate (Thornalley, 1993b). D-Lactate is well-
metabolised in human subjects but it has a fractional renal clearance compared to 
L-lactate (Connor et al., 1983). D-lactate infusion in human subjects is at 1.0-1.3 
mmol sodium D-lactate/kg/hr resulted in almost 90% of the D-lactate metabolised 
while the remaining 10% is secreted in urine (Oh et al., 1985). Metabolism of D-
lactate dropped by almost 75% of the overall clearance with a higher rate of 
infusion of 3.0 - 4.6mmol/kg/hr (Oh et al., 1985). The concentration of D-lactate 
in blood plasma increase ca. 2 - 3 fold after exercising or meal consuming 
(Ohmori and Iwamoto, 1988, Kandoh et al., 1992a). The cell permeability of D-
lactate occurs through transport mechanisms: inorganic anion exchange system, 
lactate specific transporter, and by non-ionic diffusion. D-lactate is excreted in 
urine with lower levels excreted in sweat or stool (Ohmori and Iwamoto, 1988, 
Kandoh et al., 1992a, Kandoh et al., 1992b). 
 Increased D-lactate is a sign that there is increased formation of MG, 
particularly where cells studied are unable to metabolise it. For instance, red blood 
cells, lens fibre cells and vascular endothelial cells (Thornalley, 1993a, Irshad et 
al., 2019). The concentration of D-lactate increases in culture media of endothelial 
cells and red blood cells when high glucose is used in culturing those cells 
(Thornalley, 1988, Karachalias et al., 2005, McLellan et al., 1994a). In healthy 
human subjects, the plasma level of D-lactate is ca. 10 µM (Thornalley, 1988, 
Phillips and Thornalley, 1993, Karachalias N, 2005, McLellan et al., 1994a). D-
Lactate may be overestimated if racemisation of L-lactate occurs in pre-analytic 




fold higher concentration than D-lactate (de Vrese and Barth, 1991, McLellan et 
al., 1992a, Ohmori and Iwamoto, 1988, Brandt et al., 1980). 
 D-Lactate is measured using endpoint enzymatic assay with either 
absorbance or fluorescence detection of NADH formed in presence of D-lactic 
dehydrogenase. The amount of D-Lactate in the sample is equivalent to the 
amount of NADH formed from NAD+ at endpoint, formed concomitantly with the 
oxidation of D-lactate to pyruvate (McLellan and Thornalley, 1992a). D-Lactate 
may also be detected from the amount of pyruvate formed in this reaction where 
pyruvate is detected by derivatisation with 1,2-diaminobenzene to form 2-
hydroxy-3-methylquinoxaline and assay by high performance liquid 
chromatography (HPLC) with fluorescence detection (Ohmori and Iwamoto, 
1988, Ohmori et al., 1991). 
 
1.1.8 Non-glyoxalase detoxification of methylglyoxal. 
In cases where the glyoxalase system is impaired or inhibited, glyoxal is 
metabolised and converted to glycolaldehyde by aldoketo reductase (AKR) 
isozymes 1B1 (aldose reductase), 1B3 and 1B8 may metabolise glyoxal to 
glycolaldehyde. In such circumstances, AKR isozymes 1A4, 1B1 and 1B3 
metabolise MG to mainly hydroxyacetone (Baba et al., 2009).  The majority of 
glyoxal and MG metabolism by AKR1B1 takes place in the renal medulla where 
AKR1B1 has a high expression in comparison with Glo1 (Nishimura et al., 1993, 
Larsen et al., 1985). Glyoxal and MG concentrations may be increased in renal 
failure and this is due to impaired Glo1 activity. The activity of Glo1 in vascular 
and renal cell may be decreased in renal failure by several factors such as the 
reduced concentration of GSH during oxidative stress, Glo1 expression decline 
and glutathionylation of Glo1. Glo1 expression may decreased due to stimulation 
of RAGE and suppression of Nrf2 signalling. Glo1 and AKRs 1B3,1B1and 1B8 
are ARE-regulated genes with inducible expression controlled by Nrf2 (Xue et al., 
2012, Kwak et al., 2003, MacLeod et al., 2009, Nishinaka and Yabe-Nishimura, 
2005, Mercado et al., 2011). 
It is thought that aldehyde dehydrogenase contributes to the degradation of 




dehydrogenase oxidises MG to pyruvate in a NAD+ - dependent reaction (Nemet 
et al., 2006). There are approximately more than 17 known aldehyde functional 
dehydrogenase genes (Vander Jagt and Hunsaker, 2003). Most significant genes: 
aldehyde dehydrogenase 3 (ALDH3), aldehyde dehydrogenase 1 (ALDH1) and 
aldehyde dehydrogenase 2 (ALDH2). These gene product enzymes detoxify many 
different aldehydes in human subjects (Vander Jagt and Hunsaker, 2003, Vander 
Jagt et al., 2001). The preferred substrates for these ALDHs are unhydrated 
aldehydes. MG is highly hydrated and hence is not readily oxidized by ALDH2 
and ALDH1 (Vander Jagt and Hunsaker, 2003, Nemet et al., 2006, Izaguirre et al., 
1998). 
 
1.1.9 The critical role of glyoxalase 1 in enzymatic defence against glycation 
Protein glycation by MG leads to the modification of protein which results 
in loss of side chain charge, function impairment, rearrangement of its structures 
and misfolding. Recent research has shown that increased MG glycation leads to 
activation of the cellular unfolded protein response, with downstream pro-
inflammatory and pro-thrombotic cell signalling (Irshad et al., 2019) Activation of 
the unfolded protein response in high glucose treated endothelial cells is mediated 
by methylglyoxal. Increased formation of glycation adducts have been linked with 
chronic disease. 
At physiological level, protein glycation is prevented and repaired by the 
enzymatic defence against glycation. In 2003, Thornalley established the concept 
of the enzymatic defence against glycation which prevents and repairs the 
glycation adduct formation (Thornalley, 2003a, Thornalley, 2003b). Enzymes 
involved are:  fructosamine-3-kinase - which catalyses the repair of early 
glycation adducts; and Glo1, aldehyde reductases and aldehyde dehydrogenase – 
which prevent the formation of AGEs by metabolising dicarbonyl precursors. The 
detoxification of reactive α-oxoaldehydes, glyoxal and MG, is catalysed by Glo1. 
The enzymatic defence against glycation decreases endogenous glycation damage 
to the proteome. Nevertheless, some residual glycation of nucleotides, proteins 
and basic phospholipid occurs but it is reduced to a tolerable level (Thornalley, 




failure, the enzymatic defence against glycation is overcome and therefore 
glycation adducts rise. Glo1 expression is thought to be reduced with aging and 
aging linked disease (Morcos et al., 2005). 
 
1.2 Other aspects of glycation  
1.2.1 Definition of glycation 
Glycation can be defined as the non-enzymatic reaction of reducing sugars 
and related derivatives with proteins, nucleic acids and basic phospholipids to 
form one or several adducts. Glycation takes place in several sequential complex 
and parallel reactions called the Maillard Reaction. Protein glycation by glucose 
occurs by initial reaction of N-terminal and lysine side chain amino group with 
the acyclic aldehyde form of glucose to form firstly a Schiff’s base intermediate 
followed by slow rearrangement, called the Amadori, leading to formation of the 
Amadori product or ketoamine. For proteins glycated by glucose, the Amadori 
products are: Nα(1-deoxyfructos-1-yl) amino acids – by reaction with N-terminal 
amino groups, and Nε(1-deoxyfructos-1-yl) lysine residues – by reaction with 
lysyl side chain amino groups. The above mentioned adducts may undergo 
enzymatic repair catalysed by fructosamine-3-phosphokinase, spontaneous 
reversal to unglycated amino groups and glucose and mannose, or may slowly 
















Glycation by MG, glyoxal and other reactive α-oxoaldehydes found in 
physiological systems and reacts with proteins to form AGEs directly (Rabbani 
and Thornalley, 2008c). The reaction between proteins and reactive α-
oxoaldehydes occurs mainly with arginine side-chain guanidine groups to form 
hydroimidazolone adducts. 
The normal level at steady state of protein glycation is mainly around ≤ 
5% of protein substrate this may have a little impact on function of protein. In 
cases where modified proteins assume a different pathogenic function, increase of 
low level may be physiologically important. Examples are: MG-modified low 
density lipoproteins (LDL) which has increased binding to walls of arteries; and 
MG-modified collagen-IV which has decreased binding of cell surface integrin 
proteins of endothelial cells producing cell detachment and potential initiation of 
thrombosis by the exposed subendothelium. Moreover, glycation could speed up 
the degradation of proteins, decreasing the half-life of protein substrates; and if 
there is no increase in synthesis of proteins, this will affect the steady state 
concentration of unglycated proteins. Thus, protein glycation may result in 
impairment of normal physiological function, tissue or cellular dysfunction 
production and have a major contribution towards disease. For these reasons, 
glycation is considered a type of protein damage (Rabbani and Thornalley, 2015).  
1.2.2 Historical perspective of glycation 
Arthur Robert Ling was the first investigator to develop a process 
involving drying proteins with sugar in 1908. This drying process produced a 
flavoured coloured mixture. He studied the formation of pigments by heating 
glucose with asparagine (Ling, 1908). This was the first time the formation of 
adducts between amino acids and glucose was reported. In 1912 Louise Camille 
Maillard, considered to be the father of glycation research, studied the reaction 
between glucose and glycine at high temperature (Maillard, 1912a). He concluded 
that the production of brown pigments, melaniodins, occurred by initial reaction 
between amines and saccharides which led to production of Schiff’s base adducts 
(Maillard, 1912b). This complex process of reversible and parallel sequential 




enzymatic defence against glycation was discovered the glyoxalase system which 
converts MG to D-lactate systems (Dakin and Dudley, 1913, Neuberg, 1913b). 
From 1925 to 1931, the condensation of D-glucose was investigated by 
Mario Amadori. The condensation of D-glucose with amines such as p-
phentidine, or p-anisidine or p-toluidine formed two isomers which were not 
anomers (Amadori, 1929b). He showed that one of the isomers was more labile 
than the other towards hydrolysis and was also more susceptible to decomposition 
on standing in the solid state in air.  He correctly recognised this as the N-
glycosylamine but he mistakenly thought that the more stable isomer was a 
Schiff’s base, overlooking its resistance to acid hydrolysis (Amadori, 1929a). 
Furthermore, Kuhn and Dansi in 1936 showed that the stability of the isomer was 
due to a rearrangement of Schiff’s base. Kuhen and Dansi were able to confirm 
Amaodri discovery about the labile isomers (Kuhn and Dansi, 1936). Kuhn and 
Weygand were the first to report the structure of the stable isomer which was an 
unbranched N-substituted 1-amino-1-deoxy-2-ketose (Kuhn and Weygand, 1937). 
In 1953, Hodge proposed that Schiff’s base reaction is followed by Amadori 
rearrangement which involved in the starting steps of Mallard reactions. 
Moreover, Hodge suggested that oxidation, enolization and fragmentation 
reactions have a major contribution in degradation of fructosamine to glucosone 
and several other adducts (Hodge, 1953).  
Allen and colleagues were the first investigators to study the glycation of 
proteins in vivo. They reported a type of glycated haemoglobin, HbA1c, showing 
that it was a negatively charged variant of human blood cell haemoglobin (Allen 
et al., 1958). In addition, the first researchers to investigate the role of glycated 
haemoglobin and its elevation in diabetes were Bookchin and Gallop in 1968 
(Bookchin and Gallop, 1968). In 1975, Bunn and colleagues were able to describe 
the reaction where glycated haemoglobin are formed (Bunn et al., 1975). Later in 
1976 it was suggested by Anthony Cerami and co-worker to use HbA1c as a 
biomarker for glycaemic control in diabetic patients (Koenig et al., 1976). 
In 1960, Anet investigated fructosamine degradation (N,N-
difructosylglycine) to 3-deoxyglucosone (Anet, 1960). Furthermore, Kato was 




with glucose and ribose (Kato, 1960, Shin et al., 1988). These reactive -
oxoaldehyde products of the Maillard reaction are now seen as important 
precursors of glycation adduct formation in biological systems. 
In 1973, it was described for the first time by Bonsignore et al.  that the 
triosephosphate glycolytic intermediate, glyceraldehyde-3-phosphate, degrades 
non-enzymatically to form MG under physiological conditions (Bonsignore et al., 
1973). In 1977, Takahashi described the reaction of amino acids with glyoxal 
derivatives, including glyoxal and MG. Arginine was identified as the 
predominant amino acid modified and a hydroimidazolone was one molecular 
structure proposed for the adducts (Takahashi, 1977b). In 1980, Hayashi and 
Namiki made a remarkable contribution by finding the formation of α-
oxoaldehydes by saccharide moiety fragmentation in Maillard reactions. This is 
termed Namiki pathway of the Maillard reaction which involves glyoxal and MG 
formation by saccharide fragmentation reactions (Hayashi and Namiki, 1980). 
In 1980, Nakayama et al. reported the formation of 6-(2-formyl-5-
hydroxymethylpyrrol-1-yl)-L-norleucine from 3-deoxyglucosone and lysyl 
residues in proteins, now commonly known as  pyrraline - an AGE (Nakayama et 
al., 1980).In 1986, Cerami was first to use the term “advanced glycation 
endproducts” and refer to such compounds as “brown fluorescent pigment which 
crosslink proteins ”(Cerami, 1986). Baynes and colleagues were the first to 
describe Nε(carboxymethyl)lysine (CML) and erythronic acid  formation from 
glycated protein degradation by glucose (Thorpe and Baynes, 2002). The presence 
of these compounds in human urine was later found (Ahmed et al., 1986). The 
formation of CML comes from the degradation of fructosyl-lysine and also 
reaction of lysine residues with glyoxal and ascorbate which is formed from 
peroxidation of lipids (Thorpe and Baynes, 2002). 
In 1988, Thornalley made the remarkable contribution by confirming the 
link between hyperglycaemia in diabetes and the increased flux of MG formation 
and concentration and its probability as the main pathway leading to the 
appearance of diabetes complications (Thornalley, 1988). Thornalley reported that 
there is 3 - 5 fold increase in concentration of MG in blood samples of patients 




acid-stable fluorescent compound formed from glycated collagen called 
pentosidine was reported by Sell and Monnier (Sell and Monnier, 1989). This 
compound is result of the crosslink formation by a pentose moiety and arginine 
and lysine residues. 
Since the start of twenty first century, there has been a remarkable 
advancement in glycation research specifically in measuring and quantifying 
glycation adducts and free adducts by stable isotopic dilution analysis LC-MS/MS 
(Thornalley, 2003a, Thornalley and Rabbani, 2010). The application of high 
resolution mass spectrometry proteomics was able to identify proteins prone to 
glycation by glucose and reactive metabolites such as MG (Rabbani and 
Thornalley, 2014, Zhang et al., 2007). Mutant mouse models with increased 
glycation have been developed: for example, Glo1 deficient mice and F3K 
knockout mice (El Osta et al., 2008, Veiga-Da-Cunha et al., 2006). Transgenic 
mice with glycation exposure have been developed: for example, Glo1 
overexpressing transgenic mice (Inagi et al., 2002). The conception of “dicarbonyl 
stress” has emerged: this is defined as the abnormal accumulation of dicarbonyl 
metabolites resulting in increased DNA and protein modification contributing to 
cell and tissue impairment and dysfunction in ageing and disease. The role of 
dicarbonyl glycation in health impairment has been described, including diabetes, 
renal failure, CVD, schizophrenia, Parkinson’s disease, carcinogenesis and 
mechanism of action of anticancer drugs including Glo1 overexpression-linked to 
multi-drug resistance (Rabbani and Thornalley, 2015). 
The role of AGE receptors has been investigated in relation to health and 
disease leading to the development of receptor of advanced glycation endproducts 
(RAGE). Although there is thought to be involvement of RAGE in cell responses 
to glycated proteins, this has been questioned and the non-glycated ligands 
considered as a physiological agonists. The relation between RAGE and glycation 
was further complicated by the notion that the activation of RAGE is related to 
Glo1 down regulation leading to an increase in dicarbonyl sensitivity (Thornalley, 
2007). 
There is an important role of glycation in aging and disease. It also has an 




tumour suppressor protein (Zender et al., 2008) and cancer chemotherapy where 
overexpression of Glo1 is a mediator of multidrug resistance, diabetes, obesity, 
renal failure, Alzheimer’s disease, arthritis, cirrhosis and schizophrenia 
(Thornalley et al., 2010, Ahmed et al., 2005, Agalou et al., 2005, Ahmed et al., 
2004, Chen et al., 2004, Arai et al., 2010, Chen et al., 2013, Hambsch et al., 
2010). 
Dicarbonyl scavengers and inducers of Glo1 expression or “Glo1 
inducers” are considered emerging therapeutic approaches to decrease dicarbonyl 
glycation. Currently, treatment under evaluation are small molecule Glo1 inducers 
and dicarbonyl scavengers such as pyridoxamine. For example trans-resveratrol 
and hesperetin (Xue et al., 2016) and sulforaphane (Xue et al., 2012). The 
timelines of key discoveries in glycation research is summarized in Figure 3.  
Figure 8. Timeline of the key discovery and development in glycation 
research between 1900 to 2000.   
From (Rabbani and Thornalley, 2012b)  
 
1.2.3  Early-stage and advanced-stage glycation 
Glycation of proteins by glucose with the formation of fructosamines is 
considered as an early-stage glycation. Schiff’s base, glycosylamine and 




advanced stages, fructosamine undergoes degradation to form end-stage adducts 
called advanced glycation endproducts (Rabbani and Thornalley, 2012b). 
 
Figure 9. Early glycation and metabolic sources of AGEs.  
From (Rabbani and Thornalley, 2012b) 
 
1.2.4 Advanced glycation endproducts  
AGEs compound are considered as collection of compounds with complex 
heterogeneous characteristics. Examples illustrated in Figure 5. 
Figure 10. Protein oxidation, glycation and nitration adducts residues in 




(a) Early glycation adducts - FL and Nα-(1-deoxy-D-fructos-1yl) amino acid 
residues. Advanced glycation endproducts: (b) Hydroimidazolones, (c) 
Monolysyl AGEs, (d) Fluorescent AGEs and (e) Non-fluorescent 
crosslinks. (f) Protein oxidation adducts. (g) Protein nitration adduct. 
Adapted from (Thornalley and Rabbani, 2014). 
 
1.2.5 Biochemical formation and physiological effects of protein glycation 
In physiological systems protein glycation is usually low; that is, ca. 0.5 - 
10% of protein have one glycation adduct residue. FL residue formation enhances 
steric demands on the intermediate environment of the glycation site. However, 
there is no change in side positive charge (Roper et al., 1983). CML and CEL 
residues add a negative charge while preserving positive charge of the side chain. 
Formation of hydroimidazolones increases steric demand of the precursor Arg 
residue and also result in loss of positive charge. Formation of hydroimidazolones 
are particularly damaging because precursor Arg residues have a high probability 
of being in a functional domain of proteins – 42% for the human proteome and 
loss of positive charge on hydroimidazolone formation produces loss of functional 
electrostatic interactions (Rabbani and Thornalley, 2012c, Irshad et al., 2019). 
Sites of lysine and arginine susceptible to glycation are thought to have 
activating positive and negative charge in amino acids residues close by; 3 - 4 
residues distance in the primary sequence for an α-helix. However, this is yet to be 
confirmed experimentally (Rabbani and Thornalley, 2012c). Glycation of protein 
may have important functional impact. For example, AGE modification of the 
integrin binding sites of vascular IV collagen (Dobler et al., 2006), AGE damage 
of protein in mitochondrial resulting in increased ROS leakage from mitochondria 
(Morcos et al., 2008), neuronal voltage sodium gate modification by MG result in 
in diabetic neuropathy (Bierhaus et al., 2012), and modification of LDL by 
methylglyoxal producing atherogenic small LDL (Rabbani et al., 2011). 
Protein glycation could also affect the formation of non-sulfhydryl 
crosslink. AGE-enhanced cross linking of proteins may result in low protein 
solubility and prone to enzymatic digestion (Schnider and Kohn, 1981). This is 
particularly important in connective tissues and extracellular matrix where 
crosslinking may result in changes in structural and mechanical properties- 




changes are linked with ageing (Lee et al., 1993). The formation of soluble 
collagen fibrils in vitro are inhibited by glycation. Glycation leads to an elevation 
of intermolecular spacing in the collagen fibril and loss of structure and expanding 
the molecular packing (Tanaka et al., 1988, Brownlee, 2001). 
 
1.3 Protein oxidation 
Proteins are often susceptible to oxidative damage and other oxidation-
derived process. Formation of ROS occurs under normal metabolism in organelles 
such as mitochondria and peroxisomes and contributes to endogenous protein 
damage (Petropoulos and Friguet, 2005). Furthermore, environmental factors such 
toxins and UV radiation can increase the formation of ROS leading to increased 
protein oxidation. Enzymatic and non-enzymatic antioxidants suppress the levels 
of ROS to maintain cellular redox homeostasis. When the impairment of redox 
haemostasis is affected by elevated ROS formation, oxidative damage becomes 
excessive can significantly impair protein, DNA and lipids - resulting in 
accumulation of oxidized product. Accumulation of oxidized products is found in 
ageing and ageing related disorders (Berlett and Stadtman, 1997). Aromatic amino 
acid and sulphur-containing amino acids, cysteine and methionine, are more 
sensitive to oxidation. Protein damage caused by oxidation may be irreversible 
and is then only cleared through proteolysis. Degradation of oxidised proteins 
occurs via the proteasome for cytosolic proteins and Lon protease (Grune et al., 
1997). Some oxidative damage adducts can reversed back to the unmodified 
precursors: for example, cystine and cysteine sulfonic acid may be reduced by 
thioredoxin reductase and methionine sulfoxide by methionine sulfoxide 
reductases (Holmgren, 2000, Bakala et al., 2003). 
 
1.4 Protein nitration 
Nitration is a chemical reaction where a nitro group (-NO2) is introduced into 
a chemical compound. In protein nitration there are different amino acids which 
can be nitrated such as tyrosine, tryptophan, cysteine and methionine residues 
(Ischiropoulos and biophysics, 1998). The most common is tyrosine nitration with 




of the hydroxyl group from 10.07 in tyrosine to 7.50 in nitrotyrosine (Turko and 
Murad, 2002). It is thought that tyrosine nitration is a selective process but it is 
very low, ca. 0.003 mol% - reviewed in (Rabbani and Thornalley, 2008b). The 
site of nitration depends on protein structure, function and nitration mechanism as 
well as protein location. Tyrosine nitration may loss of protein function and 
influence phosphorylation status (Turko and Murad, 2002). 
 
1.5 Measurement of protein glycation, oxidation and nitration 
1.5.1 Fluorescence 
Fluorescence can be used to measure protein glycation and oxidation. 
However, this method is limited to minor number of glycation and oxidation 
adducts analytes that are fluorescent. The use of chromatographic resolution is 
essential for quantitative measurement. Fluorescent AGEs are measured by 
determine emission and excitation wavelengths of 350nm and 450 respectively 
(Sebekova et al., 2001). Fluorescent AGE peptides or free adducts have also been 
measured (Thomas et al., 2004). This methods have several limitations and 
analytical difficulties: (1) Most of AGEs are not florescent and therefore cannot 
be detected (Rabbani and Thornalley, 2009); (2) there are multiple fluorophores 
related to total florescence measurement with different specific fluorescence, 
hence quantification cannot be performed. Table 1 shows different total AGE 
fluorescence estimates which provide qualitative measurement of glycation and 
oxidation damage. 
Tryptophan oxidation can produce fluorophores NFK and kynurenine 
(Fukunaga et al., 1982). Protein interaction with lipid peroxidation product such 
as malondialdehyde may generate fluorophores such as 3,5-diformyl-1,4-
dihydropyridin-4yl-pyridinium derivatives (Yamada et al., 2001) and associated 





Table 1. Different fluorophores linked to oxidation glycation protein damage.  
Adapted from (Xue, 2009). 
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Lipofuscin Several fluorophores 340 – 390 nm, 
430 – 490 nm 
(Li et al., 2006, Sohal, 
1981) 
 
1.5.2 Immunoassay  
Immunoassays were first used for the quantification of protein glycation, 
oxidation and nitration adduct analysis. They have good analytical performance 
for high affinity binding for of peptides and proteins. Nevertheless, there are 
limitations in antigen specificity for detection of glycation, oxidation and nitration 
adducts. For instance, monoclonal antibody 6D12 was thought to bind to CML 
residues but it was shown later that it is bound both CML and CEL; in fact, it 
preferably binds to CEL rather CML (Ikeda et al., 1996, Koito et al., 2004). 
Several studies show that immunoassay can give variable overestimation of 
glycation adduct contents with the lack of reproducibility. However, 
immunoassay can be a good in assessing the localisation of antigen in 
immunohistochemical analysis and is relatively high throughput compared to 
other methods. 
 
1.5.3 Analysis of stable isotopic dilution liquid chromatography using 
tandem mass spectrometry (LC-MS/MS) 
Stable isotopic dilution liquid chromatography with tandem mass 
spectrometric detection (LC-MS/MS) is the best analytically performing and 
reference technique to quantify glycation, oxidation and nitration adducts in 
proteins and free adducts – reviewed in (Thornalley et al., 2003). The 
determination of glycation, oxidation and nitration adducts is performed after 
exhaustive enzymatic hydrolysis. Free adducts from protein glycation, oxidation 
and nitration are measured in ultrafiltrate prepared from physiological fluids by 
using a 3kDa or 12 kDa cut-off microspin filter. The development of this method 
was made in our group and it is used by several research groups around the world. 
Ultra-high performance liquid chromatography is now used with automated 
exhaustive enzymatic hydrolysis. Examples for proteins free adducts measured 




Table 2. Adducts marker from proteins oxidation, glycation and nitration 
measured by isotopic stable analysis LC-MS/MS. 
Analyte group Analyst 
Early glycation adduct FL 
Advance glycation adduct AGEs  
Monolysyl AGEs CEL, CML, pyrraline 
Fluorescent AGEs Pentosidine, argpyrimidine 
Hydroimidazolones MG-H1, G-H1, 3DG-H 
Other Nω-Carboxymethylarginine 
S-Carboxymethylcysteine, ornithine 
Nitration adducts 3-NT 
Oxidation adducts α-Aminoadipic semialdehyde, glutamic 




Proteomics can be defined as one focus of study in the science of post-
genomics where all proteins in the whole or fraction of proteome are detected and 
post-transitional modifications and protein turnover investigated. It may also 
include investigations of the interaction and the distribution of proteins at 
subcellular level (Ong and Mann, 2005). 
The word “proteomics” were first used in the research to describe the use 
of two dimensional gel electrophoreses (2-DE) of proteins with removal of 
separated protein spots from gels for identification by mass spectrometry. Staining 
patterns of proteins in 2-DE experiments showed changes in protein abundances. 
However, there are several limitations using 2-DE methods. For example, the 
dynamic range of proteins detected are limited and it is not possible to 
accommodate 7 - 12 orders of magnitude within sample. More importantly, it is 
not possible to completely resolve of all protein into discrete spots.  2-DE has now 
been superseded by nanoflow liquid chromatography-high resolution mass 
spectrometry (MS) in proteomics research (Anderson and Anderson, 1998, 




The standard procedure in MS proteomics analysis includes proteolysis by 
Lys-C or/ and trypsin (Fang et al., 2002), partial resolution of peptides using 
nano-flow liquid chromatography and fragmentation and detection of peptides 
using positive ion electrospray ionisation mass spectrometry. Fragment ion series 
mass spectra and MSn spectra are used to sequence peptides and identify related 
proteins. The use of bioinformatics tools is essential for data analysis. By current 
convention, detection of at least two unique peptides is required for protein 
identification. High sensitivity and high mass resolution MS can identify around 
1000s proteins in each sample. The common used method for protein 
identification score using the Mascot algorithm (Aebersold and Mann, 2003b). 
Quantitation of protein remains challenging. There are two forms of 
protein quantitative data: the relative change in protein amount between two 
conditions tested or the absolute protein amount in the sample. In absolute 
quantification the amount of substance of interested is measured for instance, ng 
ml−1 of protein or protein copy number per cell. Relative quantification is 
measuring the ratio of the substance between two different conditions in the same 
sample. For examples, investigation of protein fold changes abundance caused by 
a chemical or drug treatment (Ong and Mann, 2005, Sadygov et al., 2004). 
 
1.6.1 Label-free quantification  
Label-free quantitation of proteins involves the quantitation of proteins 
without use of stable isotopic dilution analysis. There are two approaches using 
label-free quantitative approaches: spectral counting and peptide ion intensities. 
Spectral counting involves counting fragment ion spectra (MS/MS) detected for a 
specific protein. The number of fragment ion spectra increases as protein 
abundance increases (Liu et al., 2004). An alternative approach used herein is 
measuring the chromatographic peptide precursor ion intensities. The peak 
intensity is directly related to protein abundance (Bondarenko et al., 2002, Chelius 
and Bondarenko, 2002). This type of approach is convenient and straightforward. 
For reliable estimations, the raw LC-MS generated from experiments undergoes 




intensities normalisation. In this method a typical interbatch coefficient ≥30% 
(Megger et al., 2013). 
 
1.6.2 Sample preparation for label-free quantification 
Different samples can be used in proteomics analysis such as body fluids 
(plasma, serum, urine and bile) and cell and tissue extracts (Megger et al., 2013). 
This is followed by cell lysis – where applicable, protein isolation and digestion. 
The sample preparations and buffer of cell lysis is chosen based on whole or 
fractional proteome of interest. For example, nuclei protein, cytosolic protein or 
membrane proteins (Shevchenko et al., 2012).  
Digestion methods involve the use of lys-C or trypsin or other protease 
(Wiśniewski et al., 2009). The most widely used protease in mass spectrometry is 
trypsin. This is because it has high proteolytic activity and cleavage specificity. 
However, one limitation of using trypsin is incomplete digestion (Saveliev et al., 
2013). Moreover, tightly folded proteins can cause resistance in trypsin activity. 
Lys-C has the ability to overcome this proteolytic resistance of tightly folded 
proteins by cleaving the lysine sites with high efficiency and specificity. One of 
the widely used method for sample purification is spin columns and filter 
digestion. Another method is in solution digesition method which is used for 
small sample amounts developed by Vekey and colleagues (Turiák et al., 2011). 
It is important to determine the total protein concentration in samples, 
specifically when label-free quantification is used. Protein concentration 
measurement is performed after protein extraction from the sample. It is important 
in assessing if the protein isolation has been achieved successfully and in 
deducing if protease digestion has been successful (Megger et al., 2013). Several 
methods can be used in determining protein content:  Bradford (Bradford, 1976), 
bicinchroninic acid (BCA) (Smith et al., 1985) and Popov assays. Amino acid 
analysis may also be used (Tyler, 2000). 
Peptides obtained from the digestion step are partially resolved using 
revered phase liquid chromatography (RP-LC) before analysis by mass 
spectrometry. To achieve chromatographic reproducibility using label free study, 




Retention times of the isotopic standards peptides can be used for chromatography 
alignment during data analysis (Burkhart et al., 2011). Nowadays, there are 
several mass analysers with high resolution used for free label proteomics. 
Predominant amongst these is the orbitrap analyser (Panchaud et al., 2008, 
Aebersold and Mann, 2003). This is due to its high mass resolution, relatively 
easy to handle output data and its applicability to different peptides fragmentation 
types such as electron-transfer dissociation ETD and higher energy-collisional 




























1.7 Introduction to mass spectrometry  
1.7.1  Mass Spectrometry 
Mass spectrometry is an analytical method to measure mass-to-charge 
ratio (m/z) of ions in the gas phase. The basic mass spectrometer is compised of an 
ionisation source to produce ions, mass analyser to measure m/z and a detector to 
quantify ions number at specific m/z value, with the use of computer system for 


































1.7.2 Ionisation method 
There are several method can be used to ionise the sample prior the 
introduction to the mass spectrometer. Some of the ionisation technique is 
considered to be soft ionisation leaving the ion intact. Other techniques uses high 
energy which leads to the fragmentation of ion (de Hoffman and Stroobant 2007). 
Previously, mass spectrometry instrument uses chemical ionisation, 
electron ionisation or field ionisation. The use of these methods require the 
analyte to be in a gas phase before the analysis, therefore it was unsuitable for 
biological sample analysis and only were used for thermally volatile stable analyte 
(Feng, Liu et al. 2008). 
Recent development of the ionisation sources are able to transfer an 
analyte into the gas phase from either solid or liquid phase as part of the ionisation 
procedures. For example, the emergence of electrospray ionisation ESI (Wong, 
Meng et al. 1988, Fenn, Mann et al. 1989) and matrix-assisted laser 
desportion/ionisation (MALDI) (Karas, Bachmann et al. 1987, Karas and 
Hillenkamp 1988, Tanaka, Waki et al. 1988). 
Electrospray ionisation (ESI) was first developed by John Fenn (Fenn, 
Mann et al. 1989). Since then, it has become the principle method for the study of 
biological molecules using MS. Electrospray ionisation is considered to be a soft 
ionisation techniques. For ESI, sample is normally introduced in aqeous solution 
containing organic solvent such as methanol (MeOH) or acetonitrile (ACN). For 
analysis of positive ions, a small acid amount is typically added to the solution in 
order to help the ionisation process. The solution is then sprayed through the 
capillary needle and high electric field is applied. Most common mechanism of 
ion formation by ESI is summarised in Figure12. 
The charged solution inside the capillary produces a Taylor cone at the 
needle end which then releases small droplet with high charge. This droplet 
formation is aided by nebulising gas such as nitrogen. There are two mechanism 
suggested to describe the ion formation by ESI. These are the charge residue 
model (CRM) and the ion evaporation method (IEM). Both of the two models 




solvent to evaporate. The repulsion charge leads to a Coulombic explosion and the 
division of the droplets. In CRM, this procedures is repeatedly occurred until 
multiply-charged ion is produced. In cases where ions are multiply charged at 
high m/z ratio, CRM is thought to be the major mechanism. In IEM, it is thought 
to be the model of ions with low m/z are formed. The starting process is similar 
however, after the Coulombic explosion ions within the droplet form are desorbed 
in the gas phase and entering the mass spectrometer. The ionisation produced by 
ESI gives the ability to be coupled with high performance liquid chromatography 
(HPLC) system which enable the separation of the biomolecule before MS 
analysis. 
  
Figure 12. Electrospray ionisation. Adapted from (Steen and Mann 2004). 
Another commonly used ionisation techniques is matrix laser desorption 
ionisation (MALDI) by Kiochi Tanaka (Tanaka, Waki et al. 1988). The process of 
this ionisation is taken place when the sample are embedded in a suitable matrix, 
mainly a small organic acid that absorbs UV radiation strongly. Under vacuum 
conditions, samples are focused using UV laser leading to local heating of the 
matrix molecule. This result in desorption of the sample and charged and neutral 
analyte and matrix molecule are ejected. During MALDI process, little 
fragmentation take place and mainly the ions formed are singly charged.   
1.7.3 Mass analyser 
1.7.3.1 Quadrupole 
A quadruple mass analyser compromised of four metal rods in parallel 
orientation. Combination of both direct current voltage and radio frequency are 
applied to the opposite rods pair. This will allow the quadrupole to act as mass 




Steinwedel 1953). Quadrupole is considered to be a low-resolution mass analyser 
that operate at unit mass resolution. Usually they are combined with other mass 
analyser. This will allow the use of quadrupole in targeted analysis of specific 
compounds and increase the selectivity of the experiment. 
 
Figure13. Schematic representation of quadrupole analyser. 
A quadrupole mass analyser can performed in a multiple modes. In RF-
only mode, several range of m/z ions traverse the quadrupole (ion guide). 
Performed in static electric field , this will only allow a small window of ions to 
go through. With variable voltage applied to the quadrupole, a range of m/z ions 
may be detected over relatively short period of time.  
One of the methods widely used on the triple quadrupole is the selected 
reaction monitoring (SRM) methods. In this process, sample are injected onto an 
LC directly coupled with the MS instrument. The elution of peptides takes place 
and the first quadrupole is used as mass filter to isolate peptide with a m/z of 
interest. The second quadrupole acts as collision cell in order to break the peptide 
into fragments. Finally, the third quadrupole performed as a second mass filter for 
particular m/z fragment from the initial parent peptide. Each of these fragment ion 
pairs is called transition and the detectors record their intensity. The total peak 








Figure14. Simplified schematic representation of triple quadrupole mass 
spectrometer. 
Recent developments of triple quadrupole mass spectrometers allow 
scanning of hundreds of transitions in a single run to detect simultaneously 
multiple peptides. Moreover, the use of stable isotopic labelled peptides with 
known amount as an internal standards allows the quantification with high 
accuracy. 
1.7.3.2 Orbitrap 
Based on the design of the ion trap by Kingdon (Kingdon 1923), 
Alexander Makarov revealed a new mass analyser in 2000 (Makarov 2000) which 
is commercially known as orbitrap. Ions move in an orbital trajectory around 
central axis electrode in harmonic oscillation (frequency proportional to m/z-1/2) 
which then can be detected by ion image current and the conversion to mass 
spectra is acheived using Fourier Transform (FT) techniques (Hu, Noll et al. 
2005). 
The orbitrap analyser can be considered as high-resolution and high mass 
accuracy instrument. However it should be considered that orbitrap resolution 
relies on both m/z and scan time. The resolution is specified at 60,000 (FWHM) at 
m/z and scan time of 1second. This increased as scan time increase and it could 
reach over 100,000. The desired resolution is inversely proportional to (m/z)-1/. 






1.7.4 Tandem Mass spectrometry 
Mass spectrometers with ether multiple or single mass analyser are able to 
perform tandem mass spectrometry (MS/MS). Generally, for mass spectrometers 
consisting of two mass analysers, ions are selected by the first mass analyser and 
fragmented into smaller ions and then measured by the second mass analyser. 
The use of tandem mass spectrometry experiment is highly important for 
obtaining peptide ion sequence information. One of the widely used techniques 
involved selecting an ion of specific m/z (the precursor), colliding with an inert 
gas and then followed by analysing the ion formed, known as product ions. This 
process is called collisional induced dissociation (CID) which is first introduced 
by Jennings (Jennings 1968) and McLafferty (McLafferty and Bryce 1967). Once 
dissociation method applied to a peptide ion, fragmentation can occurr at different 
sites. Figure 15 represent the nomenclature for the possible fragment ion that can 
be produced from a peptide suggested by Roepstroff, Fohlmann and Beimann 





Figure 15. Peptide fragmentation nomenclature. 
 
During low CID energy a series of b and y ions are generated from the 
peptide fragmented at the amide bonds of peptide backbone. These ions are 
produced when the charge is retained on either C- and N-terminal fragment. This 
process leads to a production of fragmented ions that differs in mass by a single 
amino acid residue which allow in theory to interpret the peptide sequence of the 
amino acid. This fragmentation mode can be used in various type of mass 
spectrometers and has reproducible fragmentation patterns. However, other labile 




this technique. Other fragmentation techniques such as Electron capture 
dissociation (ECD) (Zubarev et al. 1998) and electron transfer dissociation (ETD) 
(Syka et al. 2004) can be used. These fragmentation method allows the PTMs to 
be intact and this is because it dissociates peptides in a non-ergodic manner and 
inducing random breakage of peptide backbone from cleavage of the Cα-N bond 
generating c and z ions. For the ECD and ETD product to be observable, the 
precursor ion must hold at least two positive charges. The electron capture by 
singly charged ion leads in net charge of zero which cannot be detected by mass 
spectrometry. Several proteomics experiments uses both ETD and CID to have 
more comprehensive peptide sequence analysis (Kim et al. 2011; Shen et al. 
2011). 
Mass spectrometers can carry out several tandem mass spectrometry 
experiments automatically. This is vital for analysing samples with thousands of 
peptides. However, it is too difficult technically to sequentially select each single 
ion observed and perform MS/MS. Proteomics studies can be focussed on the 
quantification and identification of peptide/protein as many as possible. This can 
be done by using liquid chromatography to achieve peptide separation and 
collecting ion spectra on the eluting peptides by data-dependant acquisition 
(DDA) or by data-independent acquisitions (DIA). 
Thousands of ions mass spectra are generated from proteomics works. It is 
essential to use bioinformatics approaches to analyse the data obtained. In silico 
digestion can be performed to generate list of peptide mass and linked fragment 
ions, based on the fragmentation and protease used. This is only done if the 
database including protein sequence is available. The database searches are 
performed once experimental data obtained are matched to theoretical data to infer 
peptide identification and protein originated from those peptide. In cases where 
database of an organism is not available, expermtinal data can be searched against 
non-specific database to find the most related sequences in other organism. Also, 
data can be interpreted using de novo method which work by assigning primary 







2.1 Tumours and tumour growth 
2.1.1 Definition of tumours and cancer 
Tumour can be defined as cells or tissue with abnormal growth 
characteristics. Tumours cannot respond to growth and maturation signals or even 
differentiation factors. The three main types of tumour:  
Benign tumours – These can be observed in any tissue. Benign tumours 
can grow locally but lack the ability of spreading to distant tissues. They can 
cause damage by obstruction or local pressure. Several types of benign tumours 
do not become malignant. In most cases, benign tumours are removed surgically 
and this is due the risk of becoming malignant in the future. 
In situ tumours – These types of tumours found in the epithelium and 
mainly are small sized and non-invasive.  
Cancers - Fully developed tumours with malignant characteristics. They 
have the ability to attack, evade and destroy neighbouring mesenchymal tissues. 
They can arise in any tissue and also have the ability to develop their own blood 
vessels and seeds another tumours in a process called metastasis. 
The hallmarks of cancer was first proposed by Hanahan and Weinberg in 
2011. (Hanahan and Weinberg, 2011). There are six biological characteristics 
which are essential in cancer development: (i) evading growth suppressors, (ii) 
sustained proliferative signalling, (iii) replicative immortality, (iv) angiogenesis, 
(v) invasion and metastasis and (vi) resistance of cell death. Moreover, there are 
further emerging hallmarks of cancer such as evading immune system and 
reprogramming energy metabolism.  
One of the key aspects of the six hallmarks in cancer is evading growth 
suppressor. This relies on tumour suppressor genes actions (Hanahan and 
Weinberg, 2011). There are several tumour suppressor gene but the two main 
tumour suppressor genes are: tumour suppressor P53 (TP53) and retinoblastoma-
associated (RB). These two proteins play a vital role in controlling and 





Another emerging hallmark of cancer is the characteristic of 
reprogramming energy metabolism, with respect to non-tumour tissue (Hanahan 
and Weinberg, 2011). High level of metabolic energy aids and helps cell growth 
and division in premature tumours. Moreover, aerobic glycolysis is one of the 
phenomenon of tumours. In non-malignant cells, when there is low oxygen supply 
of hypoxia, cellular metabolism switches to high flux of anaerobic glycolysis – 
the conversion of D-glucose to L-lactate. Once the concentration of oxygen 
returns to normal, non-malignant tissues decreased anaerobic glycolysis and again 
utilize aerobic glycolysis – oxidation of pyruvate oxidation to CO2. In malignant 
tissues, there is a high rate of conversion of glucose to L-lactate even under well-
perfused and oxygenated conditions. This is referred to as tumour “aerobic 
glycolysis”. It was first showed by Otto Warburg and is termed as the “Warburg 
effect” (Warburg and Dickens, 1930). It has been suggested that this is an 
adjustment to intermitted hypoxia in pre-malignant lesions may confer a growth 
advantage (Gatenby and Gillies, 2004). Moreover, an increase in 
pentosephosphate pathway activity provides pentoses for nucleotide synthesis and 
an increased flux of NADPH for biosynthesis (Mitsuishi et al., 2012). It is thought 
the Warburg effect is part of a wider spectrum of metabolic reprogramming in 
tumour to offer growth, tissue invasion and metastasis with a varying nutrient 








 Figure 16. The hallmarks of cancer proposed by Hanahan and Weinberg  






2.1.2 Social impact of cancer  
Cancer is a disease considered to be one of the major current health issues. 
The World Health organisation (WHO) reported in 2012 that there were 14 
million new cases of cancer globally. In the same year, the estimated number of 
deaths globally from cancer was 4.7 million males and 3.5 million females. The 
most common type of cancer causing death in males is lung cancer. In contrast, 
breast cancer is the most common cause of death by cancer in females. The most 
common cancer types globally are: cancers of the lung, bowel, breast stomach and 
prostate cancer. In the USA, common types of cancer are: lung, prostate and 
colorectal cancer which occurred in 42% of all cancer in men. The most common 
cancer types in females are: breast, lung and colorectal (Siegel et al., 2015). In the 
UK, the most common cancer types in female are breast and lung cancers while in 
males prostate and lung cancers are the most common (Office for National 
Statistics, 2015). In 2014, the number of deaths caused by cancer in the UK was 
ca. 160,000: 53% males and 47% females. Gender differences plays a vital role in 
cancer death rates. Cancer is the most common cause of death in the UK. 
Survival rates in cancer treatment in the UK have improved over the last 
50 years – Figure 7. This is because of improved treatment and early diagnosis. 
Some types of cancer still poor survival rates - such as pancreatic cancer. Between 
1971 to 2011, there was a minor improvement in survival rate for most cancers, 




























Figure 17. Survival rate changes from 1971-2011 for different types of cancer 
in the UK  
























Figure 18. Estimated number of cancer death and incidence in 2017in the 
USA.  





2.1.3 Clinical treatment of cancer 
There are three main methods for tumour treatment in clinical settings:  
Surgical resections – Tumours are removed by surgery. This method is only 
suitable for solid mass tumour. 
Radiotherapy – This type of treatments act by ionizing radiation. The current 
application involves the use of high energy photon (x- rays, gamma rays) and 
particles beams (light-ions, electrons, protons, helium and heavy ions – neon, 
argon , silicon ions) (Baumann et al., 2016). 
Chemotherapy – tumour treatments with drugs. This includes immunological 
reagents. (Chabner and Roberts Jr, 2005).   
Recent developments are cell-based therapy, specifically T-cells 
engineered to have the ability to express chimeric antigen receptor (CARs) or 
engineered T cell receptor to enhance host immune response to tumours (Fesnak 
et al., 2016). 
These treatment options can be used as mono or combined therapy. In 
most cases, surgery is used as the first line of treatment. Radiotherapy is usually 
used in combination with surgery. However, certain cancer types cannot use 
surgery as treatments; for instance, leukaemia. Around 45% of new cancer cases 
are managed using radiotherapy. The number of cases where radiotherapy are 
used is increasing with new approaches such as the use of particle ion therapy, 
customised based on type and stage of tumour a precision medicine approach 
(Urruticoechea et al., 2010, Baumann et al., 2016). Radiotherapy is mainly used in 
head and neck tumours. Combination of surgery and radiotherapy are used but in 
a limited cases such as oesophageal and rectal carcinoma (Weichselbaum et al., 
2017). 
In 1940, cancer chemotherapy was first proposed to be used in cancer 
treatment. The historical development of cancer chemotherapy. reviewed in- 
(Chabner and Roberts Jr, 2005). Radiotherapy along with surgery was the 
common treatment method used in cancer in the 1960s. This became notable that 
cure rates had maximised it around 33%. This is because of the existences of 




chemotherapy can cure patients even at advance stages. Early studies proposed the 
use of alkylating agents such as “nitrogen mustered” derivatives and anti-folates 
such as methotrexate. Development of anti-cancer agents improved remarkably in 
the 1970: in the period 1966 – 2000, > 28 anticancer drugs were registered for use 
by the USA Food & Drug Administration (FDA). The development of anti-cancer 
drugs has declined since then. 
The historical advancement of the anticancer agents can be broadly 
divided into three main types (Dobbelstein and Moll, 2014) – Figure 9. Firstly, 
drugs targeting DNA replication and cell division blockage. For example, cancer 
agents act by modifying DNA or interfering with tubulin associations 
(Dobbelstein and Moll, 2014). The second type used drugs to target cell signalling 
contributing to cancer growth - primarily targeting receptors and kinases (for 
instance, BRAF). Recently, the third type of drug has been developed which acts 
by targeting cellular machineries and is not involved directly in DNA replication 
or cell division but it is highly important in tumour growth and survival. For 
instance, the proteasome, chaperones and modifier of chromatin (Dobbelstein and 
Moll, 2014). 
In the last century, the DNA modifying agents were used to treat 
lymphoma in 1943 (Gilman and Philips, 1946, Goodman et al., 1946). Later, the 
use of such drugs developed based on clinical observation (Mukherjee, 2010).  For 
instance, topoisomerase inhibitors and platinum derivatives are still considered to be 
one the most used chemotherapeutic agents. They are still used in treatment of 
testicular carcinoma and leukaemia in children (Travis et al., 2005). In the last two 
decades, several types of chemotherapy have been developed to target specific 
singling pathway or oncogene. Example: imatinib (Novartis) - a small molecule 
inhibitor of BCR-ABL used for treating Philadelphia chromosome positive myeloid 
leukaemia CML (Chakravarty et al., 2016). Monoclonal antibodies can be used to 
target cell surface receptors that are expressed specifically on cancer cells. For 
instance, trastuzumab (Herceptin) is a monoclonal antibody specific for HER2 and 
used to treat approximately 25% of breast cancer with overexpression of HER2 

















Figure 19. Key discoveries of anticancer drugs (1943-2013).  






Table 3. Anticancer drugs that target cell surface molecule and signalling intermediates. From (Dobbelstein and Moll, 2014). 




Well established for clinical use    
Replicative stress  Enzymes for nucleotide synthesis  
 
Nucleoside analogues: for example, 
5-fluorouracil (5-FU) and gemcitabine  
 DNA polymerases  
 
Nucleoside analogues: for example, 
gemcitabine or cytosine-arabinoside (AraC)  
 
 Topoisomerases  
 
Topoisomerase inhibitors: for example, 
anthracyclines (doxorubicin, daunorubicin, 
epirubicin), camptothecin and irinotecan  
 
Mitotic stress  Microtubules, mitotic spindle  
 
Taxanes (paclitaxel, docetaxel), epothilones 
(ixabepilone, patupilone, sagopilone) and 
vinca alkaloids (vincristine, vinblastine)  




Platinum compounds (cisplatin, carboplatin, 
oxaliplatin) and alkylating agents 
(cyclophosphamide, ifosfamide)  
More recently developed drugs    
Altered chromatin dynamics  HDAC enzymes, DNA methyltransferases  SAHA (vorinostat), romidepsin| LBH589 
(panobinostat) azacytidine and decitabine  
 
Proteotoxic stress: protein folding  




20S core unit of the proteasome  
  
Geldanamycin, 17-AAG ,ganetespib and 
NVP-AUY922  







2.1.4 Refractory tumour and multidrug resistance in chemotherapy 
One the main treatment approaches in cancer is the use of chemotherapy. 
It often has limited effectiveness due to multidrug resistance (MDR). The 
resistance of chemotherapy can be divided widely into two categories: acquired 
and intrinsic (Holohan et al., 2013). The presence of pre-existing factor in the bulk 
of tumour cells leading to ineffective treatment is known as intrinsic resistance. 
Acquired resistance is due to mutations or other changes in tumours that were 
originally chemotherapy sensitive. For example, increased expression of target 
therapeutic and alternative activation of signalling pathways. There are three 
levels of multidrug resistance (MDR): macroscopic level (systemic), mesocopic 
level (regional) and microscopic level (local). (Alfarouk et al., 2015) – Figure 10. 
MDR is influenced by both pharmacodynamics and pharmacokinetic 
factors. The effect of pharmacokinetic happens when drug undergoes absorption, 
distribution, metabolism and elimination process (ADME) resulting in limited 
systemic administration of drug to reach the location of tumour. The activity of 
anti-cancer drugs could be limited due to insufficient drug reaching the tumour by 
decreased influx or excessive efflux (Alfarouk et al., 2015). Decreased drug 
activation and increased drug inactivation may cause MDR (Holohan et al., 2013). 
This type of MDR can affect both molecular targeted agents and 
chemotherapeutic agents. For instance, glutathione can inactivate platinum drugs 
(Meijer et al., 1992).  
One of the key roles influencing drug resistance is DNA damage repair. 
Several cancer chemotherapeutic agents induce DNA damage. This damage to the 
DNA can be indirect such as topoisomerase inhibitors or directly such as 
platinum-based drugs. DNA damage can also induce cell cycle arrest which has 
an involvement in allowing cells to repair damage. In some cancer types, 
regulation of cell cycle is interrupted leading to loss of function and alteration to 
tumour suppressor gene and gain of function alteration to oncogene. For example, 
mutation of p53 can affect the DNA damage. It is known that p53 have a vital role 
in cell cycle checkpoint and apoptosis regulation (Enoch and Norbury, 1995). p53 










Figure 20. Multidrug resistance types  in cancer chemotherapy.  
P-gp is permeablility glycoprotein defined as multidrug drug resistance protien. 
MRPs is multidrug resistance associated protien. Assocation of MRP and MDR 
identified first on lung cancer cell line. MXR is mitoxanthrone resistance protein 
– a protein involved in trafficking biological molecules in cell membrane 





2.2 Role of glyoxalase system in cancer  
2.2.1 Historical  
In the last century, there were several studies linking the glyoxalase 
system with cancer treatment and development. Furthermore, in 1923 Warburg 
proposed that increased aerobic glycolysis is one tumour characteristics tumours 
(Warburg and Dickens, 1930). Although there was no clear relation to the 
glyoxalase system, it has an important consequences for flux differential of MG 
via the glyoxalase system in non-tumour and tumour tissues. Platt and Schroeder 
and Jowett and Quastel reported the glyoxalase activity of malignant and non-
malignant in laboratory rodents (Jowett and Quastel, 1934, M. E. Platt, 1934). In 
1955, McKinney and Rundles reported glyoxalase activity in human malignancies 
of human leukaemia (McKinney and Rundles, 1956). French and Freedlander first 
reported the anticancer activity of MG (Freedlander et al., 1958). The MG anti-
tumour activity was investigated by Apple and Greenberg (Apple and Greenberg, 
1968). Conroy showed later that MG treatment was ineffective - requiring a high 
dose of MG, rapid development of resistance and narrow therapeutic index 
(Conroy, 1979). This is due to metabolism of tumour tissue of MG by Glo1 and 
high capacity of non-malignant.  
The development of Glo1 inhibitors suggested by Vince and Wadd (Vince 
and Wadd, 1969) in 1969 appeared to provide a more effective alternative. 
Although Glo1 inhibitor derived from glutathione thioethers was developed in 
1969, it was lacking cell permeability and therefore could not reach Glo1 
receptors in the cells. Lo and Thornalley later produced a Glo1 inhibitor which is 
a cell permeable Glo1 inhibitor prodrug, S-p-bromobenzylglutathione diester, 
which delivered the active inhibitor S-p-bromobenzylglutathione into cells and 
had potent anti-tumour activity both in vivo and in vitro. The diesterification 
stabilised Glo1 inhibitors from degradation by ɣ-glutamyl transferase and 
provided pro-drug modifications which aid cell permeability and entry inside the 
cell (Lo and Thornalley, 1992, Thornalley, 1996).  Creighton and co-workers later 
developed more potent Glo1 inhibitors (Creighton et al., 2003). In 1974, 
Jerzykowski and co-workers  reported that Glo2 activity was absent or had very 




1975), with a re-evaluation of similar conclusion published in 1978 (Jerzykowski 
et al., 1978). 
In 2000, a notable relation between high expression of Glo1 in tumours 
and MDR in cancer chemotherapy was discovered by Sakomoto and colleagues. 
Further studies showed that tumours with high Glo1 expression are sensitive to Glo1 
inhibitors (Sakamoto et al., 2001, Sakamoto et al., 2000). Furthermore, recent 
studies shows Glo1 gene amplification is one of the causes to increase Glo1 
expression in some human tumours (Santarius et al., 2010). Recently, studies have 
shown that prevalence of increased GLO1 copy number and expression in human 
tumours negatively correlates to patient survival - reviewed in (Rabbani et al., 2018). 
Mechanism of elevated GLO1 copy number is thought to be through the activation of 


















Figure 21. The historical timeline of the glyoxalase system: from the 
discovery of the glyoxalase system in the last century until the 2010.  







2.2.2 Glyoxalase 1 and tumour growth 
Increased expression and activity of Glo1 in human tumours has been 
found in a several studies – reviewed in (Thornalley and Rabbani, 2011a). It has 
been proposed that Glo1 is an oncogene. However, overexpression of Glo1 
experimentally does not increase cell growth or malignancy in vitro nor in vivo. 
This suggests Glo1 is not an oncogene. In the non-malignant state, Glo1 act as 
tumour suppressor gene (Rabbani et al., 2018). Glo1 is likely increased in tumours 
to protect against increased flux of formation of MG associated with increased 
tumour glycolysis. Many tumours have elevated anaerobic glycolysis (Rabbani et al., 
2018). 
Hypoxia is a potential threat to tumour cell survival through dicarbonyl stress. 
Hypoxia normally induces down regulation of Glo1 expression through a putative 
hypoxia response element (HRE) in the GLO1 gene and stimulation of hypoxia-
inducible factor 1-alpha (HIF1α). Hypoxia may increase the flux of formation of 
MG, due to switching of cells to dependence on anaerobic glycolysis. Some 
tumours have, however, subverted this control and increase Glo1 expression in 
hypoxia (Rabbani et al., 2018). This metabolic limitation may in future be 
exploited for therapy using cell preamble Glo1 inhibitor in hypoxia altered 
tumours (Hutschenreuther et al., 2016, Takeuchi et al., 2010). 
 
2.2.3 Glyoxalase 1 and multidrug resistance  
The link between elevated Glo1 expression and anticancer drug resistance 
was first observed by a wide transcriptome-wide study of gene expression in cell 
line survival (Sakamoto et al., 2000). Several anti-cancer drugs are expected to 
increase cellular MG concentration as part of their cytotoxic effect. Later studies 
revealed that the cell permeable Glo1 inhibitor, S-p-bromobenzylglutathione 
cyclopentyl diester (BBGCp2), offered effective treatment for tumour cell line in 
vitro  and tumour bearing mice with Glo1 linked MDR (Hosoda et al., 2015, 
Santarius et al., 2010). Tumours with elevated Glo1 expression show a high 
sensitivity to short hairpin RNA knockdown of Glo1 in xenograft tumours 
primary culture from HCC cells. This may lead to an assumption that cell 




et al., 2014). The overexpression of Glo1 is likely to have a major impact on 
MDR in prevalent refractory tumours in clinical treatment (Rabbani et al., 2018). 
Furthermore, the overexpression of Glo1 may also predict the outcome of 
treatment, For instance study conducted in colorectal cancer showed that the 
increase of Glo1 protein evaluated by immunohistochemistry IHC was linked with 
rapid tumour progression and poor survival (Sakellariou et al., 2016). 
The overexpression of Glo1 may also contribute to ineffective treatment 
outcome in other type of treatment such as surgery and radiotherapy. This is due 
to the elevated level of Glo1 expression is permissive of increased glycolytic rate 
and growth of tumours. For instance, recent research on neuroendocrine tumours 
(NETs) showed the Glo1 expression acts as negative survival factor in patients 
treated by surgery (Xue et al., 2017). 
 
2.2.4 GLO1 gene copy number in cancer  
GLO1 copy number is one of the factors influencing the Glo1 expression 
(Santarius et al., 2010). The Thornalley group was the first to note the increased 
Glo1 expression and GLO1 copy number (gene copy number >2) in human 
tumours in 2010 (Santarius et al., 2010). In tumours, GLO1 DNA is elevated 
higher than gene duplication in healthy individuals (Redon et al., 2006). 
Furthermore, increased GLO1 copy number correlates with increased Glo1 
mRNA expression and protein in clinical tumours. In 225 human tumours of 
variable types, the top prevalence of GLO1 copy number increase was in: breast 
cancer (22%), sarcomas (17%) and non-small lung cancer (11%) (Santarius et al., 
2010). Additionally, several in vitro studies proposed that GLO1 copy number 
increase may play an important role in MDR (Rabbani et al., 2018).  
The mechanism of increase in GLO1 copy number is not fully understood. 
Insights were gained from mouse embryonic stem cell studies in hypoxia 
suggesting that low level Glo1 copy number was induced in hypoxia conditions 
(Shafie et al., 2016). It is proposed that during hypoxia histone demethylase 
KDM4A/JMD2A may mediate the increase in copy number of GLO1. The high 
level of demethylation is assumed to generate more open chromatin which 




proteins and DNA polymerases at the GLO1 locus and thereby produce 
replication and increase of GLO1 copy number (Black et al., 2013). Hypoxia 
activates KDM4A demethylation to possibly increase GLO1 copy number. There 
is a high expression of KDM4A in multiple tumours which also involved in 
metabolic reprogramming of increased tumour anaerobic glycolysis (Wang et al., 
2016). The high level of GLO1 copy number in early development of tumours 
may become dominant through clonal selection to MDR. Anticancer agents may 
also lead to an increase in MG concentration and enhance GLO1 copy number 
increase (Rabbani et al., 2018) - Figure 12. 
 
Figure 22. Suggested mechanism of GLO1 gene amplification. 
 From (Rabbani et al., 2018). 
 
2.2.4.1 GLO1 copy number variation 
In human subjects, GLO1 gene is found in chromosome 6 at locus 6p21.2 
(Tripodis et al., 1998). Gene cloning method revealed that human GLO1 coding 
region comprises of 12kb with introns splitting six exons (Ranganathan et al., 
1999, Gale and Grant, 2004). Copy number variation (CNV) of GLO1 was first 




around the world. They found 1447 CNV regions were establish covering only 
12% of the human genome. There was only five subjects with copy number 
increase, suggesting a GLO1 duplication prevalence of approximately 2% (Redon 
et al., 2006). Latter studies confirmed GLO1 CNV in the human population and 
other primates (Wong et al., 2007, Perry et al., 2008). 
In mouse, Glo1 is found in chromosome 17 at locus 17a3.3, almost 3cM 
from Ss locus of the H-2 histocompatibility region (Meo et al., 1977). Murine 
Glo1 was initially reported among inbred mice strains. The CNV was categorised 
as 475 kb tandem duplication on chromosome 17 (30174390–30651226) which 
involved Glo1 copies and other gene copy partly (Williams et al., 2009). Latter 
reports found Glo1 CNV as part of genome–wide study. Studying the CNV 
content to sub-10-kb resolution, more than 1300 regions of CNV were found in 
sapping 3.2% of the genome. The majority of CNVs mapped outside of the 
transcribed regions of genes. Approximately 600 CNVs were linked with gene 
expression changes with only three genes were found with high expression 
(Schrider and Hahn, 2010). GLO1 was one of these genes with functional CNV 
increase in all tissues tested – haematopoietic, hypothalamus and adipose tissue 
(Schrider and Hahn, 2010, Cahan et al., 2009, Xue et al., 2011).  
 
2.2.4.2 Methods of measurement of gene copy number 
CNVs discovery was one of the result of the new genomic technologies 
which have enabled a high resolution of Genomic DNA analysis. There are 
different methods can be used to detect CNVs, both at locus specific level or 
genome wide scale. The primary genome wide scale screening approach involves 
array comparative genomic hybridization (aCGH), fluorescence in situ 
hybridisation (FISH), next generation sequencing and single nucleotide 
polymorphism. Moreover, the primary approach in locus specific methods consist 
of multiplex ligation dependent probes amplification (MLPA), paralogue ratio test 







2.2.5 Anticancer activity of methylglyoxal  
The cytotoxicity of increased cellular MG was investigated by inhibiting 
Glo1 expression by siRNA silencing of Glo1, by the addition of cell permeable 
Glo1 inhibitor and addition of exogenous MG (Rabbani et al., 2018).The use of 
exogenous MG has its drawbacks as it offers a steep negative concentration from 
the outside to the inside of the cells. Furthermore, commercial MG often used by 
some investigators contains formaldehyde and other compound contamination 
(Pourmotabbed and Creighton, 1986, Rabbani and Thornalley, 2014c). 
Studying the changes occuring early in the time course of cytotoxicity under 
MG concentrations is important to understand the key process mediating MG 
inhibition of cell growth in tumours (Rabbani et al., 2018). Research conducted on 
human leukaemia 60 (HL60) cells in vitro shows their commitment to death occurs at 
primarily one point of cell cycle growth (Ayoub et al., 1993). Additionally, analysis 
of cell cycles treated with MG showed by 12 hour there is an increase formation 
of cells G0-G1, low number of S-phase and apoptosis induction. This is suggest that 
cells are commit to death and arrested at the S-phase entry and DNA synthesis is 
inhibited (Ayoub et al., 1993). Time courses experiment using [14C]MG revealed 
adduct formation of protein, DNA and RNA. MG adducts with DNA is elevated 
shortly after 2 hours (Ayoub et al., 1993). 
Addition of exogenous MG, Glo1 siRNA silencing and cell preamble Glo1 
inhibitor initiate tumour cells apoptosis under concentration-response limited 
conditions – using MG concentrations close to the median toxic concentration 
TC50 (Kang et al., 1996, Thornalley et al., 1996, Santarius et al., 2010). High 
concentrations of MG induced necrosis in tumour cells (Du et al., 2000) – Table 
4. Key factors are:  reduction of the mitochondrial membrane potential, initiation 
of mitochondrial apoptotic pathway with release of cytochrome c into the cytosol; 
activation of cascapase-3 and cascapase-9 and decreased anti-apoptotic factors, 
and growth at entry into the S-phase of the cell cycle. 
It is likely that MG initiate mitochondrial apoptotic pathway by modifying 
a high conductance channel protein known as mitochondrial permeability 
transition pore protein (MPTP).  Elevated level of MG-H1 residues production by 




and swelling, cytochrome c release (Speer et al., 2003). In the downstream, 
caspase -3 and casapase-9 are activated and interact with XIAP, Bcl-xL and BCL2 
(Czabotar et al., 2014). Activation of Chk1, Chk2 and ATM kinases may be in 
response to DNA damage induced by MG modification (Rabbani et al., 2018). 
MGdG is known to be the major adducts from MG which converted DNA to a 
single strand breaks (ssDNA). Coating of ssDNA occurred rapidly by ssDNA-
binding protein replication protein A (RPA). As result of DNA damage, Chk1/2 
and other proteins intra-S-phase proteins are activated which causes replication 
delay (Tapia-Alveal et al., 2009). Once DNA damage is too high for repairing 
procedures, DNA undergoes stall replication termed as “replication catastrophe” 















Table 4. Mechanism of methylglyoxal induced cell death from  
(Rabbani et al., 2018) 
Cell type [MG] 
(µM) 
Characteristics References 









GC50: 282 μM. 24 h exposure period required for growth inhibition and toxicity. 
Growth inhibition increased with medium serum content (growth rate).  
Apoptosis. Growth inhibition linked concentration-dependently to inhibition of DNA 
synthesis; early decrease in S-phase cells. Protein adducts maximized at 30 min and 
DNA adducts at 1 h. 







1,000 Activates mitochondrial apoptotic pathway potentiated by Glo1 silencing (Brownlee, 2005) 
HEK393 cells 400 & 
800 
Activation of ATM-Chk1 and Chk2 kinases, p38 kinase, MAPK and ASK1-JNK, 
kinase pathways. 










Apoptosis (250 μM) with necrosis (500 μM). JNK and caspase-3 driven apoptosis (Paraskevas et al., 
2008) 
Jurkat cells 250 MG-induced activation of caspase-3 and caspase-9, release of cytochrome c, decline 
of mitochondrial membrane potential and JNK activation 
(Preshaw et al., 
2007) 




MG suppressed the expression of anti-apoptotic factor XIAP, survivin, cIAP1, Bcl-2, 
and Bcl-xL. Potentiated TRAIL apoptosis. GLO1 siRNA had the same effect. 
























Growth inhibition, decreased invasiveness and tubule formation, MAPK activation 
and decreased Bcl-2 at ≥ 800 μM MG, increasing apoptosis; decreased cell migration 
at 400 μM ; decreased colony formation at 100 – 200 μM. GLO1 siRNA had the 
same 
effect. 





Thus, cell death induced by MG involves both the mitochondrial and DNA 
damage activated apoptotic pathways. Decreased angiogenesis may also occur due 
to MG modification to of extracellular matrix (ECM) proteins and blockage of 
integrin migration (Dobler et al., 2006, Ahmed et al., 2008). MG modification of 
ECM protein induced cell detachment which result in cell detachment-activated 
cell death where apoptosis is activated extrinsic pathway termed anoikis. The 
missing contact of ECM results in death receptor activation and the intrinsic 
pathway-mitochondrial apoptotic pathway (Paoli et al., 2013). 
A study by Oya and colleagues revealed the ability of MG to modify heat 
shock protein HSP27 (Oya et al., 1999). Heat shock protein has anti-apoptotic 
activity in the mitochondrial apoptotic pathway. MG modification may result in 
HSP27 suppression effect in the apoptotic pathway of the mitochondria. It is 
thought that this modification is caused by argpyrimidine but this is unlikely 
because argpyrimidine is minor MG derived AGE (Rabbani et al., 2018). Current 
study by Thornalley group suggest that MG-modified protein using direct 
detection with high resolution  mass spectrometry, MG-H1 residues modify 
HSP27 at arg-188 in cell proteins incubated with exogenous MG not 
argpyrimidine out of 344 protein modified in the cell cytosol (Rabbani and 
Thornalley, 2014). Cytotoxic mechanism through MG accumulation in tumour 











Figure 23. Mechanism of cytotoxicity of cell permeable  Glo1 inhibitor 
through cellular accumulation of methylglyoxal in tumour cells.From 





2.2.6 Cell permeable glyoxalase 1 inhibitors as anticancer agents 
Vince and Wadd was the first scientists to propose Glo1 inhibitors. This 
was based on substrate analogues, glutathione S-thioethers such as S-p-
bromobenzylglutathione (Naguib et al., 2004, O'Connell et al., 2008). This 
inhibitor lacked effectiveness because it was not permeable to the plasma 
membrane in tumour cells and lack stability to degradation by cell surface γ-
glutamyl transpeptidase. Thornalley and colleagues produced a cell preamble 
Glo1 inhibitor prodrug by diesterifying S-p-bromobenzylglutathione. The 
deesertification prevented the extracellular degradation and provided a key 
solution species that was membrane permeable: the unprotonated S-p-
bromobenzylglutathione diester. Once inside cells, the prodrug was de-esterified 
by cellular non-specific esterase. This produced the active inhibitor, S-p-
bromobenzylglutathione, in the cell cytosol where it can access the receptor, Glo1. 
To date, the most potent diester derivative is the cyclopentyl diester, BBGCp2, 
which can resist hydrolysis by serum of plasma esterase prior delivery into cells 
(Iacopino, 2001). More potent Glo1 inhibitor were developed by Creighton and 
co-workers (Cohen, 2002). Several studies found potent cytotoxicity to tumour 
cell lines by using Glo1 SiRNA silencing (Cohen, 2002). This leads to an increase 
in cellular and extracellular level of MG which induces apoptosis and anoikis 
(Dauphinee and Karsan, 2005). This suggests that the Glo1 inhibitor is likely 
producing antitumor activity by on-target effects. 
Although BBGCp2 achieved good efficacy of treatment in tumour-bearing 
mice, the dose required for potent therapeutic effect were high 50 – 200 mg/kg. 
However, at these doses, BBGCp2 does not have toxicity other than to the tumour. 
Other Glo1 inhibitor diester prodrugs had off-target effects and were toxic at 
effective doses (Covert, 2005, Patil et al., 2006, Jönsson et al., 2011). High dose 
requirement is due to the rapid metabolism and excretion of inhibitors (Sakamoto 
et al., 2001). This may not be so in human subjects as mice have much higher 
plasma esterase than human subjects (Sharkey et al., 2000). 
MG may also be metabolised by aldoketo reductase isozymes 1A4, (aldose 
reductase), 1B19 and AKR isozymes to mainly hydroxyacetone (Rabbani and 




may be over-activated in some tumours. This will lead to high capacity of MG 
metabolism by AKR in some tumour such as squamous cell carcinomas (SCCs) 
adenocarcinomas that has somatic alteration in Nrf2 pathway (Rabbani and 
Thornalley, 2012a). 
Surveying the antitumor activity of BBGCp2 has shown that some tumour cell 
lines are sensitive to Glo1 inhibitor and others are resistance. The lack of a 







2.3 Aim and objectives of this project 
2.3.1 Aim  
To characterise the dicarbonyl proteome involved in MG induced 
cytotoxicity and its role in cancer chemotherapy. 
2.3.2 Objectives 
Objective 1. To study Glo1 bioinformatics cancer cell lines and primary 
tumours. 
To achieve this objective, I will access bioinformatics databases on Glo1 
expression and copy number in human tumour cell lines and primary tumours. 
The Cancer Cell Line Encyclopaedia (CCLE) is a database of gene expression and 
gene copy number estimates for 1040 human tumour cell lines 
(https://portals.broadinstitute.org/ccle). I will studied factors linked to Glo1 
expression. I will access the KM plotter database of human tumour gene 
expression and patient survival outcomes to investigate the role of Glo1 
expression on patient survival and its effect in different chemotherapy and 
genotypic characteristics.  http://kmplot.com/analysis/ 
 
Objective 2. To study methylglyoxal modification of proteins involved in 
methylglyoxal induced tumour cell death in vitro. 
To achieve this objective, I will study changes in MG-modified proteins 
and unmodified proteins in HEK239 cells exposed to cytotoxic concentrations of 
MG. Changes in dicarbonyl proteome and unmodified proteome critical to MG 
induced cell death will be identified. An example of an MG-modified proteins 
likely critical to MG induced cell death is mitochondrial permeability transition 
pore (MPTP). These MG-modified proteins will be taken as biomarkers of MG-
induced cytotoxicity.  
Human embryonic kidney 293 (HEK-293) cells are widely used for 
transfection studies for overexpression a gene of interest (Rabbani and 
Thornalley, 2008a, Kavsan et al., 2011). This cell line generated first by Graham 
et al. with transformation of cells produced by human adenoviruses type 5 DNA 
(Thornalley and Rabbani, 2011b). HEK-293 cells are tumorigenic where 




chromosome instability. They proliferate fast in vitro.  A successful example of 
Glo1 transfection of HEK-239 cells to overexpress Glo1 mRNA in vitro was 
performed by Hutschenreuther et al. and compared to mock-transfected cells.  
 
Table 5. Medium growth inhibtory concentration GC50 values of selected 
anticancer drugs in HEK-293 cells in vitro. 
Anticancer drug  GC50  HEK-293 (µM) Reference 
Mechlorethamine  300 ± 9 (Hardej and Billack, 2007) 
Methotrexate  
  
45.4 ± 6.9 (Patel and Patel, 2011) 
Doxorubicin  16.7 ± 0.7 (Dakin and Dudley, 1913) 
Cisplatin  5.43 ± 0.72 (Akiyode et al., 2016) 
 
 
2.3.3 Study hypotheses 
The hypotheses of this study are: 
1. Increased Glo1 expresion is a negative survival factor for patients with 
breast cancer. 
2. Changes in protein abundance and modification by methylglyoxal linked to 
key pathways of cell proliferation activate the mitochondrial pathway of 













3 Materials and Methods 
3.1 Materials 
3.1.1 Cells and tissues  
Human embryonic kidney – 293 (HEK-293) cell line was purchased from 
American Type Culture Collection (ATCC), Manassas, VA 20110, USA. 
 
3.1.2 Cell culture reagents  
Foetal bovine serum (FBS) and Dulbecco’s Modified Eagles Medium 
(DMEM) were purchased from Thermos Fisher (Paisley, UK). 
Penicillin/streptomycin solution (10,000 U/ml penicillin with 10 mg/ml 
streptomycin) in 0.9% (w/v) sodium chloride solution. Tissue culture grade 
dimethylsulphoxide (DMSO) and dimethylformamide (DMF) were purchased 
from Sigma-Aldrich (Poole, Dorset, UK). Cell culture grade plastic polystyrene 
T75, T25 and flasks was purchased from Fisher Scientific (Loughborough, UK). 
Trypan blue stain (cat. no. 302643) was purchased from Sigma Aldrich (Poole, 
Dorset, U.K.). 
 
3.1.3 Enzymes and other reagents 
Proteases, peptidases, D-lactic dehydrogenase and other enzymes were 
purchased from Sigma-Aldrich. D-Lactic dehydrogenase (EC 1.1.1.28), 
lyophilised powder, was from Staphylococcus epidermidis and had activity of ≥ 
80 units/mg protein. Pepsin (EC 3.4.23.1) was from porcine stomach mucosa with 
a specific activity of 3460 units/mg protein (1 unit hydrolysed haemoglobin with 
an increase in A280 of 0.001 AU per min of trichloroacetic acid-soluble products, 
at pH 2 and 37 oC); prolidase (EC 3.4.13.9) was from porcine kidney and had a 
specific activity of 145 units/mg protein, where 1 unit of activity hydrolyses 1.0 
μmol of Gly-Pro per min, at pH 8 at 40 oC; leucine aminopeptidase (EC 3.4.11.2), 
type VI, was from porcine kidney microsomes with a specific activity of 22 
units/mg protein (1 unit of activity hydrolysed 1.0 mol of L-leucine-p-nitroanilide 
to L-leucine and p-nitroaniline per min at pH 7.2 and 37 oC);  and pronase E (EC 




activity of 4.4 units/mg protein (1 unit of activity hydrolysed casein forming 1.0 
mmol of tyrosine per min at pH 7.5 and 37 oC). 
Trypsin/ethylenediaminetetra-acetic acid (EDTA) solution (porcine 
pancreas-derived trypsin 0.25% w/v EDTA 0.02 w/v) was acquired from 
Invitrogen Life technologies (Paisley, Scotland, UK). 
 
3.1.4 Antibodies  
All the antibodies were purchased from Abcam PLC for western blotting 
experiments. The antibodies used are: rabbit anti-β-actin polyclonal IgG (cat. no. 
ab8227), rabbit anti-aldose reductase polyclonal antibody (cat. no. ab62796), 
rabbit anti-DEAD-Box helicase 5 (DDX5) monoclonal antibody (cat. no. 
ab128928), rabbit anti-Glo1 monoclonal antibody (cat. no. ab137098), rabbit anti-
splicing factor U2AF 65 kDa subunit (U2AF65) polyclonal antibody (cat. no. 
ab37530) and goat anti-rabbit IgG, heavy and light chain, horseradish peroxidase 
(HRP) conjugate secondary antibody (cat. no. ab6721). Human cytochrome c 
ELISA kit was purchased from Oncogene Research Products (San Diego, CA, 
USA). 
 
3.1.5 Other analytical reagents  
All the following reagents were purchased from Fisher scientific (all 
HPLC grade): tetrahydrofuran (THF), acetonitrile, methanol, isopropanol (IPA) 
and trifluoroacetic acid (TFA, ≥ 99% HPLC grade). Trifluoroacetic acid (TCA, 
BioUltra, ≥ 99.5%), formic acid (FA, ≥ 98%), glycine, reduced glutathione 
(GSH), aminoguanidine hydrochloride (cat. no. 369494), nicotinamide adenine 
dinucleotide, oxidised form, (NAD+; cat. no. N6522), pyruvate (cat. no. P2256), 
D-lactic acid (cat. no. L0625) were purchased from Sigma Aldrich. Methylglyoxal 
(MG) for cell culture was prepared by the hydrolysis of methylglyoxal 
dimethylacetal in dilute sulphuric acid and purified by fractional distillation under 
reduced pressure, as previously described (McLellan and Thornalley, 1992b). 
Bovine serum albumin, triton-X100, diethylenetriaminepentaacetic acid 
(DETAPAC), tween-20, hydrochloric acid (analytical grade, 1 N; HCl) (cat. no. 




inhibitor cocktail (cat: 10720825) and HaltTM phosphatase inhibitor cocktail (cat: 
10668304) were purchased from Fisher Scientific. 10 x RIPA lysis buffer (cat. no. 
20-188) (0.5 M Tris-HCl, pH 7.4, 1.5 M NaCl, 2.5% deoxycholic acid, 10% NP-
40, 10 mM EDTA) was purchased from Millipore, UK.  The 10 x premixed 
electrophoresis Tris-glycine buffer (cat. no. 1610732; 1 x dilution contains 25 mM 
Tris, 192 mM glycine, pH 8.3), 10 x Tris-buffered-saline TBS (cat. no. 1706435 ; 
1 x dilution gives 20 mM Tris, 500 mM NaCl, pH 7.4), Criterion™ TGX™ stain-
free gel 4–20 % precast polyacrylamide gel (cat. no. 3450412, 3450418, 
3450426), Trans-Blot® Turbo™ PVDF pre-cut blotting transfer pack (cat. no. 
1704157), including filter paper, buffer, polyvinyl difluoride (PVDF) membrane 
for use with Trans-Blot Turbo transfer system (cat. no. 1704155) were purchased 
from Bio-Rad (Hertfordshire, UK). Photographic film was purchased from GE 
Healthcare (Little Chalfont, UK). SpectroTM multicolor broad range protein ladder 
(10-260 kDa, for 4 – 20 % Tris-glycine SDS-PAGE), enhanced 
chemiluminescence (ECL) reagent kit (cat. no. 32106) and sodium dodecyl 
sulphate (SDS) (cat. no. 28312B) were purchased from Fisher Scientific. 
 BCA protein assay was purchased from Fisher Scientific. Bradford assay 
and dye reagents (cat. no. 5000201) were purchased from Bio-Rad. EZQ TM  
protein quantitation kit, PicoGreenTM dsDNA quantitation reagent and ProLong™ 
Gold Antifade Mountant with DAPI were purchased from Invitrogen (Paisley, 
Scotland). 
HPLC vials, caps, insets, microspin filters “Spin-X”, Microplate U bottom 
polystyrene 96-well SterilinTM plates were obtained from Fisher Scientific. 
Amicon ultrafiltration microcentrifuge tubes including filters (10k Da, 3kDa cut-
off) from Merck-Millipore (Watford, UK). 
 
3.1.6 Chromatographic materials  
For the proteomics studies, an Acclaim PepMap ODS µ-precolumn 
cartridge, 5 μm particle size, 100 Å pore size chromatography column, 300 µm 
i.d. x 5 mm, was used. For protein glycation adduct measurement by LC-MS/MS, 




2.1 mm x 250 mm) were used. These were purchased from ThermoFisher 
Scientific (Renfrew, Scotland). 
 
3.1.6.1 Analytical and preparative kits  
3.1.6.2 Calibration standards for protein glycations nitration oxidation 
adducts  
Protein damage adduct analytical standards were prepared in house by host 





2H3]-L-methionine were all >98% isotopic purity 




prepared by host research team from [guanidino-15N2]-L-arginine as described. 
[13C6]CML, [
13C6] CEL and [
13C6] pentosidine were prepared from [
13C6]-L-lysine 
after conversion to the Nα-formyl derivative. All methods for synthesis, 
purification and characterisation of the AGE analytical standards have been 
described previously (Ahmed et al., 2003). 
 
3.1.7 Instrumentation  
Enzymatic hydrolysis was performed automatically using a CTC-PAL 
Automation System (CTC-Analytics, Zwingen, Switzerland). The centrifugal 
evaporator was a Savant Instruments SpeedVac (Thermo Scientific, Waltham 
MA). For (LC-MS/MS) analysis, two different instrumentation systems were used 
from Waters (Manchester, U.K.): 1. AcquityTM UPLC system with a Quattro 
Premier XE tandem mass spectrometer; 2. AcquityTM UPLC system with a Xevo-
TQS tandem mass spectrometer. 
For cell counting, a Neubauer haemocytometer was used (cat. no. 
0630410, Marienfeld-Superior, Paul Marienfeld GmbH & Co. KG, Lauda-
Königshofen, Germany). A Nikon Eclipse TE2000-S inverted microscope 
(Kingston-Upon-Thames Surrey, U.K.) was used to visualise and count cells. For 
microplate spectrophotometry and fluorimetry, a FLUOstar OPTIMA microplate 




Vibra-Cell sonicator was used to disrupt cells (Jencons Scientific, Leighton 
Buzzard, UK). For membrane-gel transfer and western blotting, Criterion™ Cell 
electrophoresis chamber (Model no. 1656020), Trans-Blot® Turbo™ Transfer 
System (Model no. 170-4155) and PowerPac™ Basic Power Supply (Model no. 
164-5050) were used (Bio-Rad). For visualising extrachromosomal DNA staining 
an EVOS M5000 Imaging System - a fully integrated digital inverted microscope 
for four-color fluorescence, transmitted-light and color applications, was used 
(ThermoFisher Scientific). 
 
3.1.8 Software  
Optima software version 2.10 R2 (BMG Labtech) were used for microplate 
assays. For non-linear regression of viable cell number-MG concentration data to 
a dose-response curve, the ENZFITTERTM program was used (Biosoft, 
Cambridge, U.K.). For quantification of protein bands in western blotting, 
ImageQuant densitometry software was used (GE Healthcare Life Sciences, 
Amersham, U.K.). For instrumentation control and data processing from stable 
isotopic dilution analysis LC-MS/MS, MasslynxTM software, version 4.1, was 
used (Waters, Manchester, U.K). For the proteomics analysis, raw data was 
processed using Proteome Discoverer (version 1.4.0.288, Thermo Scientific), 
ScaffoldTM version 4.4.3 (Proteome Software, Portland, Oregon, USA) and 
Progenesis QITM (Nonlinear Dynamics, Newcastle upon Tyne, U.K.) SEQUEST 
and Mascot engine were used for Molecular ion fragmentation mass spectra, MS2 
search against human data proteins database. http://www.uniprot.org. For 
statistical analysis IBM SPSS were used. 
 
3.2 Bioinformatics methods 
3.2.1 Cancer bioinformatics database CCLE 
Data on gene copy number and expression in human tumour cell lines 
were extracted from the Cancer cell line encyclopaedia (CCLE) database 
(https://portals.broadinstitute.org/ccle). The CCLE project is an effort to conduct a 
detailed genetic and transcriptomic characterization of a large panel of human 




DNA copy number, mRNA expression, mutation and other data for 1040 cancer 
cell lines. Herein the full dataset and breast cancer cell line subset are analysed. 
The data, log2 transformed gene copy number and RNA seq data, were 
downloaded. Correlation analysis was performed using the R program and 
Pearson correlation analysis performed on mRNA copy number expressed as 
Reads Per Kilobase Million (RPKM). Data for 10758 genes was available. 
Pearson correlation analysis was performed to assess association of Glo1 
expression with genes and also GLO1 copy number with Glo1 expression. A 
Bonferroni correction of 10758 was applied. 
 
3.2.2 Pathway enrichment analysis tool. 
For the pathway enrichment analysis in transcriptomic and proteomic 
datasets, pathways analysis was performed using Database for Annotation, 
Visualization and Integrated Discovery (DAVID ) v6.8 
(https://david.ncifcrf.gov/). Protein ontology was evaluated using the molecular 
functions and biologic processes that may be impacted by changes in protein 
abundance and MG modification. Kyoto Encyclopedia of Genes and Genomes 
(KEGG) database was used https://www.genome.jp/kegg/ and  for pathways 
analysis and INTERPRO analysis was performed 
(https://www.ebi.ac.uk/interpro/)  and for enrichment of protein domains modified 
by MG. Pathway and domain enrichment was considered significant with 
Bonferroni significant and false positive discovery rate (FDR) of <0.05. 
3.2.3 Kaplan-Meier survival analysis database 
The Kaplan Meier plotter analysis tool was used for the analysis of the 
impact of selected gene on survival from 10,461 cancer samples in the KM Plotter 
database of gene transcription and cancer patient survival database, classified by 
treatment and, for breast cancer, major genotypes (http://kmplot.com/analysis/). 
Data on 5142 breast cancer patients, treatment and survival outcomes are 
available to be analysed against the gene of interests. The effect of target gene 
expression, as judged by mRNA level, on breast cancer patient survival was 
analysed in 3591 patients with full datasets available. Genes of interest were: 




nuclear factor erythroid 2-related factor 2 or Nrf2 (NFE2L2), kelch-like ECH-
associated protein 1 (KEAP1), receptor for advanced glycation endproducts 
(RAGE) and lysine demethylase 4A (KDM4A) – known or suspected genes 
functionally or regulatedly linked to Glo1. Types of cancer patient treatment and 
tumour genotype classification were: chemotherapy, endocrine therapy, systemic 
untreated, systemic treated, endocrine therapy, excluding endocrine therapy; any 
chemotherapy, endocrine therapy - including all chemotherapy; tamoxifen 
treatment only; tamoxifen including all chemotherapy; tamoxifen treatment only 
as adjuvant therapy; and tamoxifen only as neoadjuvant therapy. Output variables 
were: Number of patients, Hazard ratio and median survival (months) for 
low/high gene expression cohorts, and Logrank P value. Data analysis was 
restricted to patient sample size of ≥ 200 patients for statistical power.  
 
3.3 Cell Culture 
  HEK293 cells for experiments were cultured under aseptic conditions at 37 
oC, under air with 5% CO2 and 100 % humidity. Seeding density was 1.5 x 10
6 cells 
per T75 cm2 flasks containing Dulbecco’s Modified Eagles Medium (DMEM) with 
25 mM glucose, 4 mM L-glutamine, 10 % (v/v) FBS and 100 U/ml penicillin/0.1 
mg/ml streptomycin. Cells were cultured until 80 - 90% confluent for 
approximately 3 - 4 days incubated. All cells culture experimentations were 
performed after passage 3, unless stated otherwise. For cell passage, cultured cells 
were trypsinized, sedimentation by centrifugation and cell viability assessed by the 
Trypan blue exclusion method and cell number counted.  
 
3.3.1 Cell culture experiments  
3.3.2  Assessment of cell viability  
HEK293 cells were seeded in 6-well plates (20,000 cells/cm²) in triplicate 
in DMEM media containing 25 mM of glucose and cultured for four days. Total 
viable cells number was counted and cell viability assessed using the Trypan blue 





3.3.3 Effect of methylglyoxal on the growth and viability of HEK293 cells in 
vitro: growth curve 
HEK293 cells were cultured in 12 well plates containing DMEM media 
with 25 mM glucose concentration; seeding density 20,000 cells/cm². Cells were 
incubated for 24 hours for cells to adhere then 200 µM MG was added. Viable cell 
number and cell viability of control and MG-treated cultures was determined 
every day for 4 days. 
 
3.3.4 Effect of methylglyoxal on the growth and viability of HEK293 cells in 
vitro: concentration-response curve 
HEK293 cells were cultured in 12 well plates containing DMEM media 
with 25 mM glucose concentration; seeding density 20,000 cells/cm². Cells were 
incubated for 24 hours for cells to adhere then MG, 15, 50, 100, 150, 300 and 400 
µM added; cells were incubated without added MG for control. Cells were 
cultured for 2 days and then viable cell number and cell viability determined. Data 
were fitted to a concentration response curve: 
V = 100 × GC50
n / (GC50
n + [MG]n) 
where V is viable cell number (% of control), [MG] the concentration of added 
exogenous MG, GC50 - the median growth inhibitory concentration value of MG; 
and n - the logistic regression coefficient. Experimental data of V and [MG] were 
fitted by non-linear regression of V on [MG] using ENZFITTER software to solve 
for GC50 and n the logistic regression coefficient. 
 
3.4  Analytical methods 
3.4.1 Bradford Assay for total protein measurements 
Protein concentration of cell lysate were measured using Bradford protein 
assay (Bradford, 1976, Compton and Jones, 1985). Bovine serum albumin stock 
solution calibrated using UV absorption spectrophotometry at wavelength 279 nm 
using the extinction coefficient for a 1% (10 mg/ml) solution; ε279 (1%) = 6.9 cm
-1 
(Peters, 1962).  Aliquots BSA standards and tests samples (20 µl) were loaded in 




measured at 595 nm absorbance and the concentration in tests samples was 
deduced by interpolation on calibration curves. 
 
3.4.2 BCA Assay  
For western blotting studies, the detergent compatible BCA assay were 
used to measure protein concentrations in extracts of HEK293 cells containing 
RIPA buffer. It is a colorimetric assay for proteins solubilised in detergents based 
on similar chemistry to the Lowry protein assay. 
 
3.4.3 EZQ Assay  
The EZQ protein assay is used for high sensitivity protein assay in 
solutions containing detergents. It was used herein to assay protein content in 
mitochondrial fractions prior to proteomics analysis. In the commercial kit 
provided the calibration standard is ovalbumin. The standards were prepared in a 
range of 0.02–5 mg/ml. Volumes of 1 µl of both standards (0.05 – 5 µg protein) 
and samples were spotted in the EZQ microplate and fluorescence measured at 
wavelength 450 nm. Protein concentration was deduced by interpolation on 
calibration curves plotted from measurement of calibration standards. 
 
3.4.4 Enzyme activity 
3.4.4.1 Sample preparation 
HEK293 cells were cultured as described above. Followed by 
trypsinisation, cells were counted and sedimented by centrifugation (250g, 5 min). 
Cell pellets (ca. 1.5 x 10⁶ cells) were washed three times with phosphate-buffered 
saline (PBS; 10 mM, pH 7.0, 200 μl). Cells were then sonicated on ice (110 W, 30 
s). Cell membranes were then sedimented by centrifugation (20,000 g, 30 min, 4 
oC). The supernatant was retained and stored at -80 oC for later use as lysate in 
enzymatic activity assays. 
 
3.4.4.2 Glyoxalase 1 
Glo1 activity is determined by measuring the initial rate of formation of S-




MG and GSH. The reaction is followed spectrophotometrically at 240 nm; Δε240 = 
2.86 mM-1cm-1 (Allen et al., 1993b). 
 
The preparation of hemithioacetal was made using the pre-incubation of 
MG (2 μmol) with GSH (2 μmol) at 37 °C for 10 min in sodium phosphate buffer 
(50 mM, pH 6.6, 980 μl). An aliquot of cell lysate (20 μl) was added and 
absorbance were measured at 240 nm over the initial 5 min. Glo1 activity were 
deduced from the initial increase in absorbance, corrected for the blank change 
using lysate buffer only. Glo1 activity is measured in units per mg protein where 
one unit of Glo1 activity catalyses the formation of 1 μmol S-D-lactoylglutathione 
from the hemithioacetal substrate per minute under assay conditions (Allen et al., 
1993b). It is possible to assay Glo1 activity in the presence of Glo2 because the 
high concentration of MG-GSH hemithioacetal used inhibits the activity of Glo2 
in the assay solution mixture (Uotila, 1973). 
 
3.4.4.3 Glyoxalase 2 
Glo2 activity is determined by measuring the initial rate of S-D-lactoyl-
glutathione hydrolysis to GSH and D-lactate. This hydrolysis reaction is followed 
spectrophotometrically at 240 nm for which 240 = - 3.10 mM
-1cm-1 (Clelland 
and Thornalley, 1991, Allen et al., 1993a). The S-D-lactoylglutathione is 
incubated in Tris/HCl (50 mM, pH 7.4, 850 µl) at 37 oC. An aliquot of cell lysate 
is added (50 μl) and the absorbance followed at 240 nm for 5 min at 37 oC. The 
initial rate of change in absorbance is deduced and activity of Glo1 calculated in 
units where one unit of the Glo2 activity is the amount of enzyme required to 
hydrolyse 1 µmol of S-D-lactoylglutathione per minute under assay conditions 
(Allen et al., 1993b).  
 
3.4.4.4 Assay of D-lactate  
The determination of the flux of formation of D-lactate by HEK293 cells 
line is performed by measuring the concentration of D-lactate in culture media at 
the baseline and the end of the culture time. D-Lactate equilibrates across the cell 
plasma membrane by the inorganic anion exchange system, specific lactate 
           Glo1 




transporter and by non-ionic passive diffusion  (McLellan and Thornalley, 1992a) 
and therefore cellular flux of D-lactate may be estimates from measurement of D-
lactate in the culture medium. The measurement used is an end-point enzymatic 
assay with fluorometric detection  (McLellan et al., 1992b). The conversion of D-
lactate to pyruvate is catalysed by added D-lactic dehydrogenase enzyme during 
the assay reaction incubation time at 37 oC. The formation of NADH is 
determined by fluorescence (excitation = 340 nm, emission = 460 nm). 
 D-Lactate + NAD+                                  pyruvate + NADH 
Samples are initially deproteinized by adding ice-cold perchloric acid 
(PCA; 1 ml, 0.6 M) to the culture medium. Samples are vortex mixed and 
incubated on ice for 10 min to achieve complete precipitation. Samples are then 
centrifuged (7000 g, 4 oC, 5 min) to sediment the protein precipitate. Afterwards, 
the supernatant is removed and neutralised to pH 7 with potassium bicarbonate 
(200 µl, 2 M), mixed and centrifuged again (7000 g, 4 oC, 10 min) to sediment the 
precipitate of potassium perchlorate. The resulting supernatant is removed and has 
become saturated with CO2 formed in the neutralisation reaction. Samples are 
degassed using a centrifugal evaporator at room temperature, applying reduced 
pressure (20 mmHg) for 5 min. For D-lactate assay, aliquots of degassed extract 
(100 µl) are added to wells of black 96-well microplates for both assay and blank 
correction (assay mixture without added D-lactic dehydrogenase). Calibration 
standards D-lactate are prepared similarly. The assay mixtures contains NAD+ (4 
mM, 25 µl) and glycine hydrazine buffer (100 µl; 1.2 M glycine, 0.5 M hydrazine 
hydrate, 2.5 mM DETAPAC, pH 9.2). The reaction is initiated with the addition 
of D-lactic dehydrogenase enzyme to test samples (25 µl, 250 units per ml) and 
water to blanks, followed by an incubation of 2 h at 37 oC in the dark. NADH 
fluorescence is then measured at λexcitation 340 nm and λemission 460 nm. A standard 















Figure 24. Calibration curve for assay of D-lactate.  
Calibration equation: Fluorescence = (3662 ± 374) x [D-lactate (nmol)] + 2048.5 
± 393 (N= 18); R² = 0.998. 
3.4.4.5 Assay of L-lactate  
Net formation of L-lactate in HEK293 cultures was measured similarly to D-
lactate – see above. L-Lactate standards was used to generate the standard curve 
and instead of using D-lactic dehydrogenase, L-lactic dehydrogenase was used for 
this assay. The L-lactate concentration in culture medium is higher than D-lactate 
and therefore samples were diluted 10 time to ensure sample response was within 


















































































 Calibration equation: Fluorescence = (6255 ± 399) x [L-lactate (nmol)] (n= 12); 
R² = 0.98. 
 
3.4.5 Western blotting for selected proteins  
Selected proteins found to be up-regulated and downregulated by MG 
from proteomics studies were investigated for attempted corroboration of change 
by western blotting. 
 
3.4.5.1 Sample preparation  
HEK293 cells were cultured in medium containing 25 mM glucose with 
and without added exogenous MG. HEK293 were left first to adhere for 24 h and 
incubated with and without 131 µM MG for 6 h. Following this incubation, cells 
were trypsinsed and sedimented by centrifugation. Cell pellets are then washed 3 
times with ice-cold PBS. The cell pellets were resuspended in RIPA buffer 
containing phosphatase inhibitor and protease inhibitors, mixed well and left on 
ice for 10 min. Cell membranes were then sedimented by centrifugation (20,000g, 
30 min, 4 oC) and the supernatant collected and stored at -80 until further analysis. 
Protein concentration were measured using BCA assay. Aliquots of samples were 
then loaded onto SDS-PAGE gels. The loading buffer contained β-
mercaptoethanol (4x Laemmli sample buffer, Bio-rad) and the protein samples 
were mixed to make the total concentration 20 μg. Samples were heated at 95 oC 
for 5 min to denature the protein and loaded onto the gel. 
 
3.4.5.2 Western blotting  
The separation of cell protein extracts was performed using 4 – 20% 
precast polyacrylamide gels (4 - 20% criterion™ TGX stain-free™ gel), followed by 
the insertion of the gel into Criterion electrophoresis cell (Bio-rad). Electrophoresis 
premixed buffer containing 25 mM Tris, 192 mM glycine, 0.1% SDS, pH 8.3 was 
poured into the cells in order to separate proteins by SDS-PAGE. An aliquot of 
prestained protein ladder (10 µl) and test samples were loaded into the gel samples 
were then electrophoresed at 120 V for 1 h. For electrophoretic transfer of proteins 
onto nitrocellulose membranes, the semi-dry sandwich layer compromise of gel, 




Trans-Blot Turbo transfer system was used to transfer proteins from the gel into 
membrane. The semi-dry membrane transfer conditions were: 2.5A, constant 25 V 
for 15 min. 
Following the membrane transfer, membranes were intially blocked with  
5% (w/v)  dried semi-skimmed milk protein diluted in Tris-buffer saline contains 
tween-20 (TBS-T buffer; 150 mM NaCl, 10 mM Tris/HCl pH 7.6 and 0.05% 
Tween-20).  Membranes were probed according to the manufactures with pre-
determinant dilution concentrations of primary antibodies. Membranes were 
incubated overnight in 1% dried milk protein in TBST buffer (w/v) at 4 oC, 
followed by washing of the membrane with TBST buffer for 10 min for 3 cycles. 
Membranes were incubated then with secondary antibody, 1/5000 dilution anti-
rabbit IgG-HRP conjugate at room temparutre for 1 h followed by TBST washing 
and developed using ECL reagents. Images was taken using G-BOX chemi 
system (syngene). Protein band intensities were normalised to β-actin (protein 
loading control). ImageQuants software were used for quantifying. 
 
3.4.6 Membrane stripping  
Membrane stripping were used to probe membranes with different primary 
antibody. Membranes were firstly incubated with stripping buffer at 37 oC on a 
shaker for 45 min. Then, the membranes were washed with water and TBST 
buffer wash for 10 min for three times. The membranes were then blocked with 
5% of dried milk protein in TBST with incubation for 1 h. Membranes were then 
incubated with the primary antibody of interest and western blotting procedures 
performed as described above.  
 
3.4.7 ELISA of Mitochondrial and cytosolic cytochrome c  
A commercial ELISA was used to measure cytochrome c content of 
mitochondrial and cytosolic fractions of HEK293 cells incubated with and without 
MG. HEK293 cells (1 x 106) were incubated with and without MG 131 µM  for 1, 
3, 6 and 12 h, harvested and washed three times with ice-cold PBS. Cells were re-
suspended in isotonic buffer A (10 mM HEPES, 0.3 M mannitol and 0.1% BSA, 




immediately centrifuged (8500g, 5 min, 4 ºC). The collected supernatant was used 
as the cytosolic fraction. The pellet was resuspended in sonication buffer (50 mM 
Tris/HCl, pH 7.4, 150 mM NaCl, 2 mM EDTA, 1 mM PMSF and 0.5% Tween 
20), sonicated three times (20 s each) on ice, and centrifuged (10,000g, 30 min, 4 
ºC). The resulting supernatant was used as the mitochondrial fraction. The amount 
of cytochrome c in mitochondrial and cytosolic fractions was measured with a 
commercially available cytochrome c ELISA kit according to the manufacturer’s 
instructions, after appropriate dilution. 
 
3.5 Microscopy methodology 
3.5.1 Measurement of free dsDNA using florescence microscopy  
HEK293 cells were cultured in DMEM media containing 25 mM glucose. 
Cells were seeded at density of 20,000 cells/cm² in 6-well plates. Cells were 
incubated at 37 oC, 5 % CO2 and 100 % humidity for 24 h. Cell were then treated 
with 131 µM MG and incubated for 6 h.  
Following MG incubation, the medium containing MG was carefully removed 
and 4 µg/ml Pico-green reagent diluted in DMEM media was added to the cells 
and incubated for 2 h. Media containing picogreen reagent were removed and 
cells were covered with Prolonged gold DAPI reagent. Cells were then fixed with 
4% formaldehyde. Cells were visualised and image were extracted at different 
cellular location using EVOSE florescence microscope. 
 
3.6 LC-MS/ MS methodology  
 Adducts residues from protein glycation in cellular proteins were measured 
using the gold standard method of stable isotopic dilution analysis liquid 
chromatography with tandem mass spectrometric detection (LC-MS/MS) 
following exhaustive enzymatic hydrolysis. Analytes determined were: Nε-
carboxymethyl-lysine (CML), MG-H1, Nε-(1-carboxyethyl)lysine (CEL), 3-DG-H 
and Nω-carboxymethyl-arginine (CMA). MG adducts measurements were 
performed using stable isotopic dilution analysis LC-MS/MS (Rabbani et al., 





3.6.1 Sample preparation, filtration and washing for glycation adduct 
residue content of cell protein  
HEK293 cell lysate was washed ultrafiltration: 4 cycles of dilution to 500 
μl with water and concentration to 50 μl over microspin ultrafilter (10 kDa cut-
off) at 4 oC. Protein concentration in the final concentrate was assayed by the 
Bradford assay. Aliquots of protein (100 µg) were loaded in glass vials and 
diluted to 20 µl with water followed by degassing with argon and then used for 
exhaustive enzymatic hydrolysis. 
 
3.6.2 Enzymatic hydrolysis of soluble protein  
 Samples and reagents were placed an automated CTC PAL Analytics 
sample autoprocessor for enzymatic hydrolysis. All procedures were performed 
under argon in order to prevent oxidative degradation of protein substrate. The 
CTC PAL autoprocessor is programmed to perform an automated sequential 
addition of: aliquots of 100 mM HCl (10 µl), pepsin solution (2 mg/ml in 20 mM 
HCl; 5 µl), and thymol solution (2 mg/ml in 20 mM HCl; 5 µl), followed by 
sample incubation for 24 h at 37 oC.  Neutralization of the samples to pH 7.4 was 
then performed by addition of 12.5 µl 100 mM potassium phosphate buffer, pH 
7.4, and 5 µl 260 mM KOH. Pronase E solution (2 mg/ml in 10 mM KH2PO4, pH 
7.4; 5 µl) and penicillin/streptomycin (1000 units/ml and 1 mg/ml in order; 5 µl) 
was then added and samples then incubated for 24 h at 37 oC. Lastly, addition was 
made of both aminopeptidase solution (2 mg/ml in 10 mM KH2PO4, pH 7.4; 5 µl) 
and prolidase solution (2 mg/ml in 10 mM KH2PO4, pH 7.4; 5 µl). Samples were 
then incubated for 48 h at 37 oC. It is a vital to consider the order of the addition 
of these reagent and this is due to the avoidance of pH overshooting. Aliquots of 
exhaustive digest (5 µl) were then mixed with 20 µl of water and 25 µl of   
internal standards in HPLC vials and analysis of glycation adduct contents was 







Table 6.  Protocol used for hydrolysis of sample protein treated with/without 
MG using CTC-PAL automated processer.  
Addition Volume added (μl) 
Day 0 
100 mM HCl 10.0 
Pepsin solution (2 mg/ ml) 5.0 
Thymol (1 mg/ml) 5.0 
Incubate for 24 hours at 37 ºC 
Day 1 
100 mM KH2PO4/K2HPO4 buffer, pH 7.4 12.5 
260 mM KOH 5.0 
Pronase E solution (2 mg/ml) 5.0 
Penicillin (100 units/ml) and streptomycin (1 mg/ml) 5.0 
Incubate for 24 h at 37 ºC 
Day 2 
Aminopeptidase solution (2 mg/ml) 5.0 
Prolidase solution (2 mg/ml) 5.0 
Incubate for 48 h at 37 ºC 
Modified from (Rabbani et al., 2014). 
 
3.6.3 Standards curve preparation  
LC-MS/MS standards curve analysis were prepared as described in Table 
7. A mixture of normal and isotopic standards were prepared by host research 
team summarised in Table 8. There were 7 calibration standards used ranging 
from calibrants 0 to 6 using water and stock solution. Each analytes solution (50 
µl) were applied directly to the LC-MS/MS. Typical calibration curve of arginine 





















 Figure 26. Typical calibration curves for arginine and MG-H1 in stable 
isotopic dilution analysis LC-MS/MS.  
Linear regression equation: arg/[15N2]arg peak area ratio = (4.35 ± 0.0104 ) x arg 
(nmol) + (0.02 ± 0.0054); R² = 0.994 (n = 7). B. Calibration curve of MG-H1. 
Linear regression equation: MG-H1/[15N2]MG-H1 peak area ratio = (0.542 ± 















































































Table 7. Calibration standard solutions preparation from mixtures of normal 
and stable isotopic standards for protein glycation, oxidation and nitration 














0 0.00 25.00  25 50 
1 1.25 23.75  25 50 
2 2.50 22.75  25 50 
3 6.25 18.75  25 50 
4 12.50 12.50  25 50 
5 18.75 6.25  25 50 
6 25.00 0.00  25 50 
 
 
Table 8. Analyte content of calibration standard solutions for protein 
glycation, nitration and oxidation adduct residues of HEK293 protein 
extracts. 
Analytical standard (nmol) Internal  standard 
Cal no 0 1 2 3 4 5 6 (nmol) 
Lys  0 0.05 0.10 0.25 0.50 0.75 1.00 [13C6]Lys 0.25 
Arg  0 0.05 0.10 0.25 0.50 0.75 1.00 [15N2]Arg 0.25 
Analytical standard (pmol) Internal standard 
(pmol) Cal no 0 1 2 3 4 5 6 
MG-H1 0 0.125 0.25 0.625 1.25 1.875 2.50 [15N2]MG-H1 1.25 
3DG-H 0 0.125 0.25 0.625 1.25 1.875 2.50 [15N2]3DG-H 1.25 
     
3.6.4 LC-MS/MS conditions (Xevo-TQS system) 
The conditions used for the chromatographic LC-MS/MS analysis are as 
follows: two 5 µm particle size Hypercarb columns were used in series (column 1: 
2.1 x 50 mm; and column 2: 2.1 mm x 250 mm) For the mobile phase: Solvent A 
contained 0.1% TFA in water; and solvent B, 0.1% TFA in 50% acetonitrile 
(ACN). For the post run method solvents, Solvent A used for column washing 
contained 0.1% TFA in water, and solvent C - 0.1% TFA in 50% tetrahydrofuran 
(THF). Elution profiles for the assay run and washing re-equilibration of the 
column are summarised in Table 9. The flow from column to the MS/MS detector 
was directed from 4 to 35 min interval. The detection of protein damage analytes 
was performed using electrospray ionisation mass spectrometric multiple reaction 




of the desolvation gas was 350 °C. The gas flow in the cone gas were 991/h and 
for the desolvation gas was 901 1/h. Fragment ion masses, collision energies and 
optimised molecular ion are summarised in Table 10. Chromatographic peaks 
integration was performed using Masslynx software.  
 
Table 9. Elution profile for stable isotopic dilution analysis liquid 
chromatography with tandem mass spectrometric detection analysis of 










0 0.2 100 0 ---- 
5 0.2 100 0 Isocratic 
8 0.2 97 3 Linear 
12 0.2 97 3 Isocratic 
15 0.2 83 17 Linear 
18 0.2 83 17 Isocratic 
24 0.2 20 80 Linear 
24 0.2 97 3 Immediate 
35 0.2 97 3 Isocratic 
Post-run 
0 0.4 0 100 ----- 
10 0.4 0 100 Isocratic 
20 0.2 0 100 Isocratic 
20 0.2 100 0 Immediate 
25 0.2 100 0 Isocratic 
40 0.4 100 0 Isocratic 
 
Table 10. Chromatographic retention times and MRM detection conditions 
for detection of glycation, oxidation and nitration adducts by (LC-MS/MS) 
(AcquityTM-Xevo-TQS system). 
Analyte Rt (min) Molecular ion (Da) Fragment ion (Da) 
Lys 5.6 147.1 84.1 
[13C6]Lys 5.6 153.1 89.1 
3DG-H 11.7 319.1 70.1 
[15N2]3DG-H 11.7 321.1 70.1 
MG-H1 11.9 229.2 114.1 
[15N2]MG-H1 11.9 231.2 116.1 
[13C6]CEL 32.2 225.2 136.0 
Arg 32.2 176.2 70.1 





3.7 Proteomics analysis of subcellular fraction 
Approximately 3 x 106 HEK293 cells were cultured as described above to 80 
- 70% confluence. Cells were incubated with 131 µM MG for 6 h. Cells were then 
collected after trypsinisation, sedimentation and washed with PBS as described 
previously. Each subcellular fraction isolation described further below. 
 
3.7.1 Sample preparation 
3.7.1.1 Cytosolic sample preparation and isolation 
After the incubation with and without MG, cell pellets were suspended in 
10 mM sodium phosphate buffer, pH 7.0, sonicated on ice (110 W, 30s, 4 oC), and 
membranes sedimented by centrifugation (20,000g, 30 min, 4°C). The supernatant 
was then removed and stored at -80 oC until further analysis. Protein 
concentrations of samples were measured using Bradford assay, as described 
above. An aliquot of protein (300 µg) was washed with argon-purged water by 
ultradiafiltration in 4 consecutive cycles of dilution and concentration over a 10 
kDa cut-off membrane filter and then centrifuged (14,000g, 20 min, 4ºC). Protein 
concentration were measured again using the Bradford assay and aliquot (100 µg) 
digested by the trypsin/lys-C digestion method described below. 
 
3.7.1.2 Mitochondrial membrane and inner matrix isolation and 
preparation 
For mitochondrial subcellular fraction isolation, cells were re-suspended in 
isotonic buffer (25 M sucrose, 5 mM Tris⁄HCl, pH 7.5, and 0.1 mM 
phenylmethylsulfonylfluoride PMSF]; 1 ml) and homogenized using a glass 
Teflon homogeniser. Unbroken cells and nuclei are pelleted by centrifugation 
(600g, 15 min, 4 oC). Supernatants are centrifuged (10,000g, 25 min, 4 oC). The 
resulting supernatant was isolated as the cytoplasmic fraction and the pellet as the 
mitochondrial fraction. The pellet was washed once with isotonic buffer 
containing 1 mM EDTA, pH 7.5; 1 ml. 
For the extraction of the mitochondrial soluble matrix and intermembrane 




mM HEPES pH 7.4) was added and incubated on ice for 30 min Samples were 
sonicated 3 times for 30s on ice and centrifuged (1 h, 120,000g, 4ºC). Supernatant 
was transferred to 3 kDa cut-off filter and washed by ultradiafiltration by 3 cycles 
of concentration to 50 μl and dilution with 0.45 ml ice-cold water at 14,000g at 
4oC; concentrating the samples finally to 25 μl. Protein content was quantified 
with Bradford assay.  
For the mitochondrial membrane isolation protein was extracted by 
addition of 0.2 ml membrane extraction buffer ME (20 mM Tris-HCl, pH 7.4; 0.4 
M NaCl, 15% glycerol, 1 mM DTT, and 1.5% Triton-X-100) to membranes 
pellets and samples shaken gently at 4 oC for 1 h. Samples were then centrifuged 
(20,000g, 4 oC, 1 h). The supernatant was retained and protein was washed by 
ultradiafiltration by 3 cycles of concentration to 50 μl and dilution with 0.45 ml 
ice-cold water containing 1.5% Triton-X-100; concentrating finally to 25 μl. 
Protein was quantified with EZQ-protein quantification kit according to the 
manufacturer’s instructions. Protein solutions was extracted 5 times with 20 
volumes of water-saturated HPLC grade ethyl acetate to remove the Triton-X-
100. Residual ethyl acetate was evaporated by vacuum centrifugation at room 
temperature for 5 min. 
 
3.7.1.3 Nuclear isolation and preparation  
For the nuclear isolation, cells were washed in PBS and re-suspend in 
homogenization buffer [0.3 M sucrose, 10 mM MgCl2, 50 mM Tris–HCl, pH 7.8 
and 0.1 mM phenylmethylsulfonylfluoride (PMSF)]; 1 ml. Cells are homogenized 
at 0 °C in a Teflon-Glass homogenizer at 1200 rpm with 10 down-up cycles. The 
homogenate was centrifuged (1000g, 10 min, 4oC) and the pellet retained as the 
crude nuclear extract. The pellet was suspended in NF buffer [0.3 M sucrose, 
10 mM MgCl2, 50 mM Tris–HCl, pH 7.8); 0.1 ml. The suspension was layered 
onto a ‘sucrose cushion’ consisting of 2 M sucrose in the same buffer; 1 ml. After 
centrifugation (16,000g, 20 min, 4oC) the supernatant was discarded and the pellet 
containing purified nuclei was washed twice with phosphate-buffered saline. 
Purified nuclei then re-suspend in 25 µl NE buffer (20 mM HEPES, pH 7.9, 1.5 




min with gentle rocking at 4oC. Nuclei were then lysed with 10 passages through 
an 18-gauge needle. Lysate were then centrifuged at (9,000g, 30 min 4 oC). 
Protein content was measured using Bradford assay and the supernatant were then 
used for proteomic analysis. 
 
3.7.2 Protocol of tryptic digestion 
Following the subcellular protein isolation, 100 µg protein extract was 
dissolved in dithiothreitol (6 l, 6 mM) and incubated in the dark for 30 min at 37 
oC. Iodoacetamide solution (5.9 µl, 10.8 mM) was then added and samples 
incubated at 37 oC in the dark for 30 min. Residual iodoacetamide was then 
quenched by further addition of dithiothreitol (5.9 l, 6 mM) and incubated at 37 
oC in the dark for 30 min. Then, TPCK-treated trypsin was added (1 mg/ml, 5 µl) 
in 1 mM calcium chloride/500 mM ammonium bicarbonate, pH 8.0 and incubated 
for 5 h in the dark at 37 oC. An aliquot of 10% TFA in water (5 µl) was addition 
to stop the reaction. Samples were then lyophilised to dryness for removal of 
volatile salts and re-suspended in 0.1% formic acid in water. Sample analysis was 
made by nanoflow liquid-chromatography-Orbitrap mass spectrometry. 
 
3.7.3 Protocol of Lys–C/Trypsin protease digestions 
A Lys-C protease digestion protocol similar to the previous one for tryptic 
digestion was used; instead of adding TPCK-treated trypsin to the cytosolic 
protein, an aliquot of Lys-C protease (1 mg/ml, 5 µl) in 500 mM ammonium 
bicarbonate, pH 8.0, was added and incubated for 1 h at 37oC. Then TPCK-treated 
trypsin (1 mg/ml, 5 µl) in 1 mM calcium chloride/500 mM ammonium 
bicarbonate, pH 8.0, was added and samples were incubated at 37oC for 5 h in the 
dark. 
 
3.7.4  Peptide separation, protein quantitation and identifications 
The processed cell lysate samples were submitted to the Mass 
Spectrometry and Proteomics Facility at Warwick University for a label-free 
proteomic quantitation analysis. Reversed phase nanoflow liquid chromatography- 




mass spectrometer equipped with a microspray source operating in positive ion 
mode. For proteomics analysis, the column used  was: an Acclaim PepMap µ-pre-
column cartridge (trap), 300 µm i.d. x 5 mm,  5 μm particle size, 100 Å pore size, 
fitted to an Acclaim PepMap RSLC 75 µm i.d. x 50 cm, 2 µm particle size, 100 Å 
pore size main column (Thermo Scientific). It was installed on an Ultimate 3000 
RSLCnano system (Dionex). An aliquot (5 µl) of each sample was injected. After 
injection, the peptides were eluted off of the trap onto the analytical column. 
Mobile phases were: A - 0.1 % formic acid in water, and B - 0.1 % formic acid in 
acetonitrile. The flow rate was programmed at 0.3 µl/min. Mobile phase B was 
increased from 3 % to 35 % in 125 to 220 min, depending on the complexity of 
the sample, in order to separate the peptides. Mobile phase B was then increased 
from 35 % to 80 % in 5 min before being brought back quickly to 3 % in 1 min. 
The column was equilibrated at 3 % of mobile phase B for 15 min before the next 
sample. Peptides were eluted directly (300 nl min-1) via a Triversa Nanomate 
nanospray source (Advion Biosciences, NY) into a Thermo Orbitrap Fusion (Q-
OT-qIT, Thermo Scientific) mass spectrometer. Survey scans of peptide 
precursors from 350 to 1500 m/z were performed at 120K resolution (at 200 m/z) 
with automatic gain control (AGC) 4 × 105. Precursor ions with charge state 2 - 7 
were isolated (isolation at 1.6 Th [Thomson units; m/z =1] in the quadrupole) and 
subjected to high energy collision dissociation (HCD) fragmentation. The 
collusion-induced dissociation fragmentation energy was programmed to 35 %. It 
was used rapid scan MS analysis in the ion trap, the AGC was set to 1 x 104 and 
the max injection time was 200 ms. Dynamic exclusion duration was set to 45 s 
with a 10 ppm tolerance around the selected precursor and its isotopes. 
Monoisotopic precursor selection was turned on. The instrument was run in top 
speed mode with 2 s cycles. Sequence information from the MS/MS data was 
managed by converting the raw (.raw) files into a merged file (.mgf) using 
MSConvert in ProteoWizard Toolkit (version 3.0.5759) (Kessner et al., 2008). 
The resulting .mgf files were searched, and the database was searched against 






3.7.5 Data analysis  
For the data search, Mascot engine were used for searching Matrix 
Science, version 2.5.0) against Homo sapiens database (http://www.uniprot.org/). 
The search set up in the mascot assumed the digestion enzyme trypsin, in order to 
identify false positive peptide identification. The search parameter used for 
product ions and precursor mass: ± 5 ppm and ± 0.8 Da, with allowance made for 
six trypsin missed cleavages, fixed modification of cysteine through 
carbamidomethylation, MG-H1 and methionine oxidation. Only fully tryptic 
peptide matches were included. For validation, we used Scaffold (version Scaffold 
4.3.2, Proteome Software Inc.). The software was used for validating MS/MS 
based peptides and protein identification. It is only accepted if peptides could 
achieve 95% probability false discovery rate FDR provided by the software 
logarithms. This is also similar to protein identification 95% of probability or 
higher are only accepted which contains at least 2 peptides. The probabilities of 
proteins were assigned using protein prophet algorithms (Nesvizhskii et al., 2003). 
 
3.7.6 Protein function and ontology 
The evaluation of protein ontology was performed using literature reports 
of proteins roles and website tool (http://www.reactome.org/). This tool able to 
identify the functional annotation for characterisation biological process and 
molecular functions. 
 
3.7.7 Statistical analysis 
All the statistical analysis such as mean, confidence score, standards 
deviation, ANOVA were performed using the dataset of the matched HEK293 
cells replicates using statistical programme analysis provided in Progenies QI 
(QIP) for proteomics 2.0(Nonlinear Dynamics, Newcastle upon Tyne). Protein 
probabilities calculating from peptide probabilities were performed using 
Progenies. Relative protein concentration quantification was measured using non-
conflicting peptides in Progenies described in details (see 
http://www.nonlinear.com/progenesis/qi-for-proteomics/v2.0/faq/which-




summary, the method recognises non-conflicting peptides found as part of protein 
for quantification. 
For the statistical analysis performed on the proteomics data generated 
from the QIP. Data were only included if they have a P-value >0.05 produced by 
the software. The Q value, power analysis, peptide number and unique peptide 
number of the significant proteins by the software were included in Appendix III.  
The following figures is the experimental metrics of the cytoplasmic 
subcellular fraction as an example, visualised and calculated using QIP.  The 
relative abundance of peptides identified finds in each groups are shown in yellow 
– Figure17. The levels of peptide identification was similar in both test and 
control conditions. The biological replicate used in each subcellular fraction 
experiment were three replicate for each condition. In order to assess the 
reproducibility of the replicate of the samples, Power analysis were performed 
using algorithmic by QIP. For all the significant protein power analysis were 
listed in Appendix III.  The power analysis performed can be defined as the 
probability of showing a true differences between the two conditions. 0.8 Or 80% 
is acceptable value for the power. This is performed independently for each 
compound, considering variance of abundance and the size of the difference 
wanted to be detected. Nevertheless, the power analysis can give an initial thought 














Figure 27. Relative abundance of proteins identified in Control (left) and MG 
treated cells in HEK293 cells.  
Data are mean ± SD, n = 3. 
Tryptic digestion efficiency was high with approximately 70% rate of proteins 
were digested. However, ca. 22% peptides contains 1 missed cleavage and ca.3% 
were 2 missed cleavage-figure18. 
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3.8  Other statistical analysis  
All experimental work was performed in triplicate or greater. Student’s t-
test were used to assess the significance of difference between means, assuming 
normally distributed data where the F-test was used to determine where data sets 
had unequal or equal variances and appropriate t-test procedures applied. 
























4.1 Bioinformatics analysis of glyoxalase 1 expression in tumour cell lines 
and clinical cancer survival 
4.1.1 Correlation analysis of glyoxalase 1 mRNA in the cancer cell line 
encyclopaedia dataset CCLE 
In this section, I describe examination of gene expression correlation with 
expression of Glo1 in the cancer cell line encyclopaedia (CCLE). Correlation was 
performed of mRNA copy number from RNA-seq analysis data downloaded from 
the CCLE website. mRNA copy number was normally distributed and hence 
Pearson correlation analysis was performed with data from 1010 tumour cell lines 
for 10,758 genes, applying a Bonferroni correction of 10,758. Genes correlated 
with Glo1 positively and negatively listed - Appendix I. There were 4,021 genes 
correlating significantly with expression of Glo1: 3,032 correlated positively with 
Glo1 with correlation coefficients 0.134 – 0.568 and 989 genes correlated 
negatively with Glo1 with correlation coefficients from - 0.535 - - 0.134. For 
breast cancer cell lines (n = 60), the analysis had markedly less power and only 3 
significant correlations were found: RP11.312J18.5, r = 0.633; FBXO9, r = 0.619; 
and SMS, r = 0.605. 
Genes significantly correlated with Glo1 in the complete CCLE collection 
were analysed for pathways enrichment analysis (r2 ≥ 0.10, threshold criteria: 
Bonferroni corrected P-value <0.05; FDR <0.0.05). Only limited genes for which 
r2 ≥ 0.10 so that included genes were accounting for ≥ 10% variation in Glo1 
expression. For the 340 genes submitted for analysis by the DAVID 
bioinformatics pathways enrichment analysis using the Kyoto Encyclopaedia of 
Genes and Genomes (KEGG) database. Three hundred and twenty-three genes 
were recognised; seventeen were unrecognised. Unrecognised genes in pathways 
analysis were: pseudogene (2), antisense RNA (7), microRNA (2), long non-
coding RNA (4), other intronic RNA (1) and uncharacterized proteins (1). 
Recognised genes were enriched in 4 pathways (ranked ordered by statistical 
significance, most significant first): spliceosome, RNA transport, cell cycle and 




Table 11. Pathways enrichment of gene expression correlating positively with glyoxalase 1 expression in tumour cell lines of 
the CCLE.  





Spliceosome 22 7.5 7.9 x 10-11 6.9 x 10-10 CDC5L, HNRNPA1, HNRNPA3, HNRNPC, HNRNPK, LSM2, 
LSM3, LSM5, MAGOH, MAGOHB, PPIL1, PRPF4, RBMXL1, 




22 5.8 1.3 x 10-8 1.1 x 10-7 DDX20, EIF1AX, EIF2S1, EIF4E, GEMIN5, GEMIN6, KPNB1, 
MAGOH, MAGOHB, NDC1, NUP107, NUP153, NUP155, NUP35, 
NUP37, NUP43, NUP54, RPP40, SUMO1, SUMO2, XPO1, XPO5 
Cell cycle 19 7.0 1.7 x 10-8 1.5 x 10-7 CCNB1, CCNB2, CCNE2, CDC25C, CDC27, CDC7, CDK1, DBF4, 
HDAC2, MAD2L1, MCM3, ORC2, ORC3, ORC4, PTTG1, SKP1, 
SKP2, SMC3, TTK 
DNA 
replication 






Enrichment analysis was performed by the DAVID bioinformatics site using the 
Kyoto Encyclopaedia of Genes and Genomes (KEGG) database. Statistical 

















Figure 30. Correlation of selected genes and GLO1 CNV with Glo1 
expression. a. Correlation on Glo1 mRNA on PPIL1 mRNA (r = 0.568 – the 
highest correlation coefficient found), b. Correlation on Glo1 mRNA on TRADD 
mRNA (r = - 0.353 - the lowest correlation coefficient found). c. Correlation on 






































































4.1.2 Study of breast cancer patients 
Over 3951 breast cancer patients were tested in this study using Kaplan-
Meier (KM) plotter analysis tool for survival. The survival impact of expression 
of the following genes were studied (detected oligonucleotide probe-sets): GLO1 
(200681_at); HAGH or Glo2 (205012_s_at), KDM4A (203205_at); AGER or 
RAGE (217046_s_at), NFE2L2 or Nrf2 (201146_at) and MGC9454 or KEAP1 
(202417_at) of breast cancer patients. Data fitting optimised the best gene 
expression cut-off for low and high expression, relapse-free survival (RFS) was 
the clinical endpoint, and JetSetTM best probe set was used for mRNA detection. 
The maximum number of patients with breast cancer used in the data fitting was 
3951. 
In all breast cancer patients included in the analysis, increased GLO1 
expression was a negative survival factor while HAGH was not linked to survival 
and KDM4A and AGER were linked positively to survival. Expression of 
NFE2L2 was linked negatively survival with a slightly lower hazard ratio and 
lower significance than GLO1, and KEAP1 expression was linked positively to 
survival, consistent with a positive and negative regulation of Glo1 expression in 
breast cancer. These relationships were maintained for KDM4A in systemically 
untreated patients, for GLO1 in systemic endocrine therapy – including systemic 
endocrine therapy with tamoxifen only, and for KEAP1 in patients treated with 
chemotherapy - Table 12. 
The effect of tumour genotype, intrinsic subtype, lymph node status and 
stage on the association of GLO1 expression to patient survival was explored. Of 
the common breast cancer genotypes, ER, PR and HER2, there was only a 
negative association of GLO1 expression and patient survival for ER positive 
tumours. There were insufficient data in the KM Plotter database to form a 
judgement on the triple negative genotype.  There were also negative associations 
of GLO1 expression and patient survival for luminal A and luminal B intrinsic 
subtypes, and lymph node negative status patients. The association with lymph 
node negative status patients was maintained in systemically untreated patients 





treated with systemic endocrine therapy – Table 13. Kaplan- Meier plots are given 























Table 12. Effect of expression of GLO1, HAGH, KDM4A, AGER, NFE2L2 and KEAP1 on survival of breast cancer patients. 
All patients. 











GLO1 1.37 (1.22 – 1.53) 2.8 x 10-8 0.01 217 185 
KDM4A 0.64 (0.57 – 0.72) 3.0 x 10-14 0.01 140 217 
AGER 0.64 (0.57 – 0.72) 9.3 x 10-14 0.01 145 217 
NFE2L2 1.30 (1.16 – 1.45) 3.1 x 10-6 0.01 229 184 
KEAP1 0.8 (0.71 - 0.89) 8.4 x 10-5 0.02 37 57 
Systemically untreated (1010) KDM4A 0.68 (0.54 – 0.84) 4.7 x 10-4 0.05 51 912 
Systemic endocrine therapy (1873) GLO1 1.42 (1.19 – 1.88) 6.4 x 10-5 0.02 217 191 
Endocrine therapy - Tamoxifen only 
(733) 
GLO1 1.74 (1.28 – 2.35) 3.0 x 10-4 0.05 138 76 
Chemotherapy – any (1616) KEAP1 0.70 (0.59 – 0.84) 1.2 x 10-4 0.05 42 80 
 
Survival analysis: association of breast cancer patient survival analysis with expression of GLO1, HAGH, KDM4A, AGER, NFE2L2 






Table 13. Effect of GLO1 expression on breast cancer patient survival: effect of genotype, intrinsic subtype, lymph node 
status and stage. 
Treatment 
Genotype, intrinsic subtype, 













ER positive (n = 2061) 
1.65 (1.37 
– 1.92) 
1.7 x 10-8 0.01 217 163 
Luminal A (1933) 
1.54 (1.29 
– 1.84) 
1.1 x 10-6 0.01 217 185 
Luminal B (1149) 
1.53 (1.26 
– 1.85) 
1.3 x 10-5 0.01 171 122 
Lymph node negative 
(n = 2020) 
1.39 (1.17 
– 1.65) 
1.6 x 10-4 0.05 228 217 
Systemically 
untreated 
Lymph node negative 
 (n = 956) 
1.39 (1.17 
– 1.65) 




Luminal A (1093) 
1.57 (1.23 
– 2.00) 
2.3 x 10-4 0.01 217 191 
Survival analysis: association of breast cancer patient survival analysis with expression of GLO1, HAGH, KDM4A, AGER, NFE2L2 





4.2 Characterisation of the Glyoxalase system in HEK293 cell line in vitro 
4.2.1 Growth and viability of HEK293 cell line in vitro 
The growth and viability of HEK293 cells in vitro were investigated.  
HEK293 Cells, 76,000 per well in 12-well plates, were cultured incubated in 
DMEM medium containing 25 mM glucose for four days. There is an increase in 
viable cell number throughout the culture time. At day one, viable cell number 
had increased to an average of 98,700 ± 18,100 cells per well (n =3). It was then 
exponential growth with marked increase in viable cell number to 1.07 ± 0.03 
x106 cells per well at day 3. The rate of cell growth then decreased to day four and 
reaching a final viable cell number of 1.24 ± 0.13 x 106 cells per well. Cell 
viability were determined by Trypan blue exclusion test. The related growth curve 










Figure 33. Growth curve of HEK293 cells in vitro.   
HEK293 cells (seeding density 20,000 cells/cm2) were cultured for four days. 









































4.2.2 The activity of glyoxalase 1 and glyoxalase 2 in HEK293 cell line in 
vitro. 
The activity of Glo1 and Glo2 was measured in HEK293 cells cultured in 
DMEM medium containing 25 mM glucose. The activity of Glo1 was 2018 ± 577 
units per million cells (n = 3). The activity of Glo2 was 20.78 ± 6.35 units per 
million cells. 
4.2.3 The flux formation of D-lactate and net formation of L-lactate in 
HEK293 cell line in vitro  
D-Lactate is very slowly metabolised in HEK 293 cells and the activity of 
other enzymes metabolising MG, MG reductase and MG dehydrogenase, is very 
low in HEK 293 cells such that the main metabolic fate of MG is conversion to D-
lactate. The rate of formation of D-lactate is, therefore, a surrogate measure of the 
flux of formation of MG.  This was estimated by measuring the concentration of 
D-lactate in cultures at baseline and end of culture and deducing the rate of 
formation of D-lactate.  The rate of formation of D-lactate in HEK293 cells over 
four days was 37.6 ± 2.0 nmol/day/million cells.  
L-Lactate is formed and metabolized in HEK293 cells and so the net flux 
of formation of L-lactate may be measured. The net flux of formation of L-lactate 
in HEK293 cells incubated for 4 days was 2,470 ± 90 nmol/day/million cells.  
4.2.4 The effect of methylglyoxal on the growth of HEK293 cells in vitro: 
concentration-response curve  
HEK293 cells (seeding density 20,000 cells/cm2) were incubated with MG 
20 -400 μM for 48 h and viable cell number determined. There was a progressive 
decrease in viable cell number of HEK293 cells with increase in MG 
concentration over this range of MG concentration. A MG concentration - 
response curve was produced by plotting viable cell number (percentage of 
control - untreated HEK293 cells) against MG concentration - Figure 24. The 
median growth inhibitory concentration GC50 value of MG for HEK293 cells in 
vitro was deduced by non-linear regression fitting of data to a dose-response 
curve, solving for GC50 and logistic regression coefficient. The GC50 of MG was 




Figure 34. Methylglyoxal concentration-response curve for the effect on 
HEK293 cell growth in vitro.  
HEK293 cells were incubated with and without 20 -400 μM for 48 h and viable 
cell number determined. GC50 = 131± 19.1 µM, n = 0.702 ±0.05 (N = 18). 
 
4.2.5 The effect of methylglyoxal on the growth of HEK293 cells in vitro: 
growth curve  
Following the dose response study, the effect of the 131 µM MG on the 
growth and viability of HEK293 cells was investigated in vitro. HEK293 cells 
were incubated for 3 days with and without MG. Cells incubated with 131 µM 











































Figure 35. Effect of methylglyoxal on cell growth of HEK293 cells in vitro: 
effect of 131 µM methylglyoxal.  
Key: open bars, control; solid bars, + 131 µM MG. Data are mean ± SD (n = 3). 
Significance: ** and ***, P<0.05 and P<0.001, respectively (t-test) 
 
4.2.6  Effect of exposure period in the effect of methylglyoxal on growth of 
HEK293 cells in vitro 
MG induces cytotoxicity under concentration-limiting conditions, as 
applies for the GC50 concentration, by activation of apoptosis (Kang et al., 
1996).The minimum period of exposure of HEK293 cells to MG required to 
induce growth arrest and cytotoxicity will inform on the culture period when 
processes leading to commitment to apoptosis occur. To identify the minimum 
period of exposure to MG required to induce growth and toxicity to HEK293 cells 
in vitro, HEK293 cells were incubated with 131µM MG for 6, 12 and 24 h, cell 
culture medium then changed and cultures continued for a total of 48. There is a 
progressive decrease in viable cell number for exposure of HEK293 cells for 6 
and 12 h. Thereafter, no further decrease in viable cell number was achieved. This 














































Figure 36. Effect of period of exposure to methylglyoxal on growth of 
HEK293 cells in vitro. HEK293 cells were incubated with 131 µM MG for 0, 
6, 12 and 24 h.  
Data are mean and ± SD (n = 3). 
 
4.2.7 Effect of methylglyoxal on the cytochrome c release from 
mitochondria to the cytosol of HEK293 cell line in vitro 
MG is considered to induce apoptosis by activation of the mitochondrial 
apoptotic pathway (Kang et al., 1996, Thornalley et al., 1996, Santarius et al., 
2010). An indicator of this is release of cytochrome c from mitochondria to the 
cytosol (Matsura et al., 2002). The release of cytochrome c from the 
mitochondrial to cytosolic compartments were investigated by incubating 
HEK293 cells with 131 µM MG for 1.5, 3, 6 and 12 h and preparing cytosolic 
extracts for assay of cytochrome c by commercial ELISA. Data are presented as 
ng/million cells. There was a marked increase in the cytosolic content of 
cytochrome c at 3 h and 6 h. Thereafter, there was a sharp decline at 12 h – the 







































Figure 37. Cytochrome C content of the cytosol of HEK293 cells incubated 
with methylglyoxal in vitro.  
Data are mean ± SD (n = 3), (Blue) control, (Red) MG treated cells. 
 
4.2.8 Treatment period with methylglyoxal required to maximize the 
cellular protein content of methylglyoxal-derived glycation adduct 
MG-H1. 
Modification of cellular proteins by MG is an early-stage event in MG-
induced cytotoxicity and likely contributes critically to the activation of apoptosis 
under MG concentration-limited conditions (Kang et al., 1996). To detect and 
identify cellular proteins modified by MG and possibly involved in the apoptotic 
process, it is important to identify the period of treatment with MG yielding the 
maximum total modification by MG. The major adduct formed by the 
modification of proteins by MG is the hydroimidazolone MG-H1. Hence, I 
incubated HEK293 cells from 0 – 12 h – the early-stage period of exposure to MG 
when commitment to apoptosis occurs, to identify when MG-H1 adduct content of 
cell protein is maximised. HEK293 cells were incubated with 131 µM MG for 1.5 
h, 3 h, 6 h and 12 h. Thereafter cell protein extracts were prepared and content of 
MG-H1 and for comparison the 3DG-derived hydroimidazolone isomers, 3DG-H, 
by stable isotopic dilution analysis LC-MS/MS. In the time course of MG-H1 



























1.5 – 6 h and then declined thereafter at 12 h. The highest content of MG-H1 was 
achieved at 6 h: 2.78 ± 1.21 mmol/mol arg (n = 3; P<0.001). The decline in MG-
H1 content of cell protein at 12 h may be due to increased cellular proteolysis as 
commitment to apoptosis sets in– Figure 28 and Table 14.  
 
 











Figure 38. The methylglyoxal glycation adduct MG-H1 content of cellular 
protein for HEK293 cells incubated with and 131 µM MG. 
 Key: blue bar, control; red bar, + MG. Treatment period: A., 1.5 h; B, 3 h; C, 6 h; 




































































































Table 14. The methylglyoxal glycation adduct MG-H1 content of cellular protein 
for HEK293 cells incubated with and 131 µM MG. 
Treatment period (h) MG-H1 (mmol/mol arg) 
 Control MG treated  
1.5 0.23 ± 0.02 
2.60 ± 0.14*** 
 
3 0.40 ± 0.01 1.65 ± 0.12*** 
6 0.42 ± 0.02 2.78 ± 1.21*** 
12 0.23 ± 0.1 0.84 ± 0.12 
 
Data are mean ± SD (n = 3). Significance: ***, P<0.001; Student’s t-test. 
 
4.2.9 Investigating the potential significant proteins role from the previous 
proteomics study. 
an investigatigton of the content of Glo1, AKR1B1 and DDX5 at the 
protein level in HEK293 cell line incubated with 131 µM of MG for 6 h were 
pefrormed. There was a decrease in Glo1 protein expression in MG-treated cells: - 
45% (P< 0.01). There was also an increase of aldose reductase AKR1B1 but the 
increase was not statistically significant. For the DDX5, there was a significant 























































Figure 39. The protein expression changes in Control and treated 131uM of 
MG in HEK293. A Glo1, B AKR1B1 and C DDX5.  




4.3 The effect of methylglyoxal on the extrachromosomal DNA secretion.  
For the extrachromosomal DNA release analysis, HEK293 cell line were 
treated with 131 µM MG to investigate the secretion of the extrachromosomal 
DNA by staining the nuclei and the backbone of the DNA as explained in section 
3.5.1. In treating cells there was remarkable increase in DNA secretion from the 
nuclei suggesting that treating with MG also induces the secretion of the free 































































































Figure 40. Assessment of extrachromosomal DNA in HEK293 cells incubated 
with and without 131 µM MG for 6 h in vitro.  
Increase can be observed in the MG-treated cells. Key: green, extrachromosomal 











4.4 Analysis of fractional proteomes of HEK293 cells incubated with and 
without methylglyoxal  
HEK293 cells were incubated with and without 131 µM MG for 6 hr 
reaches to produce the maximum of MG-H1 adduct content of cell protein 
immediately prior to the commitment of cells to apoptosis. Cell extracts were then 
prepared for analysis of fractional proteomes: soluble proteins of the cytoplasm; 
cell nucleus; mitochondrial matrix with intermembrane space; and mitochondrial 
membranes. 
 
4.4.1 Cytoplasmic protein extract 
Four thousand and seventy proteins were detected in all replicates of 
cytoplasmic protein extract of control and MG-treated cells. There were 
abundance changes of 1365 proteins with MG treatment: 121 proteins were 
increased in abundance and 1244 decreased in abundance. For the proteins 
increased in abundance, the abundance change ranged from 1.2 to 30 fold – Table 
15. The highest increase, 30-fold, was of the calcium activated cation channel 
CSC1-like protein 2 (TMEM63B). Overexpression of TMEM63B promotes 
migration in HEK293T cells (Marques et al., 2019). There was also increase in 
abundance of the MG metabolizing enzyme aldo-keto reductase 1B1 (aldose 
reductase); + 21%. For the proteins of decreased abundance, abundance decreases 
ranged from 7 – 95%. Pathways analysis showed of protein with decreased 
abundance with MG treatment showed enrichment or overrepresentation of 
proteins in the ribosome, spliceosome, RNA transport and proteasome metabolic 
pathways – Table 20. Four hundred and eighty-one proteins were detected with 
MG-H1 modification: 42 of these increased with MG treatment and 71 decreased 
with MG treatment – Table 16 and Table 17.  MG-H1 modified proteins were not 
significantly enriched to any metabolic pathways.  
   
4.4.2 Nuclear protein extract 
Two thousand and fourty-four proteins were detected in the nuclear 
fractions of HEK293 cells in all replicates of control and test samples. Only 107 
proteins where changed in abundance by treatment with MG: 49 proteins were 
137 
 
increased and 58 proteins were decreased.  Proteins increased were not enriched in 
any pathway whereas the proteins decreased were enriched in the major mRNA 
splicing pathway – Table 21. One hundred and nineteen proteins were detected 
with MG-H1 modification but only 6 were changed in abundance with MG 
treatment. Five were increased: carbohydrate-responsive element-binding protein, 
263 fold; Protachykinin-1, 21 fold; 3-ketoacyl-CoA thiolase, mitochondrial, 15-
fold; Diphthamide biosynthesis protein 1, 7-fold; and Enoyl-CoA hydratase, 
mitochondrial, 2-fold. The MG-H1 modified protein decreased was protein 
ABHD14A; decreased - 91%. 
 
4.4.3 Mitochondrial matrix and intermembrane space proteins 
One thousand, nine hundred and twenty-eight proteins were detected in the 
mitochondrial matrix and intermembrane space. Only 150 proteins were changed 
in abundance by treatment with MG: 16 were increased and 134 were decreased – 
Table 22and Table 23. Proteins increases were in the range 1.4 – 49 fold. One of 
the proteins increased was caspase-14, increased ca. 3-fold. Decreases in 
abundances of proteins was from 21% to 98%. Forty-two proteins were detected 
with MG-H1 modification. Only two MG-H1 modified proteins were increased in 
MG-treated cells: scaffold attachment factor, increased 8-fold; and metastasis 
suppressor protein 1, increased 7-fold. One MG-H1 modified proteins was 
decreased ion MG-treated wells: B-cell CLL/lymphoma 9-like protein, - 98%. 
 
4.4.4 Mitochondrial membrane proteins 
One hundred and 168 proteins were detected in all samples for 
mitochondrial membrane proteins. Treatment with MG increased the abundance 
of 9 proteins. Two proteins are linked to mitochondrial stress responses and 
intrinsic apoptotic pathway: CREB-regulated transcription coactivator 3 and 
prohibitin, respectively – Table 24. One hundred and sixteen proteins were 
decreased in abundance by MG treatment: decreases ranging from 79 – 99%. 
Pathways analysis of these proteins revealed enrichment in 4 pathways:  
respiratory electron transport, mRNA splicing - major pathway, gluconeogenesis 
and formation of ATP by chemiosmotic coupling – Table 25. There were 26 
138 
 
proteins detected with MG-H1 modification: 9 were decreased with MG-H1 
treatment and 2 were increased – Table 26. 
a. 
Uniprot accession no: P63220 
Molecular mass: 9.111.6 Da 
Protein name: 40 Ribosomal protein S21 


















Figure 41. An example of mass spectrometric detection of a peptide in the 
trypsin/lys-C digest: 40S Ribosomal protein S21 identified in nuclear 
fraction.   
a. Protein information and sequence coverage. Key: yellow highlighting – 
sequence detected; green shading – M detected as methionine sulfoxide (+16 Da).  
b. Peptide fragmentation ion mass scan of peptide 28 - 41. c. Fragment ion 
assignment table. Ions detected are colour coded in the mass spectrum 
assignments with colour shading in the table. m/z ion values unshaded were not 







 Table 15. Proteins in the cytoplasmic extract increased in abundance by 
treatment with methylglyoxal. 
Uniprot 
accession no 
Name of protein(gene) 
Fold increase 
H0YCP6 transmembrane protein 63B(TMEM63B) 30.53 
A0A087WT97 multiple EGF like domains 11(MEGF11) 13.99 
U3KQQ5 transmembrane protein 259 (TMEM259) 8.22 
A0A0J9YX13 
tissue specific transplantation antigen P35B 
(TSTA3) 5.69 
F8VRE9 coronin 1C(CORO1C) 5.24 
D6RBW1 eukaryotic translation initiation factor 4E (EIF4E) 5.10 
A0A087X2I5 
LSM7 homolog, U6 small nuclear RNA and mRNA 
degradation associated(LSM7) 4.89 
Q14DG7 transmembrane protein 132B(TMEM132B) 4.79 
H0YDJ4 ninein(NIN) 4.77 
Q9BZL1 ubiquitin like 5(UBL5) 4.40 
A0A0G2JLQ8 NLR family pyrin domain containing 2(NLRP2) 4.13 
E9PQR4 tubby bipartite transcription factor(TUB) 3.93 
Q9H2G4 TSPY like 2(TSPYL2) 3.76 
Q96A61 tripartite motif containing 52(TRIM52) 3.59 
M0QXX8 charged multivesicular body protein 2A(CHMP2A) 3.48 
D6RBJ7 GC, vitamin D binding protein(GC) 3.47 
P01031 complement C5(C5) 3.45 
Q8TDV5 G protein-coupled receptor 119(GPR119) 3.45 
P35527 keratin 9(KRT9) 3.25 
Q7Z5M8 abhydrolase domain containing 12B(ABHD12B) 3.24 
H3BMW6 
calcium voltage-gated channel subunit alpha1 
H(CACNA1H) 3.23 
Q7L1I2 synaptic vesicle glycoprotein 2B(SV2B) 3.18 
Q7RTV0 PHD finger protein 5A(PHF5A) 2.95 
P07858 cathepsin B(CTSB) 2.88 
Q9UKX7 nucleoporin 50(NUP50) 2.83 
H3BNC9 Uncharacterized protein 2.77 
P10827 thyroid hormone receptor, alpha(THRA) 2.68 
A0A0G2JQ76 KIAA0355(KIAA0355) 2.62 
H3BNT2 coenzyme Q9(COQ9) 2.61 
H7C3A6 
Fanconi anemia core complex associated protein 
20(FAAP20) 2.57 
H0YGR4 RNA exonuclease 2(REXO2) 2.41 
A0A087X2I7 
class II major histocompatibility complex 
transactivator(CIITA) 2.37 
H0YB67 drosha ribonuclease III(DROSHA) 2.37 
K7EM19 vesicle amine transport 1(VAT1) 2.31 




peroxisome proliferator activated receptor 
delta(PPARD) 2.21 
P33552 CDC28 protein kinase regulatory subunit 2(CKS2) 2.16 
Q9BYD6 mitochondrial ribosomal protein L1(MRPL1) 2.15 
Q3ZCX4 zinc finger protein 568(ZNF568) 2.14 
P51587 BRCA2, DNA repair associated(BRCA2) 2.13 
Q6ZR64 matrix remodeling associated 7(MXRA7) 2.11 
H7BZL2 3-hydroxyisobutyrate dehydrogenase(HIBADH) 2.10 
A0A0A0MSD7 
protein tyrosine phosphatase, receptor type 
N2(PTPRN2) 2.09 
F8W9Q7 solute carrier family 25 member 37(SLC25A37) 2.09 
H0Y903 methionyl aminopeptidase 1(METAP1) 2.08 
H3BPB0 
S-phase cyclin A associated protein in the 
ER(SCAPER) 2.08 
D6RFM5 
succinate dehydrogenase complex flavoprotein 
subunit A(SDHA) 2.07 
A0A0B4J1Y4 gamma-glutamylcyclotransferase(GGCT) 2.06 
Q6KC79 NIPBL, cohesin loading factor(NIPBL) 2.05 
E7EQL8 
tubulin gamma complex associated protein 
6(TUBGCP6) 2.03 
F5GYA2 uracil DNA glycosylase(UNG) 2.03 
P53420 collagen type IV alpha 4 chain(COL4A4) 2.03 
A0A087WZY0 ceroid-lipofuscinosis, neuronal 5(CLN5) 2.03 
H0Y390 microtubule-actin crosslinking factor 1(MACF1) 2.02 
P29373 cellular retinoic acid binding protein 2(CRABP2) 2.02 
P43897 
Ts translation elongation factor, 
mitochondrial(TSFM) 2.01 
Q5T1U7 collagen type XXVII alpha 1 chain(COL27A1) 1.98 
P51608 methyl-CpG binding protein 2(MECP2) 1.93 
H3BQA6 cyclin D1 binding protein 1(CCNDBP1) 1.93 
A0A087WT80 phospholipase C beta 1(PLCB1) 1.93 
P05543 serpin family A member 7(SERPINA7) 1.90 
A0A087WWL5 chromosome 19 open reading frame 68(C19orf68) 1.90 
A0A1C7CYZ2 ceroid-lipofuscinosis, neuronal 5(CLN5) 1.89 
Q9H0W5 coiled-coil domain containing 8(CCDC8) 1.89 
Q96ST2 IWS1, SUPT6H interacting protein(IWS1) 1.85 
P02549 spectrin alpha, erythrocytic 1(SPTA1) 1.85 
J3KNP4 semaphorin 4B(SEMA4B) 1.83 
A0A024R214 
cytoplasmic polyadenylation element binding protein 
1(CPEB1) 1.83 
A6PWM2 cysteine rich with EGF like domains 2(CRELD2) 1.83 
A0A1B0GUS7 unc-13 homolog B(UNC13B) 1.82 
K7ENL0 septin 9(SEPT9) 1.81 
P01023 alpha-2-macroglobulin(A2M) 1.79 
A0A087WWW8 calcineurin binding protein 1(CABIN1) 1.79 
141 
 
Q969S3 zinc finger protein 622(ZNF622) 1.78 
H0YHS6 tyrosyl-tRNA synthetase 2(YARS2) 1.78 
Q96N66 
membrane bound O-acyltransferase domain 
containing 7(MBOAT7) 1.76 
H0Y9N9 LPS responsive beige-like anchor protein(LRBA) 1.74 
E9PJ65 solute carrier family 6 member 9(SLC6A9) 1.73 
Q5T2E8 chromosome 10 open reading frame 76(C10orf76) 1.73 
E9PJF9 aminopeptidase puromycin sensitive(NPEPPS) 1.73 
A0A087WUT0 myelin expression factor 2(MYEF2) 1.70 
Q86T26 transmembrane protease, serine 11B(TMPRSS11B) 1.70 
Q14676 mediator of DNA damage checkpoint 1(MDC1) 1.64 
H0YEZ9 ubiquilin 1(UBQLN1) 1.63 
A0A0G2JQF3 mucin 20, cell surface associated(MUC20) 1.62 
Q7Z698 
sprouty related EVH1 domain containing 
2(SPRED2) 1.62 
P41223 BUD31 homolog(BUD31) 1.62 
A0A087WX24 sterile alpha motif domain containing 11(SAMD11) 1.59 
Q9BV73 centrosomal protein 250(CEP250) 1.56 
Q9C0J8 WD repeat domain 33(WDR33) 1.56 
Q99832 chaperonin containing TCP1 subunit 7(CCT7) 1.54 
P08579 
small nuclear ribonucleoprotein polypeptide 
B2(SNRPB2) 1.52 
A0A087WWT1 
succinate dehydrogenase complex iron sulfur subunit 
B(SDHB) 1.49 
Q9P1A2 
protein phosphatase 4 regulatory subunit 1 like 
(pseudogene)(PPP4R1L) 1.48 
A0A087WZL3 anaplastic lymphoma receptor tyrosine kinase(ALK) 1.47 
A0A0G2JS85 syntrophin gamma 2(SNTG2) 1.47 
Q9GZN8 chromosome 20 open reading frame 27(C20orf27) 1.47 
A8MUM1 
tumor suppressing subtransferable candidate 
1(TSSC1) 1.47 
V9GYA7 death associated protein 3(DAP3) 1.46 
H0YL19 WD repeat domain 61(WDR61) 1.46 
H7C440 DIS3 like 3'-5' exoribonuclease 2(DIS3L2) 1.45 
J3QRD1 
aldehyde dehydrogenase 3 family member 
A2(ALDH3A2) 1.43 
P14921 ETS proto-oncogene 1, transcription factor(ETS1) 1.43 
A0A0J9YYF7 
dishevelled associated activator of morphogenesis 
2(DAAM2) 1.42 
A0A087WYK2 WNK lysine deficient protein kinase 3(WNK3) 1.41 
H3BPN4 enhancer of mRNA decapping 3(EDC3) 1.41 
Q9NZ56 formin 2(FMN2) 1.41 
P00390 glutathione-disulfide reductase(GSR) 1.35 
Q08E93 




P82933 mitochondrial ribosomal protein S9(MRPS9) 1.32 
A0A0A0MQX8 muscleblind like splicing regulator 1(MBNL1) 1.30 
P02545 lamin A/C(LMNA) 1.30 
Q9Y2W2 WW domain binding protein 11(WBP11) 1.29 
Q86US8 
SMG6, nonsense mediated mRNA decay 
factor(SMG6) 1.28 
Q01469 fatty acid binding protein 5(FABP5) 1.23 
Q96PK6 RNA binding motif protein 14(RBM14) 1.23 
A0A075B7F8 POM121 transmembrane nucleoporin C(POM121C) 1.22 
H7C537 NFU1 iron-sulfur cluster scaffold(NFU1) 1.22 
P15121 aldo-keto reductase family 1 member B(AKR1B1) 1.21 
P62995 transformer 2 beta homolog (Drosophila)(TRA2B) 1.17 
E9PNB5 nuclear autoantigenic sperm protein(NASP) 1.15 
  
 
Table 16. Proteins in the cytoplasmic extract modified by methylglyoxal and 





Multiple epidermal growth factor-like domains protein 11 
(MEGF11) 
13.99 
GDP-L-fucose synthase (TSTA3) 5.69 
NACHT, LRR and PYD domains-containing protein 2 (NLRP2) 4.13 
Tripartite motif-containing protein 52 (TRIM52) 3.59 
Charged multivesicular body protein 2a (CHMP2A) 3.48 
Glucose-dependent insulinotropic receptor (GPR119) 3.45 
Keratin, type I cytoskeletal 9 (KRT9) 3.25 
Protein ABHD12B (ABHD12B) 3.24 
Voltage-dependent T-type calcium channel subunit alpha-1H 
(CACNA1H) 
3.23 
Synaptic vesicle glycoprotein 2B (SV2B) 3.18 
Thyroid hormone receptor alpha (THRA) 2.68 
Uncharacterized protein KIAA0355 (KIAA0355) 2.62 
Fanconi anemia core complex-associated protein 20 (FAAP20) 2.57 
Oligoribonuclease, mitochondrial (REXO2) 2.41 
MHC class II transactivator (CIITA) 2.37 
Mitotic-spindle organizing protein 2A (MZT2A) 2.26 
Receptor-type tyrosine-protein phosphatase N2 (PTPRN2) 2.09 
Mitoferrin-1 (SLC25A37) 2.09 
Gamma-tubulin complex component 6 (TUBGCP6) 2.03 
Ceroid-lipofuscinosis neuronal protein 5 (CLN5) 2.03 
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Microtubule-actin cross-linking factor 1, isoforms 1/2/3/5 
(MACF1) 
2.02 
Collagen alpha-1(XXVII) chain (COL27A1) 1.98 
Phosphoinositide phospholipase C (PLCB1) 1.93 
Uncharacterized protein C19orf68 (C19orf68) 1.90 
Ceroid-lipofuscinosis neuronal protein 5 (CLN5) 1.89 
Semaphorin-4B OS=Homo sapiens (SEMA4B) 1.83 
Calcineurin-binding protein cabin-1 (CABIN1) 1.79 
Transporter (SLC6A9) 1.73 
Myelin expression factor 2 (MYEF2) 1.70 
Mucin-20 (MUC20) 1.62 
Sterile alpha motif domain-containing protein 11 (SAMD11) 1.59 
Centrosome-associated protein CEP250 (CEP250) 1.56 
pre-mRNA 3' end processing protein WDR33 (WDR33) 1.56 
Putative serine/threonine-protein phosphatase 4 regulatory 
subunit 1-like (PPP4R1L) 
1.48 
Gamma-2-syntrophin (SNTG2) 1.47 
28S ribosomal protein S29, mitochondrial (DAP3) 1.46 
Serine/threonine-protein kinase WNK3 (WNK3) 1.41 
Enhancer of mRNA-decapping protein 3 (EDC3) 1.41 
Protein FAM27E3 (FAM27E3) 1.33 
Telomerase-binding protein EST1A (SMG6) 1.28 
Nuclear envelope pore membrane protein POM 121C 
(POM121C) 
1.22 
Nuclear autoantigenic sperm protein (NASP) 1.15 
 
 
Table 17. Proteins in the cytoplasmic extract modified by methylglyoxal and 




heterogeneous nuclear ribonucleoprotein K(HNRNPK) 0.91 
heterogeneous nuclear ribonucleoprotein K(HNRNPK) 0.88 
FUS RNA binding protein(FUS) 0.86 
zinc finger CCHC-type containing 2(ZCCHC2) 0.84 
DEAH-box helicase 15(DHX15) 0.82 
tripartite motif containing 46(TRIM46) 0.81 
casein kinase 2 alpha 2(CSNK2A2) 0.81 
heterogeneous nuclear ribonucleoprotein M(HNRNPM) 0.81 
heterogeneous nuclear ribonucleoprotein M(HNRNPM) 0.81 
EWS RNA binding protein 1(EWSR1) 0.81 
KRI1 homolog(KRI1) 0.79 
144 
 
lactate dehydrogenase A(LDHA) 0.79 
espin-like(ESPNL) 0.78 
mutS homolog 6(MSH6) 0.78 
interleukin enhancer binding factor 2(ILF2) 0.76 
peroxiredoxin 1(PRDX1) 0.76 
MAK16 homolog(MAK16) 0.76 
heterogeneous nuclear ribonucleoprotein U(HNRNPU) 0.75 
RecQ like helicase 5(RECQL5) 0.75 
eukaryotic translation elongation factor 2(EEF2) 0.73 
histone cluster 1 H2B family member n(HIST1H2BN) 0.73 
bromodomain adjacent to zinc finger domain 1B(BAZ1B) 0.71 
ataxin 10(ATXN10) 0.71 
PH domain and leucine rich repeat protein phosphatase 
1(PHLPP1) 
0.70 
SPT6 homolog, histone chaperone(SUPT6H) 0.68 
potassium channel tetramerization domain containing 
9(KCTD9) 
0.67 
carboxypeptidase X, M14 family member 2(CPXM2) 0.67 
ubiquitin specific peptidase 5(USP5) 0.66 
zinc finger RNA binding protein(ZFR) 0.66 
nuclear pore complex interacting protein family member 
A3(NPIPA3) 
0.64 
myosin XVA(MYO15A) 0.62 
ATP/GTP binding protein like 4(AGBL4) 0.62 
hydroxyacylglutathione hydrolase(HAGH) 0.62 
zinc finger protein 513(ZNF513) 0.62 
zinc finger protein 345(ZNF345) 0.61 
signal recognition particle 54(SRP54) 0.61 
ubiquitin A-52 residue ribosomal protein fusion product 
1(UBA52) 
0.61 
myeloid differentiation primary response 88(MYD88) 0.61 
uncharacterized LOC105372343(LOC105372343) 0.61 
RNA pseudouridylate synthase domain containing 
3(RPUSD3) 
0.60 
dedicator of cytokinesis 2(DOCK2) 0.60 
tRNA isopentenyltransferase 1(TRIT1) 0.58 
spen family transcriptional repressor(SPEN) 0.56 
desmoplakin(DSP) 0.55 
ankyrin repeat domain 1(ANKRD1) 0.54 
RNA polymerase I subunit A(POLR1A) 0.53 
myosin XVIIIA(MYO18A) 0.53 
A-kinase anchoring protein 6(AKAP6) 0.52 
par-3 family cell polarity regulator beta(PARD3B) 0.51 
intraflagellar transport 172(IFT172) 0.51 
topoisomerase (DNA) II beta(TOP2B) 0.50 
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kelch like family member 33(KLHL33) 0.50 
ankyrin repeat and sterile alpha motif domain containing 
3(ANKS3) 
0.49 
atypical chemokine receptor 2(ACKR2) 0.47 
carboxypeptidase E(CPE) 0.46 
glycerol-3-phosphate dehydrogenase 2(GPD2) 0.46 
chromodomain helicase DNA binding protein 3(CHD3) 0.42 
solute carrier family 39 member 11(SLC39A11) 0.39 
testis expressed 33(TEX33) 0.39 
MAP3K12 binding inhibitory protein 1(MBIP) 0.38 
periaxin(PRX) 0.38 
microtubule associated protein 7(MAP7) 0.35 
V-set and transmembrane domain containing 2A(VSTM2A) 0.25 
mitochondrial ribosomal protein S21(MRPS21) 0.24 
tripartite motif containing 21(TRIM21) 0.24 
KIAA0556(KIAA0556) 0.21 
ciliary rootlet coiled-coil, rootletin(CROCC) 0.18 
lipase E, hormone sensitive type(LIPE) 0.17 
TATA-box binding protein associated factor 3(TAF3) 0.13 
F-box and WD repeat domain containing 8(FBXW8) 0.10 
olfactory receptor family 4 subfamily A member 15(OR4A15) 0.05 
 
Table 18. Proteins in the nuclear extract increased in abundance by 
treatment with methylglyoxal. 
Uniprot 
Accession 




Carbohydrate-responsive element-binding protein 
(MLXIPL) 
262.60 
P02775 Platelet basic protein (PPBP) 48.34 
P01859 Immunoglobulin heavy constant gamma (IGHG2) 23.81 
P20366 Protachykinin-1 (TAC1) 20.60 
Q5T7N2 LINE-1 type transposase domain-containing protein 




RNA binding motif protein 10, (RBM10) 19.14 





3-ketoacyl-CoA thiolase, mitochondrial (ACAA2) 14.74 
Q9BS19 HPX protein (HPX) 13.93 
P04196 Histidine-rich glycoprotein (HRG ) 11.31 
P02776 Platelet factor 4 (PF4) 10.92 
F8W696 Apolipoprotein (APOA1) 9.56 
P01860 Immunoglobulin heavy constant gamma (IGHG3) 7.77 
P01023 Alpha-2-macroglobulin (A2M ) 6.28 
Q96M27 Protein PRRC1 (PRRC1) 6.22 
Q13541 Eukaryotic translation initiation factor 4E-binding 
protein 1 (EIF4EBP1) 
5.41 
P19878 Neutrophil cytosol factor (NCF2) 4.02 
Q8TBY9 WD repeat-containing protein 66 (WDR66) 2.94 
Q9BT09 Protein canopy homolog 3 (CNPY3) 2.79 
X6R700 Chromatin target of PRMT1 protein (CHTOP) 2.73 
E9PDQ8 Succinate--CoA ligase [GDP-forming] subunit beta, 
mitochondrial (SUCLG2) 
2.28 
O14828 Secretory carrier-associated membrane protein 3 
(SCAMP3) 
2.16 
Q5M9N0 Coiled-coil domain-containing protein (CCDC158) 2.07 
P30084 Enoyl-CoA hydratase, mitochondrial (ECHS1) 2.01 
O14745 Na(+)/H(+) exchange regulatory cofactor NHE-RF1 
(SLC9A3R1) 
1.90 
Q6S8J3 POTE ankyrin domain family member (POTEE ) 1.77 
Q9UMX5 Neudesin (NENF) 1.64 
P60709 Actin, cytoplasmic 1 (ACTB) 1.56 
Q562R1 Beta-actin-like protein 2 (ACTBL2) 1.55 
P14735 Insulin-degrading enzyme (IDE) 1.54 
P52907 F-actin-capping protein subunit alpha-1 (CAPZA1) 1.53 
P680325 Actin, alpha cardiac muscle 1 (ACTC1) 1.51 





A8K7Q2 Heat shock cognate 71 kDa protein (HSPA8) 1.37 
C9JIZ6 Prosaposin OS=Homo sapiens (PSAP) 1.33 
O43923 Matrix metalloproteinase (mmp20) 1.31 
C9J8T6 Cytochrome c oxidase copper chaperone (COX17) 1.25 
P10253 Lysosomal alpha-glucosidase (GAA) 1.20 
 
Table 19. Proteins in the nuclear extract decreased in abundance by 
treatment with methylglyoxal. 
Gene Name of protein 
Fold 
increase 
P13010+ X-ray repair cross-complementing protein 5 (XRCC5) 0.78 
A0A087W
ZR9 
Pyrroline-5-carboxylate reductase (PYCR2 PE) 0.77 
F5H6P7 Protein mago nashi homolog 2( MAGOHB) 0.72 
Q10570 
Cleavage and polyadenylation specificity factor 




Heterogeneous nuclear ribonucleoprotein U-like 
protein 1 (HNRNPUL1) 
0.67 
Q14011 Cold-inducible RNA-binding protein (CIRBP) 0.67 
P09661 U2 small nuclear ribonucleoprotein A (SNRPA10 0.66 
F8VZX2 Poly(rC)-binding protein 2 (PCBP2) 0.63 
E7EQY1 Protein FAM136A (FAM136A ) 0.61 
H0Y5B4 60S ribosomal protein L36a (RPL36A) 0.60 
Q96KR1 Zinc finger RNA-binding protein (ZFR ) 0.60 
A0A0A0M
SI2 
Polyhomeotic-like protein 2 (PHC2) 0.59 
J3QLW7 
60S ribosome subunit biogenesis protein NIP7 
homolog (NIP7) 
0.58 
Q9BXT5 Testis-expressed protein 15 (TEX15) 0.57 
Q04760 Lactoylglutathione lyase (GLO1) 0.56 





Polypyrimidine tract-binding protein 1 (PTBP1) 0.55 
P32322 





Protein arginine N-methyltransferase 1 (PRMT1) 0.50 
Q3SX64 Outer dense fiber protein 3-like protein 2 (ODF3L2) 0.50 
H0YKD8 60S ribosomal protein L28 (RPL28) 0.49 
A0A087W
WR2 
Myc-associated zinc finger protein (MAZ) 0.47 
P53999 
Activated RNA polymerase II transcriptional 
coactivator p15 (SUB1) 
0.47 
F8WBM4 Follicle-stimulating hormone receptor (FSHR) 0.47 
F5H1S9 tRNA pseudouridine synthase (PUS1) 0.46 
O60832 H/ACA ribonucleoprotein complex subunit 4 (DKC1) 0.44 
Q9H0A0 RNA cytidine acetyltransferase (NAT10) 0.43 
Q15427 Splicing factor 3B subunit 4 (SF3B4) 0.42 
A0A0A0M
SE2 
Hydroxyacyl-coenzyme A dehydrogenase, 
mitochondrial (HADH) 
0.42 
Q9Y2H1 Serine/threonine-protein kinase 38-like (STK38L) 0.42 
E7EVA0 Microtubule-associated protein (MAP4) 0.41 
P21953 
2-oxoisovalerate dehydrogenase subunit beta, 
mitochondrial (BCKDHB) 
0.40 
P41208 Centrin-2 (CETN20 0.39 
Q5JSZ5 Protein PRRC2B (PRRC2B) 0.38 
A0A024R3
41 
Ngg1 interacting factor 3 like 1 binding protein 1, 
isoform CRA_b (NIF3L1BP1) 
0.37 
D6RAV8 Carbonyl reductase family member 4 (CBR4) 0.36 
Q9UNZ5 Leydig cell tumor 10 kDa protein homolog ( C19 ) 0.36 
A0A0A0M
RZ6 
Lysosomal-trafficking regulator LYST 0.34 




Telomeric repeat-binding factor 2-interacting protein 
1 (TERF2IP) 
0.30 
Q9UII2; ATPase inhibitor, mitochondrial (ATPIF1) 0.29 
H0YMV8 40S ribosomal protein S27 (RPS27L) 0.26 
F5H2A4 High mobility group protein (HMGA2) 0.20 
Q9UK45 U6 snRNA-associated Sm-like protein LSm7 (LSM7) 0.18 
F8WAH1 




Transcription initiation factor IIE subunit beta 
(GTF2E2) 
0.17 
P13807 Glycogen [starch] synthase, muscle (GYS1) 0.16 
A0A087X2
I5 
U6 snRNA-associated Sm-like protein LSm7 (LSM7) 0.13 
Q92947 Glutaryl-CoA dehydrogenase, mitochondrial (GCDH) 0.13 
H3BNT7 
26S proteasome non-ATPase regulatory subunit 7 
(PSMD7) 
 
P98179 RNA-binding protein 3 (RBM3) 0.02 
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Ribosome 51 4.4 4.2 x 10-18 2.2 x 10-17 
RPL18, RPL17, RPL13, RPS10, NUDT3, RPLP2, RPS27L, RPL22L1, 
RPS3, RPL10, FAU, RPL11, RPL12, MRPL1, MRPL3, MRPS5, 
RPS18, RPS19, RPS16, RPS14, RPS13, RPS11, UBA52, MRPS11, 
RPL35, RPL36, RPL38, MRPL11, RPS25, MRPL13, RPS27, RPS28, 
RPL32, RPL7, RPS29, RPL6, RPL31, RPL34, RPL8, RPS20, RPSA, 
RPL26, RPL23A, MRPS21, RPS6, RPS8, RPL29, RPL23, RPL22, 
MRPL27, RPL13A, RPL21 
Spliceosome 43 3.8 3.3 x10-12 1.7 x 10-11 
SRSF1, CCDC12, TRA2B, U2AF2, LSM7, SF3B6, SF3B5, BUD31, 
SF3B3, SF3B2, CTNNBL1, PRPF19, HNRNPM, SF3B1, HNRNPK, 
DDX23, DHX15, DHX16, MAGOHB, SNRNP70, PRPF40A, 
MAGOH, EFTUD2, DDX39B, SNW1, PRPF3, SF3A2, DDX5, 
RBMX, PRPF4, SF3A1, HNRNPU, PRPF6, PPIE, EIF4A3, PPIH, 
SRSF5, SRSF4, SRSF6, SNRNP200, THOC3, PRPF38B, RBM17 
RNA transport 46 3.1 6.8 x 10-10 3.5 x 10-9 
NUP98, ELAC2, XPO5, PABPC4, RANGAP1, PNN, SUMO3, 
EIF3C, SUMO2, EIF3D, EIF3CL, SUMO1, EIF4EBP1, EIF3G, 
RAE1, EIF3H, EIF3E, RPP30, MAGOHB, EIF3I, EIF1, PABPC1, 
EIF3J, TPR, GEMIN4, NMD3, GEMIN5, NUP133, EEF1A1, RGPD8, 
UPF1, RAN, MAGOH, EEF1A2, DDX39B, TACC3, TRNT1, 
EIF4G1, EIF4A3, UPF3B, NUP205, EIF2S1, THOC6, POP1, CYFIP1, 
THOC3 
Proteasome 16 4.3 4.1 x 10-4 2.1 x10-3 
PSMC5, PSMB6, PSMD12, PSME1, PSMB1, PSMA6, PSMD11, 
PSME2, PSMA4, PSMB2, PSMA3, PSMD3, PSME3, PSMD4, 
PSMD7, PSMD8 
Threshold criterion for significance: Bonferroni-corrected P<0.05 and FDR<0.05.  
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Table 21. Pathways enrichment analysis of proteins decreased in the cell 














CPSF1, HNRNPUL1, LSM7, 
MAGOHB, PCBP2, PTBP1, 
SF3B4, SNRPA1, SNRPD1 
Significance: Bonferroni corrected P-value, 5.11 x 10-5; FDR, 5 x 10-4. 
Threshold criterion for significance: Bonferroni-corrected P<0.05 and FDR<0.05.  
Table 22. Proteins of the mitochondrial matrix and intermembrane space 







A0A024R3B9 49.3 crystallin alpha B (CRYAB) 
Q15554 27.3 telomeric repeat binding factor 2 (TERF2) 
A8MYB8 20.6 
aldehyde dehydrogenase 3 family member A1 
(ALDH3A1) 
P13647 18.4 keratin 5 (KRT5) 
A0A1B0GVP8 10.7 solute carrier family 26 member 10 (SLC26A10) 
Q14151 8.0 scaffold attachment factor B2 (SAFB2) 
H0YBL3 6.8 MTSS1, I-BAR domain containing (MTSS1) 
Q9NWZ3 6.6 interleukin 1 receptor associated kinase 4 (IRAK4) 
Q9NZT1 4.1 calmodulin like 5 (CALML5) 
P31944 3.0 caspase 14 (CASP14) 
G3V1V0 2.0 myosin light chain 6 (MYL6) 
P46778 1.9 ribosomal protein L21 (RPL21) 
G5E9G0 1.7 ribosomal protein L3 (RPL3) 
H3BMM9 1.7 
RNA binding protein with serine rich domain 
1(RNPS1) 
P39023 1.6 ribosomal protein L3 (RPL3) 










Table 23. Proteins of the mitochondrial matrix and intermembrane space 
decreased by HEK293 cell treatment with methylglyoxal. 
Uniprot accession 
no. 
Name of protein (gene) 
J3KRC4 5', 3'-nucleotidase, cytosolic(NT5C) 
F5GZY1 acidic residue methyltransferase 1(ARMT1) 
G3V2E7 kinesin light chain 1(KLC1) 
A0A087X060 E2F associated phosphoprotein(EAPP) 
Q9BV57 acireductone dioxygenase 1(ADI1) 
E7ER27 hydroxysteroid 17-beta dehydrogenase 4(HSD17B4) 
P50990 chaperonin containing TCP1 subunit 8(CCT8) 
G3V1C3 apoptosis inhibitor 5(API5) 
Q96GX2 ataxin 7 like 3B(ATXN7L3B) 
Q13257 MAD2 mitotic arrest deficient-like 1 (yeast)(MAD2L1) 
F8VQZ7 methionyl aminopeptidase 2(METAP2) 
Q96JG6 VPS50, EARP/GARPII complex subunit(VPS50) 
P36871 phosphoglucomutase 1(PGM1) 
E7ENV7 copine 8(CPNE8) 
P62937 peptidylprolyl isomerase A(PPIA) 
Q96CT7 coiled-coil domain containing 124(CCDC124) 
Q86WV7 coiled-coil domain containing 43(CCDC43) 
F2Z2Y4 pyridoxal (pyridoxine, vitamin B6) kinase(PDXK) 
O15067 phosphoribosylformylglycinamidine synthase(PFAS) 
Q6P2E9 enhancer of mRNA decapping 4(EDC4) 
M0R0Y2 NSF attachment protein alpha(NAPA) 
O15160 RNA polymerase I subunit C(POLR1C) 
Q14980 nuclear mitotic apparatus protein 1(NUMA1) 
A0A087WY61 nuclear mitotic apparatus protein 1(NUMA1) 
P46108 CRK proto-oncogene, adaptor protein(CRK) 
A0A0A0MTN3 glutathione S-transferase mu 3(GSTM3) 
Q15527 surfeit 2(SURF2) 
A0A087WTP3 KH-type splicing regulatory protein(KHSRP) 
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Q4G0X9 coiled-coil domain containing 40(CCDC40) 
K7EJX8 dihydrouridine synthase 3 like(DUS3L) 
Q8WU90 zinc finger CCCH-type containing 15(ZC3H15) 
O15455 toll like receptor 3(TLR3) 
P24666 acid phosphatase 1, soluble(ACP1) 
H7C170 
Williams-Beuren syndrome chromosome region 
22(WBSCR22) 
Q99543 
DnaJ heat shock protein family (Hsp40) member 
C2(DNAJC2) 
Q7Z4Q2 HEAT repeat containing 3(HEATR3) 
E5RGS4 prefoldin subunit 1(PFDN1) 
H0YIV4 nucleosome assembly protein 1 like 1(NAP1L1) 
F8VV59 nucleosome assembly protein 1 like 1(NAP1L1) 
A0A087WTB8 ubiquitin C-terminal hydrolase L3(UCHL3) 
 
Table 23. Proteins of the mitochondrial matrix and intermembrane space 




Name of protein (gene) 
Q99956 dual specificity phosphatase 9(DUSP9) 
O00178 GTP binding protein 1(GTPBP1) 
P62487 RNA polymerase II subunit G(POLR2G) 
H7C0X7 methionine adenosyltransferase 2B(MAT2B) 
A0A087WY
55 
vesicle trafficking 1(VTA1) 
Q99733 nucleosome assembly protein 1 like 4(NAP1L4) 




RNA polymerase II subunit A(POLR2A) 
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PHD finger protein 6(PHF6) 
P02647 apolipoprotein A1(APOA1) 
P0DN79 cystathionine-beta-synthase(CBS) 
Q6Y7W6 GRB10 interacting GYF protein 2(GIGYF2) 
P35609 actinin alpha 2(ACTN2) 
P17480 
upstream binding transcription factor, RNA polymerase 
I(UBTF) 
O14776 transcription elongation regulator 1(TCERG1) 
F5H6C2 intraflagellar transport 88(IFT88) 




bolA family member 2(BOLA2) 
Q92922 
SWI/SNF related, matrix associated, actin dependent regulator 
of chromatin subfamily c member 1(SMARCC1) 
H0YJH9 poly(A) binding protein nuclear 1(PABPN1) 
H3BPJ9 NADH:ubiquinone oxidoreductase subunit B10(NDUFB10) 
I3L2H7 ubiquitin conjugating enzyme E2 G1(UBE2G1) 
A0A087WS
W9 
thioredoxin reductase 1(TXNRD1) 
Q96GX9 APAF1 interacting protein(APIP) 
Q5T7U1 general transcription factor IIIC subunit 5(GTF3C5) 
P36404 ADP ribosylation factor like GTPase 2(ARL2) 
P13797 plastin 3(PLS3) 
C9JA08 NMD3 ribosome export adaptor(NMD3) 
Q8TDD1 DEAD-box helicase 54(DDX54) 
Q14247 cortactin(CTTN) 
P22059 oxysterol binding protein(OSBP) 





ADP ribosylation factor like GTPase 6 interacting protein 
4(ARL6IP4) 
J3KTF8 Rho GDP dissociation inhibitor alpha(ARHGDIA) 
O95433 activator of Hsp90 ATPase activity 1(AHSA1) 
F6TLX2 glyoxalase domain containing 4(GLOD4) 
 
Table 23. Proteins of the mitochondrial matrix and intermembrane space 
decreased by HEK293 cell treatment with methylglyoxal (cont’d). 
Uniprot 
accession no. 
Name of protein (gene) 
Q3YEC7 RAB, member RAS oncogene family-like 6(RABL6) 
E7EVX8 pre-mRNA processing factor 31(PRPF31) 
Q16762 thiosulfate sulfurtransferase(TST) 
Q16513 protein kinase N2(PKN2) 
P43652 afamin(AFM) 
M0R389 
platelet activating factor acetylhydrolase 1b catalytic 
subunit 3(PAFAH1B3) 
P53004 biliverdin reductase A(BLVRA) 
P31942 heterogeneous nuclear ribonucleoprotein H3(HNRNPH3) 
B2WTI3 arginine demethylase and lysine hydroxylase(JMJD6) 
Q9Y224 chromosome 14 open reading frame 166(C14orf166) 
D6RGE2 isochorismatase domain containing 1(ISOC1) 
Q9Y5X3 sorting nexin 5(SNX5) 
C9JJP5 TRK-fused gene(TFG) 
I3L397 eukaryotic translation initiation factor 5A(EIF5A) 
E7EPN9 proline rich coiled-coil 2C(PRRC2C) 
Q5T4U8 Rab geranylgeranyltransferase beta subunit(RABGGTB) 
F5H5U2 DEAD-box helicase 55(DDX55) 
F5GZQ9 purinergic receptor P2X 4(P2RX4) 
Q9BQC6 mitochondrial ribosomal protein L57(MRPL57) 
H0Y9N5 TROVE domain family member 2(TROVE2) 
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O75794 cell division cycle 123(CDC123) 
A0A087WZX0 B-cell CLL/lymphoma 9-like(BCL9L) 
Q15056 eukaryotic translation initiation factor 4H(EIF4H) 
P18615 negative elongation factor complex member E(NELFE) 
Q06124 
protein tyrosine phosphatase, non-receptor type 
11(PTPN11) 
P49770 
eukaryotic translation initiation factor 2B subunit 
beta(EIF2B2) 
K7EM18 eukaryotic translation initiation factor 1(EIF1) 
A6NIR2 heat shock protein family B (small) member 11(HSPB11) 
O43172 pre-mRNA processing factor 4(PRPF4) 
P78362 SRSF protein kinase 2(SRPK2) 
E9PEB5 far upstream element binding protein 1(FUBP1) 
P48147 prolyl endopeptidase(PREP) 
Q13564 NEDD8 activating enzyme E1 subunit 1(NAE1) 
Q8WUM0 nucleoporin 133(NUP133) 
O75792 ribonuclease H2 subunit A(RNASEH2A) 
J3KPM9 signal transducer and activator of transcription 1(STAT1) 
Q96KP4 
CNDP dipeptidase 2 (metallopeptidase M20 
family)(CNDP2) 
P62993 growth factor receptor bound protein 2(GRB2) 
H7BYN3 transcription factor A, mitochondrial(TFAM) 
P08670 vimentin(VIM) 
 
Table 23. Proteins of the mitochondrial matrix and intermembrane space 
decreased by HEK293 cell treatment with methylglyoxal (cont’d). 
Uniprot accession 
no. 
Name of protein (gene) 
Q9GZL7 WD repeat domain 12(WDR12) 
A0A087X1A5 staufen double-stranded RNA binding protein 1(STAU1) 




acidic nuclear phosphoprotein 32 family member 
B(ANP32B) 
F8VXU5 VPS29, retromer complex component(VPS29) 
I3L2B0 clustered mitochondria homolog(CLUH) 
O75153 clustered mitochondria homolog(CLUH) 
B5MBZ8 protein phosphatase 1 regulatory subunit 7(PPP1R7) 
Q8IXS0 
family with sequence similarity 217 member 
A(FAM217A) 
Q9Y5X1 sorting nexin 9(SNX9) 
D6REK3 
CWC27 spliceosome associated protein 
homolog(CWC27) 
Q9BRS2 RIO kinase 1(RIOK1) 
Q5VZU9 tripeptidyl peptidase 2(TPP2) 







Table 24. Proteins of the mitochondrial membrane of HEK 293 cells increased by treatment with methylglyoxal. 
Gene Protein  
Fold 
change 
Comment on function References 
RPS5 Ribosomal protein S5 9.6 Involved in malignant cell differentiation 
(Vizirianakis 
et al., 1999) 




5.0 Mitochondrial biogenesis and stress response 
(Than et al., 
2011) 
GRIN2D 
Glutamate receptor ionotropic, 
NMDA 2D 
4.4   
RPS23 40S ribosomal protein S23 4.0   
STATH Statherin 3.2   
GRM6 Metabotropic glutamate receptor 6 2.7   
PHB Prohibitin 2.5 
Stabilizes the mitochondrial genome and modulate 
mitochondrial dynamics, morphology, biogenesis, and 
the mitochondrial intrinsic apoptotic pathway 
(Peng et al., 
2015) 














10 12.1 2.3 x 10-5 1.3 x 10-4 
COX5A, UQCR10, CYCS, COX7C, UQCRB, 
NDUFB10, NDUFA5, COX5B, NDUFA4, 
SDHB 
mRNA Splicing - Major 
Pathway 
12 7.0 2.0 x 10-4 1.1 x 10-3 
HNRNPH, RBMX, HNRNPA1, HNRNPC, 
DDX5, SRSF3, ALYREF, SNRPC, HSPA8, 
YBX1, SRSF1, PTBP1 
Gluconeogenesis 6 19.3 2.6 x 10-3 1.5 x 10-2 
SLC25A11, GAPDH, GOT2, MDH2, ENO1, 
ENO2 
Formation of ATP by 
chemiosmotic coupling 
5 28.6 4.8 x 10-3 2.8 x 10-2 
ATP5F1D, ATP5F1B, ATP5H, ATP5PO, 
ATP5F1A 
 











Toll/interleukin-1 receptor domain-containing 
adapter protein 
TIRAP 0.007 
Synaptonemal complex protein 2 SYCP2 0.050 
Dedicator of cytokinesis protein 8 DOCK8 0.055 




Steroidogenic acute regulatory protein, 
mitochondrial 
STAR 0.181 





Polyhomeotic-like protein 3 PHC3 0.237 














Potassium voltage-gated channel subfamily KQT 
member 2 
KCNQ2  
Adenomatous polyposis coli protein APC  
Vacuolar protein sorting-associated protein 72 VPS72   




40S ribosomal protein S15 RPS15  
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RNA-binding protein 42 RBM42  








Eukaryotic translation initiation factor 3 subunit A EIF3A  




Kelch-like protein 40 KLHL40  




Glutamate receptor ionotropic, NMDA 2D GRIN2D 4.4 
Metabotropic glutamate receptor 6 GRM6 2.7 
 














5.1   Methylglyoxal, glyoxalase 1 and cancer – a historical and re-occurring 
association    
MG and Glo1 have long been associated with control of cell growth and 
cancer therapy. They were initially thought to be key controllers of cell growth 
and then discounted with discovered of other more potent and well-evidenced 
growth factors (Apple and Greenberg, 1968). MG was initially proposed as a 
cancer treatment but discounted due to poor efficacy (Conroy, 1979). Recent 
research has seen the emergence of high Glo1 expression as permissive of rapid 
tumour growth – rather than mediator of growth – through metabolism of MG and 
thereby facilitating tumours to develop high glycolytic activity to sustain high 
tumour growth (Rabbani et al., 2018). The latter effect has suggested that MG-
induced cytotoxicity has an unrecognised role in the mechanism of action of 
several clinical anticancer drugs. The association of MG and Glo1 with cancer and 
cancer chemotherapy is historical yet recurring with improved scientific evidence 
and qualified yet critical mechanistic insights in tumour development and 
treatment responses emerging. It is not certain but is becoming increasingly likely 
that treatment of cancer – particularly breast cancer – may be improved with 
better understanding of this system and a Glo1 inhibitor available for clinical 
evaluation. 
 
5.2 Bioinformatics of glyoxalase 1 expression: correlation and survival 
analysis in human tumour cells lines and breast cancer patients, 
respectively 
 
5.2.1 Bioinformatics of glyoxalase 1 expression: correlation analysis in 
human tumour cells lines 
To my knowledge this study is the first to examine and identify the genes 
that correlate with Glo1 mRNA expression in human tumour cell lines. In this 
section, I investigated gene expression correlation with Glo1 expression from data 
available in the cancer cell line encyclopaedia (CCLE). Data analysis was 
performed in on the mRNA copy number from RNA-seq analysis data (Reads Per 
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Kilobase Million or RPKM). Data were normally distributed therefore Pearson 
correlation was used.  
The findings produced new insights into Glo1 and cell growth. Glo1 
expression correlated positively with genes enriched in spliceosome, RNA 
transport cell cycle and DNA replication pathways. Two of the top four genes 
rank-ordered by correlation coefficient, high r value first, were genes of the 
spliceosome - PPIL1 (first) and CDC5L (fourth). To my knowledge, this is the 
first association of the Glo1 to the spliceosome – the high enrichment, 7.5 fold, 
and extremely strong statistical association (Bonferroni-corrected P-value = 7.9 x 
10-11, FDR = 6.9 x 10-10) making it of likely importance and highly unlikely to 
be a chance observation. I suspect this association reflects a high level of 
importance for the spliceosome to be protected against MG modification to work 
effectively. Indeed, the spliceosome function depends on a family of the serine- 
and arginine-rich proteins (SR proteins) which are involved in spliceosome 
assembly and interactions with RNA regulatory sequences on the pre-mRNA and 
with multiple cofactors.(Bourgeois et al., 2004). Genes involved in RNA transport 
were also strongly correlated – partricularly of the nuclear core complex 
(NUP107, NUP153, NUP155, NUP35, NUP37, NUP43, NUP54, SUMO1 and 
SUMO2). This may not be arginine-rich itself but its carrier substrate, α-importin, 
binds carried molecular cargo via arginine-rich nuclear localization sequences 
(McLane and Corbett, 2009, Kosugi et al., 2009).There are also critical functional 
arginine residues in the orgin recognition complex proteins, ORC2, ORC3 and 
ORC4, for initiation of DNA replication (Bleichert et al., 2015) and arginine 
finger sensors of RFC2, RFC3, RFC4, and RFC5 proteins to drive DNA binding 
and proliferating cell nuclear antigen loading for multiprotein ATP-driven DNA 
replicase to duplicate chromosomal DNA prior to cell division (Johnson et al., 
2006). Protection of these proteins from MG modification and inactivation may 
underly the enrichment of genes of cell cycle regulation and DNA replication with 
positive correlates of Glo1 expression in human tumor cell lines. A link between 
Glo1 activity and tumour cell proliferation, cell cycle changes and differentiation 
status system was examined previously by the Thornalley team (Thornalley, 
1990). The study have shown that cells such as Raji(+)  had  increased Glo1 
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activity during growth arrest which is consistent with increased Glo1 activity on  
entry of cells into  G0 –G1 phase of the cells cycle. (Hooper et al., 1988b). There is 
no evidence of Glo1 interacting directly with components of the spliceosome, 
RNA transport cell cycle and DNA replication pathways. The spliceosome is 
involved in pre-RNA processing, mRNA metabolism and splicing. This positive 
correlation with Glo1 suggest a stronger links in between the Glo1 expression and 
the pre-mRNA splicing. In cancer, evidence is accumulating to suggest that 
aberrant splicing events play a role in cancer chemotherapy. Multiple cancer-
related genes have been shown to be associated with this: such as tumour 
suppressor, p53, apoptosis regulator BCL2L1, HRAS, CD44 and others (Wang and 
Lee, 2018, El Marabti and Younis, 2018). 
For the negative correlation, eight genes found to be correlated with Glo1 
expression: 3 pseudogenes, 2 long non-coding RNAs, N-acetylglucosamine-1-
phosphate transferase subunit gamma (GNTPG) – part of aTop of Form complex 
involved in targeting of lysosomal hydrolases to the lysosome, Tapasin binding 
protein like (TAPBPL) – involved in antigen processing in the endoplasmic 
reticulum, and tumor necrosis factor receptor type 1 (TNFR1)-associated death 
domain protein (TRADD). TRADD is an adaptor protein for multiple receptor-
mediated pathways of apoptosis: TNFR1, TNF receptor-associated factor 2 
(TRAF2), recruitment of inhibitor-of-apoptosis proteins and  tumor necrosis factor 
receptor superfamily member 6/FAS cell death receptor (TNFRSF6/FAS) and 
adaptor protein Fas-associated protein with death domain  (FADD/MORT1) 
(Pobezinskaya and Liu, 2012). This negative correlation between Glo1 expression 
and TRADD may indicate that tumour cells with high Glo1 expression have 
decreased propensity to undergo apoptosis.  
For GLO1 gene copy number, normal GLO1 copy number was assumed 
for the range 2.39 - 1.61, mean 2.00, which reflects the precision with which 
GLO1 copy number may be measured (range of mean ± 3SD) (Shafie et al., 
2014). GLO1 copy number correlated positively and strongly with Glo1 
expression: r = 0.53 (P = 9 x 10-68). This suggests that increase of GLO1 copy 
number is a major determinant of increased GLO1 copy number is often, but not 
always, functional and gives rise to proportionate change in Glo1 expression 
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(Redon et al., 2006, Santarius et al., 2010). These findings compare well with 
previous studies showed that GLO1 DNA increased in clinical tumors. Glo1 
expression in tumour cell lines. Increased GLO1 copy number is also highly 
prevalent and correlates with increased Glo1 expression in some clinical tumours 
– reviewed in (Rabbani et al., 2018). 
 
5.2.2 Bioinformatics of glyoxalase 1 expression and survival analysis in 
breast cancer patients 
For the impact of Glo1 expression on cancer patient survival, I performed 
Kaplan-Meier survival analysis using Glo1 expression and cancer patient survival 
data in the KM-Plotter database. Most data available was for breast cancer 
patients – 3951 patients, and hence analysis was performed for this cancer type 
with progression-free survival as the clinical endpoint. The results showed that 
Glo1 is a negative survival impact on breast cancer patients regardless of the 
treatment type, common genotype variants (ER, PR and HER2), intrinsic type and 
stage. The hazard ratio (HR) of 1.37 compares well with outcomes of algorithm-
selected multivariate analysis. For example, in a recent study 88 genes with HRs 
>1.22 were combined in an algorithm but only produced an overall HR of ca. 1.26 
(Zhang et al., 2018). Assessment of Glo1 expression alone is performing better 
than this. Glo1 expression was suggested previously in a small, under-powered 
study of 121 cancer patients (Peng et al., 2017).   
The negative survival impact appears not linked to AGE receptor signaling 
via RAGE as increased AGER expression was a positive survival factor; nor to 
KDM4A – considered a potential mediator of GLO1 copy number 
increase(Rabbani et al., 2018), as increased KDM4A expression was a positive 
survival factor. The effect may be linked to increased expression of Glo1 through 
the functional antioxidant response element by binding of Nrf2 and suppression of 
Glo1 expression by the antagonist of Nrf2, Keap1, as NFE2L2 and KEAP1 had 
HRs of 1.30 and 0.80, respectively (Xue et al., 2012). Nrf2 is thought to be 
hyperactivated by HER2 in breast cancer (Kang et al., 2014). However, the 
negative and positive survival associations with NFE2L2 and KEAP1 found 
herein applied to all cancer genotypes.   
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The HR of GLO1 was particularly high in patients treated with tamoxifen; 
1.74. This impacted markedly on median survival: high Glo1 expression, 75 
months; low Glo1 expression, 138 months. Tamoxifen is an oestrogen receptor 
modulator. It competes with oestrogen for binding to the ligand binding domain of 
ER and is used for treatment of both pre- and postmenopausal patients. 
Tamoxifen-bound ER binds to the same genomic binding sites as oestrogen-bound 
ER but target genes are counter-regulated, with the downstream effect decreased 
tumour cell proliferation or antagonism at ERs (Johnston et al., 2018). Tamoxifen 
was found to increase Glo1 expression in breast cancer cell lines although there is 
no classical oesterogen response element in the GLO1 promoter (Rulli et al., 
2006).This effect and the high HR for Glo1 in Tamoxifen-treated breast cancer 
patients may be explained by activaton of Nrf2 by Tamoxifen and induction of 
Glo1 expression and related increase breast cancer cell prolferatiion. Tamoxifen is 
an activator of Nrf2 and this make explain these effects(Feng et al., 2017). 
 The effect of breast cancer genotypes, lymph node status and intrinsic 
subtype were further investigated with Glo1 expression. GLO1 had a slightly 
higher and significant HR of 1.65 in ER positive breast cancer may be due to 
estrogen signalling activating Nrf2 and increasing Glo1 expression in these 
patients (Wu et al., 2014). The negative survival impact of Glo1 expression was 
found in tumours of intrinsic subtypes luminal A and luminal B which account for 
24% and 39% of breast cancers, respectively. Luminal subtypes usually have a 
good prognosis, with luminal B tumours having worse prognosis than the luminal 
A subtype. Luminal tumours response well to hormone therapy but poorly to 
conventional chemotherapy. Glo1-linked MDR may contribute to this (Györffy et 
al., 2010, Dai et al., 2015). The negative survival impact of high Glo1 expression 
was maintained in lymph node negative breast cancer, suggesting that the impact 
of Glo1 overexpression is experienced at least from primary, pre-metastatic breast 
tumours. The link between GLO1 expression and the molecular subtypes in 
cancer patients needs to be investigated further in order to understand the impact 
of Glo1 in these subtypes in preclinical studies. I was unable to explore the link of 
so-called triple negative breast cancer patient survival to GLO1 copy number as 
there are insufficient data in the public databases for reliable analysis. However, 
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increased GLO1 copy number was found at high prevalence in triple negative 
breast cancer and this may contribute to increased Glo1 expression in this 
genotype of clinical breast cancer and negative survival impact (Santarius et al., 
2010).  
 
5.3 The glyoxalase system and methylglyoxal metabolism in HEK293 cell in 
vitro 
HEK293 cell line is widely used in cancer research studies. Here I have 
characterised the glyoxalase system by measuring the Glo1 and Glo2 activity in 
order to have in depth understanding of activity of the major enzymes that 
metabolised MG. I also measured the flux of formation of D-lactate and the net 
formation of L-lactate. D-Lactate is little metabolised in HEK293 cells and the 
glyoxalase pathway accounts for >99% of MG metabolism (Abbas, H. and 
Thornalley, P.J., unpublished observation) and so the flux of D-lactate is 
approximately equivalent to the flux of formation of MG. The net formation of L-
lactate is a measure of glycolytic activity of HEK293 cells. Both of these 
estimates were relatively high compared to corresponding fluxes found in cultures 
of corresponding non-malignant cells – renal proximal tubular epithelial cells (Al-
Gambdi, O. and Thornalley, P.J., unpublished observations). 
I found exogenous MG induced growth arrest and toxicity of HEK293 
cells in vitro. The GC50 of MG was 131 µM. The normal cellular concentration of 
in HEK293 cells was 4.3 ± 2.6 pmol per 106 cells, equivalent to a cellular 
concentration of ca. 2 µM (Abbas, H. and Thornalley, P.J., unpublished 
observations). Therefore, with an active glyoxalase system, a high concentration 
of exogenous MG is required to induce cytotoxicity. From mathematical 
modelling studies of MG metabolism and the effect of a cell permeable Glo1 
inhibitor, it was estimated that a cellular concentration of MG of ca. 12 fold 
higher that in control, or ca. 24 µM, for 24 h is required to induce effective 
cytotoxicity. Without the Glo1 inhibitor, a higher concentration of exogenous MG 
is required as most of the dose is metabolised to D-lactate. 
Cytotoxicity of MG develops in human tumour cells treated with MG after 
24 h and under concentration limiting conditions – such as at the GC50 
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concentration, cells die by apoptosis. From previous studies, we know that under 
limiting concentration condition such as GC50 of MG may induce growth arrest 
and cell growth which leads to cell death via apoptosis (Kang et al., 1996, 
Thornalley et al., 1996, Santarius et al., 2010) and under high concentration of 
MG cause cell death via necrosis  (Du et al., 2000). Commitment to apoptosis 
occurs earlier. Previous studies in the human leukaemia 60 (HL60) cell line 
showed that commitment to cell death begins after 6 h, and is maximised after 24 
h (Ayoub et al., 1993). It is likely, therefore, that if we wish to identify processes 
leading to commitment to apoptosis we need to analyse cells after ca. 6 – 12 h 
exposure. In HEK293 cells I found that the maximum decrease in viable cell 
number was produced by exposure to 131 µM MG for 12 h and ca. 50% of the 
effect was achieved at 6 h exposure. I reasoned that the effects of MG were 
produced by modification of cell protein and I measured the time course of 
increase of the steady-state concentration of MG-derived adducts, MG-H1, in 
HEK293 cells protein extracts. This maximised at 6 h and so this was the chosen 
time point for analysis of fractional cell proteomes to assess changes in protein 
abundances and MG modification with MG treatment. 
Several studies have shown that MG incude cell death via apoptosis. It is 
thought that MG intiates the mitochondrial apoptotic pathway by the modification 
of mitochondrial permeability transition pore. High levels of MG-H1 formation 
may lead to depolarisation of membrane, release of the cytochrome c and 
activation of caspase-3 and caspase-9 (Czabotar et al., 2014). Alternative way of 
MG activating apoptosis is by the activation of ChK1, Chk2 and ATM kinases. 
This activation due to response to DNA damage caused by MG modification 
(Rabbani et al., 2018). MGdG is one of the major adducts are known to convert 
DNA to single strands break (ssDNA). In cases where DNA damage is too high 
for repair, DNA undergoes stall replication which may results in activation of 
apoptosis or necrosis (Dobbelstein and Sørensen, 2015). 
Herein I measured the release of cytochrome c from mitochondria into the 
cytosol by ELISA and I could confirm that cytochrome c was released by 
treatment of cells with 131M MG at both 3 - 6 h. This suggests that HEK293 
cells commit to cell death via the mitochondrial apoptotic pathway at these time 
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points. In 1.5 h of treatment there was no change in the cytochrome c level when 
treating with MG; nevertheless, by this time protein adducts of MG-H1 had 
increased. It is likely that protein modification by MG preceding activation of 
apoptosis leads to the commitment to cell death.  
 
5.4 Analysis of fractional proteomes of HEK293 cell line incubated with 
and without MG  
I adapted pre-analytic processing methods for proteomics to avoid sample 
heating and high pH to avoid loss of MG-H1 adducts and migration between 
protein sites. Protocols had been optimised in a previous study by the host team 
applied to endothelial cells (Irshad et al., 2019).In this study, I have investigated 
MG-induced abundance changes and protein modification in HEK293 cells with 
131 M MG after treatment for 6 h. This was done to investigate the proteomic 
changes at the time when cells are undergoing MG-induced commitment to 
apoptosis. As far as I am aware, this is the first study to show the modification of 
MG at the subcellular level in cytoplasm, nuclear and mitochondrial membrane 
and matrix in HEK293 cell line in vitro. Moreover, there have been no studies 
prior to this one attempting to measure protein abundances and MG-modified 
proteins in fractional proteomes at the period when cells undergoing MG-induced 
commitment to apoptosis. 
 
5.4.1 Proteomic changes during methylglyoxal-induced commitment to 
apoptosis in HEK293 cells in vitro. 
I detected 4391 proteins in the cytoplasmic extract. Since the extract was 
prepared by sonicating cells, it is expected to contain soluble protein from both 
cytosol and organelles. The highest increase abundance change induced by MG 
was a 30-fold, increase of calcium activated cation channel CSC1-like protein 2 
(TMEM63B). Overexpression of TMEM63B promotes migration in HEK293T 
cells (Marques et al., 2019). There was also increase in abundance of the MG 
metabolizing enzyme aldo-keto reductase 1B1 (aldose reductase), which may be a 
stress responsive induction to support metabolism of MG along with that 
occurring by the glyoxalase system. The major effect was decrease of protein 
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abundances ranging from 7 – 95%. Proteins with decreased abundances were 
enriched or overrepresented in the ribosome, spliceosome, RNA transport and 
proteasome metabolic pathways. There are two main causes of cellular decreased 
protein in apoptosis: proteasome degradation and proteolysis by caspases and 
other proteases. As subunits of the proteasome were decreased (mean ± SD 
fraction: 0.70 ± 0.06), the likely mechanism driving the decrease of these proteins 
is proteolysis other than by the proteasome. In apoptosis this is mediated by 
caspases and other proteases (Julien et al., 2017). An example is decrease of 
spliceosome subunit SF3B1 (Wiita et al., 2013). This may also account for 
decrease of proteasome subunits at least 20 proteasome subunits are cleaved by 
the caspases during apoptosis (Gray et al., 2010). Some of the proteins decreased 
were also detected with MG-H1 modification: for example, heterogeneous nuclear 
ribonucleoproteins K (HNRNPK) and M (HNRNPM). In such cases, increased 
MG modification may drive the degradation through increased targeting for 
proteolysis. Decrease of the spliceosome was confirmed by selective study of the 
nuclear proteome where components of the found in pathways enrichment had a 
mean decrease in abundance of 48% - similar to the decrease in viable cell 
number of 50% with 131 µM used. Interestingly, components of the nuclear 
spliceosome are imported into mitochondria for splicing of mitochondria RNA, 
mtRNA (Herai et al., 2017). During MG-induced commitment to apoptosis I 
detected decrease in components of both the nuclear and mitochondrial splice 
machinery. Decreases common to both were decreased of RBMX, DDX5, SRSF1 
and PTBP1. This suggest that impaired splicing of RNA is a target for MG-
induced commitment to apoptosis in both nuclear and mitochondrial 
compartments. 
 A further profound effect of MG-induced commitment to apoptosis was 
the decrease of key proteins of energy production in cells: respiratory electron 
transport and formation of ATP by chemiosmotic coupling. The mean decreases 
in abundance of these components was: respiratory electron transport, 82 ± 8%; 
and formation of ATP by chemiosmotic coupling, 76 ± 12%. Clearly, during the 
commitment to apoptosis induced by MG, HEK293 cells are being starved of 
ATP. Collapse of oxidative phosphorylation as well as release of ATP has been 
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observed previously in apoptosis (Ricci et al., 2004)) but this is first time it has 
been implicated in MG-induced commitment to apoptosis. The depletion of ATP 
in MG-induced apoptosis of human tumour cells in vitro has been reported 
previously (He et al., 2016). 
 
5.4.2 Potential impact of the significance proteins modified by 
methylglyoxal in cancer chemotherapy MDR 
In order to validate the finding from the proteomics works. Western blot 
were in DEAD (Asp-Glu-Ala-Asp) box polypeptide 5 DDX5, AKR1B1 and Glo1. 
Cells were incubated with the same GC50 and time point which is 6 hours. DDX5 
has vital role in cell growth and in cancer several studies have shown its link in 
different multiple dysregulation of cellular process (Hashemi et al., 2019). 
Komori showed that Silencing DDX5 inhibit proliferation of four different breast 
cancer cell line (Komori, 2010). From the western blot data, we found that in MG 
treated cells there is a significant increase in DDX5 expression in comparison 
with control. This is suggesting that MG may play roles in DDX5 expression and 
further validation needed to be confirmed.  
Measurement of the Glo1 protein were significantly increased in MG treated 
cells this is expected to be seen as Glo1 metabolising MG therefore there is high 
expression of protein in MG treated cell. There is no significant found when 
looking at the AKR1B1 protein by Western blotting. Experimental errors on 
Western blotting estimates were large, however, and further optimisation of 
procedures may produce data that corroborate the proteomics analysis.   
5.5 The effect of methylglyoxal in free extrachromosomal DNA release in 
HEK293 
In order to investigate the DNA damage caused by MG, Cells were 
incubated with MG at the same GC50 and the time point. This was done to see the 
effect of MG on the extrachromosomal DNA secretion caused by MG. From the 
data obtained, there is a remarkable increase in ssDNA released by MG. this is 
agrees with the notion that MG caused DNA damage within 2 hours of exposure 
(Dobbelstein and Sørensen, 2015). There is a persistence in increase of DNA in 
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MG treated cell in comparison to control. The staining of picogreen showed the 
level of DNA secreted by MG. 
5.6 Emergence of the spliceosome as a target of impairment in MG-induced 
commitment to apoptosis 
The emergence of the spliceosome as a target of impairment in MG-
induced commitment to apoptosis is, perhaps, one of the most interesting findings 
of my work. If important in MG-induced cytotoxicity clinically, we might expect 
the spliceosome to be impaired by anticancer drugs that increase cellular MG and 
are susceptible to Glo1-linked MDR – such as doxorubicin and mitomycin C 
(Abbas, H. and Thornalley, P.J., unpublished observations). These drugs do 
induce changes in the spliceosome, leading to alternative splicing that contributes 
to cytotoxicity (Dutertre et al., 2011). It might also be expected that there is 
impairment of the spliceosome in other clinical conditions where MG 
concentration is increased and linked to pathobiological processes: such as the 
chronic vascular complications of diabetes – for example, peripheral diabetic 
neuropathy (Bierhaus et al., 2012). Evdience from the literaure suggests that there 
is impairment of the spliceosome in peripheral diabaetic neuropathy (Kobayashi et 
al., 2017). So this research may open a new aspect of the mechanism of MG-
linked pathogenesis and cytotoxicity with applications for cancer survival and 




6 Conclusion and future works 
6.1 Conclusion  
The main aim of this project is to characterise the dicarbonyl proteome 
involved in MG induced cytotoxicity and its role in cancer chemotherapy. In order 
to achieve this aim, I have studied the bioinformatics cancer cell line and the 
survival analysis of mRNA Glo1 to investigate the role of Glo1 expression in 
linked in Cancer MDR. The results shown that Glo1 mRNA correlated positively 
with one of the causes of its expression GLO1 CNV. Nevertheless, we have 
shown that Glo1 correlated with several genes positively and negatively. These 
genes showed an interesting pathway enrichment outcome such as spliceosome, 
RNA transport, and cell cycle and DNA replication positively.  
In this project, I investigated methylglyoxal of protein involved in 
methylglyoxal induced cell death. This was performed by studying the modified 
protein in HEK293 in vitro. I have characterised the glyoxalase system by 
measuring the Glo1 and Glo2 activity. Nevertheless, I measured the D-lactate and 
L-lactate in HEK293 cells in order to have in depth understanding of how MG are 
metabolised and secreted in this cell line.  Time course study were also performed 
to confirm the time point needed for MG to initiate cell death in HEK293 cell line. 
Measurement of the cytosolic cytochrome c were performed in order to confirm 
the cell death pathway caused by MG which was agreed with previous study via 
apoptosis. Moreover, we have quantify the major protein adducts caused by MG 
which is MG-H1 by LC-MS/MS at different time point to gain more 
understanding of the modification caused by MG. The level MG-H1 were found 
to be maximum at 6 hr points in comparison to other time points.  
Proteomics analysis were performed on four subcellular fraction to see the 
protein abundance change caused by MG and the protein modification by MG-H1. 
The data have shown for the first time the role of MG in the spliceosome 
assembly which may linked to anti-cancer drug resistance. The data for the 
proteomics also showed several pathway analysis which also agrees with the 
findings from the bioinformatics such as the mRNA major pathway and other cell 
cycle related pathway.  
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Finally, we have shown the MG ability to induce cell death via the 
secretion of extrachromosomal DNA released from the nucleus when treated with 
MG. This is confirming the previous finding that showed MG induce DNA 
damage leading to cell death via apoptosis. 
 
6.2 Future works 
In this project, I have analysed the role MG in modification and change of 
abundance in subcellular protein. I also have investigated the role of GLO1 on the 
database of cancer cell line and the impact of GLO1 in the survival analysis in 
cancer patient. Several pathway analysis enrichments were performed to 
investigate the role Glo1 expression and its metabolites MG in inducing cell 
death. However, I did not test the role of Glo1 inhibitor in modifying protein by 
inducing endogenous level of MG. it would highly interesting to see the role of 
endogenous MG to see the modified protein which may linked to Glo1 MDR 
chemotherapy resistance.  
Nevertheless, the study was performed in cell line and it would be highly 
valuable to examine the role of inducing the concentration of MG in primary 
tumour cells to see the modification of MG occurs. Nevertheless, Other MG 
adducts should be tested to see what further information could be extracted.  
Along with this bioinformatics finding about the increased GLO1 copy 
number changes which results in overexpression of Glo1 it is highly important to 
measure the GLO1 copy number in primary tumour to see changes may linked 
Glo1 expression MDR linked. from the data obtained in the impact of negative 
survival the role of Glo1 in endocrine therapy could be further investigated in 
animal model which may give more understanding of how GLO1 expression have 
an impact negatively on those patients. 
 
All the data generated from this work will be soon published in scinftific journal 
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Appendix I   
Gene expression correlating positively with glyoxalase 1 expression in 







PPIL1 0.567545 0.322108 
RPL7L1 0.566208 0.320592 
PRIM2 0.530774 0.281722 
CDC5L 0.516734 0.267014 
CCT4 0.506131 0.256169 
CENPQ 0.489336 0.239449 
SF3B14 0.481207 0.231561 
SNRPC 0.479415 0.229838 
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AC107081.5 0.458086 0.209842 
GPN3 0.453936 0.206058 
TAF11 0.448653 0.20129 
TTK 0.446596 0.199448 
RPS10 0.445359 0.198344 
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LSM2 0.438242 0.192056 
CDK1 0.435797 0.189919 
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MAD2L1 0.41329 0.170808 
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NUDCD1 0.396837 0.157479 
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SNRPE 0.357179 0.127577 
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OSGEPL1 0.346479 0.120048 
HSF2 0.346333 0.119946 
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CSNK2B 0.34586 0.119619 
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ILF2 0.339443 0.115222 
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RP5.1113E3.3 0.33791 0.114183 
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NUP107 0.336948 0.113534 
MCM3 0.336814 0.113444 
KIF15 0.336698 0.113366 
MRPL50 0.336627 0.113317 
RP11.474G23.2 0.336619 0.113312 
RACGAP1 0.336324 0.113114 
CCT3 0.336195 0.113027 
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ATAD2 0.335757 0.112733 
ORC4 0.33572 0.112708 
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LTV1 0.335367 0.112471 
TIMM8A 0.33533 0.112446 
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ARMC1 0.334051 0.11159 
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DONSON 0.333517 0.111234 
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DSN1 0.331952 0.110192 
POLA1 0.330856 0.109465 
DENR 0.330834 0.109451 
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EIF1AX 0.330395 0.109161 
SKA3 0.330375 0.109148 
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AASDHPPT 0.328814 0.108119 
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MCMBP 0.328214 0.107725 
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HNRNPA1 0.327186 0.10705 
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WDR75 0.324704 0.105433 
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MRPL39 0.322906 0.104268 
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MRPL3 0.322283 0.103866 
FAM104B 0.321855 0.10359 
TUBB 0.321777 0.10354 
210 
 
CDKN2AIPNL 0.321331 0.103253 
BAG4 0.321218 0.103181 
CCNE2 0.321139 0.10313 
SPAG5 0.321076 0.10309 
ERAL1 0.320695 0.102845 
CMSS1 0.320565 0.102762 
TOMM22 0.320428 0.102674 
NUFIP1 0.320371 0.102638 
NEK2 0.320296 0.10259 
RP11.144G7.2 0.319764 0.102249 
NDC80 0.31949 0.102074 
NDUFB4 0.319311 0.10196 
EIF2S1 0.319205 0.101892 
SKP1 0.319171 0.10187 
MAGOH 0.318761 0.101609 
PSMA4 0.3186 0.101506 
WDR46 0.31839 0.101372 
TIMM23 0.3182 0.101251 
RRM2 0.318015 0.101133 
DESI2 0.317959 0.101098 
MRPS23 0.317947 0.101091 
FARSB 0.317613 0.100878 
EXO1 0.317582 0.100858 
MRPS15 0.317457 0.100779 
MRPL51 0.317446 0.100772 
HAUS1 0.316431 0.100129 
PRPF4 0.3163 0.100046 







Appendix II  
Gene correlates negatively with Glo1mRNA  






RASA4CP 0.31905 0.101791 
KB.1027C11.4 0.32147 0.103342 
CTB.134H23.2 0.33338 0.111141 
TAPBPL 0.33516 0.11233 
GNPTG 0.33612 0.11298 
RP11.109L13.1 0.34757 0.120805 
RP11.490O6.2 0.35131 0.12342 


































Q9UKX7 2 2 88.49 0.042942 0.074824 0.572963 
H3BNC9 3 0 110.49 0.049847 0.080881 0.537236 
P10827 1 1 20.94 0.000449 0.01194 0.999871 
A0A0G2JQ76 1 1 20.29 0.020731 0.051151 0.737904 
H3BNT2 2 2 110.11 0.003257 0.023854 0.972966 
H7C3A6 1 1 18.47 0.015038 0.043801 0.800756 
H0YGR4 2 2 31.81 0.007458 0.032224 0.90642 
A0A087X2I7 1 1 14.22 0.01482 0.043603 0.803415 
H0YB67 1 1 18.67 0.033032 0.064512 0.634855 
K7EM19 1 1 58.54 0.032581 0.064279 0.638038 
H7C202 1 1 21.16 0.032736 0.064391 0.63694 
Q03181 1 1 29.64 0.009896 0.036482 0.869417 
P33552 2 2 151.7 0.034489 0.06598 0.624799 
Q9BYD6 2 1 73.21 0.005625 0.028058 0.935688 
Q3ZCX4 1 1 17.83 0.045807 0.077692 0.557516 
P51587 1 1 15.44 0.043005 0.074878 0.572612 
Q6ZR64 1 1 71.27 0.004716 0.026727 0.950336 
H7BZL2 3 3 252.3 0.002133 0.020448 0.988079 
A0A0A0MSD7 1 0 20.6 0.002372 0.021693 0.985165 
F8W9Q7 1 0 17.09 0.002372 0.021693 0.985165 
H0Y903 1 1 59.53 0.005179 0.02729 0.942886 
H3BPB0 1 0 13.99 0.021678 0.051735 0.728558 
D6RFM5 10 5 679.59 0.002892 0.02346 0.978225 
A0A0B4J1Y4 1 1 69.13 0.039098 0.07078 0.595278 
213 
 
Q6KC79 1 1 14.5 0.041195 0.073184 0.582867 
E7EQL8 1 1 20.04 0.046891 0.078534 0.551905 
F5GYA2 1 1 19.91 0.04821 0.079762 0.545251 
P53420 1 1 14.14 0.033393 0.065056 0.632329 
A0A087WZY0 1 1 22.5 0.004606 0.026569 0.952091 
H0Y390 1 1 19.64 0.002431 0.021894 0.984414 
P29373 1 1 115.48 0.005095 0.027257 0.944242 
P43897 2 2 123.56 0.004311 0.026216 0.956773 
Q5T1U7 2 2 38.35 0.043271 0.075286 0.571141 
P51608 1 1 52.04 0.008628 0.034953 0.888322 
H3BQA6 2 2 93.36 0.022441 0.052734 0.721225 
A0A087WT80 1 1 20.02 0.039578 0.071236 0.592382 
P05543 1 1 25.09 0.030669 0.061737 0.65198 
A0A087WWL5 1 1 22.24 0.023135 0.053354 0.714712 
A0A1C7CYZ2 1 0 13.98 0.018018 0.047442 0.766341 
Q9H0W5 1 0 20.92 0.018018 0.047442 0.766341 
Q96ST2 2 2 54.61 0.005316 0.027446 0.940685 
P02549 1 1 18.75 0.045543 0.077412 0.5589 
J3KNP4 1 1 18.98 0.027759 0.05806 0.674619 
A0A024R214 2 0 35.35 0.046281 0.078069 0.555046 
A6PWM2 1 1 49.14 0.026027 0.055872 0.689007 
A0A1B0GUS7 2 1 43.76 0.047508 0.079043 0.548773 
K7ENL0 1 1 21.44 0.024939 0.054886 0.698414 
P01023 2 2 145.01 0.02629 0.056379 0.68677 
A0A087WWW8 1 1 18.6 0.039259 0.070879 0.594304 
Q969S3 1 1 76.4 0.037146 0.068681 0.607382 
H0YHS6 2 2 122.96 0.032981 0.064466 0.635213 
Q96N66 1 1 43.03 0.02261 0.052867 0.719627 
H0Y9N9 1 1 46.47 0.014819 0.043603 0.803428 
E9PJ65 1 0 17.47 0.035051 0.066262 0.621018 
Q5T2E8 1 0 15.18 0.035051 0.066262 0.621018 
E9PJF9 2 0 95.97 0.040852 0.072768 0.584857 
214 
 
A0A087WUT0 1 1 14.82 0.046602 0.078198 0.553389 
Q86T26 1 1 16.89 0.008656 0.034953 0.887895 
Q14676 6 6 410.48 0.043405 0.075407 0.570402 
H0YEZ9 1 1 49.13 0.006401 0.029496 0.923196 
A0A0G2JQF3 1 0 19.04 0.023875 0.054112 0.707921 
Q7Z698 1 1 17.45 0.025601 0.055616 0.692653 
P41223 2 1 103.84 0.027084 0.057065 0.680141 
A0A087WX24 1 0 17.42 0.024274 0.054385 0.704322 
Q9BV73 1 0 17.15 0.005091 0.027257 0.944313 
Q9C0J8 1 0 17.24 0.005091 0.027257 0.944313 
Q99832 25 23 1731.02 0.027081 0.057065 0.680167 
P08579 4 3 375.24 0.03413 0.065691 0.627245 
A0A087WWT1 3 2 123.69 0.032948 0.064456 0.635442 
Q9P1A2 1 1 22.59 0.044403 0.076465 0.564968 
A0A087WZL3 1 1 18.94 0.02153 0.051735 0.730001 
A0A0G2JS85 1 1 17.17 0.00481 0.026891 0.948823 
Q9GZN8 3 3 216.45 0.020006 0.050626 0.745248 
A8MUM1 1 1 31.52 0.013269 0.041518 0.822975 
V9GYA7 3 3 213.94 0.011926 0.039829 0.840797 
H0YL19 5 3 285.05 0.011621 0.039394 0.844968 
H7C440 1 1 15.75 0.042217 0.073997 0.577028 
J3QRD1 1 1 71.82 0.001899 0.018919 0.990729 
P14921 1 1 18.61 0.042732 0.074622 0.574135 
A0A0J9YYF7 1 1 26.17 0.023399 0.053497 0.712269 
A0A087WYK2 1 1 15.43 0.044876 0.076943 0.562432 
H3BPN4 1 0 16.74 0.034615 0.06598 0.623947 
Q9NZ56 1 0 14.51 0.034615 0.06598 0.623947 
P00390 8 5 521.58 0.044387 0.076465 0.565055 
Q08E93 1 1 16.97 0.006811 0.030378 0.916642 
P82933 2 2 104.75 0.040081 0.07191 0.589385 
A0A0A0MQX8 1 0 15.41 0.030546 0.061595 0.6529 
P02545 13 0 605.77 0.002746 0.022994 0.980237 
215 
 
Q9Y2W2 3 3 153.86 0.038464 0.070238 0.599145 
Q86US8 2 2 60.97 0.041638 0.073489 0.580316 
Q01469 6 3 340.21 0.049771 0.080869 0.537603 
Q96PK6 6 6 391.38 0.013045 0.041268 0.825881 
A0A075B7F8 2 2 43.43 0.026446 0.056465 0.685455 
H7C537 3 2 150.99 0.036856 0.068359 0.609231 
P15121 12 4 840.49 0.006556 0.029869 0.920724 
P62995 6 3 339.66 0.0347 0.066021 0.623378 
E9PNB5 8 1 405.61 0.005701 0.028198 0.934463 
 
















A0A0C4DG26 1 1 14.31 0.027587 0.875668 0.718782 
P02775 1 1 19.41 0.000196 0.409851 1 
P01859 2 2 79.03 0.002727 0.42943 0.997125 
P20366 3 1 72.54 0.001578 0.409851 0.999706 
Q5T7N2 1 1 17.22 0.023 0.832407 0.764368 
A0A0A0MR66 1 1 22.56 0.009714 0.681657 0.926565 
P01042 11 10 576.13 0.000841 0.409851 0.999992 
A0A0B4J2A4 5 5 127.76 0.00571 0.560698 0.975023 
Q9BS19 2 2 50.5 0.008549 0.681657 0.94164 
P04196 1 1 55.9 0.005851 0.560698 0.973554 
P02776 1 1 26.33 0.047751 0.990711 0.56968 
F8W696 6 6 270.14 0.001382 0.409851 0.999848 
P01860 4 1 110.34 0.046522 0.986356 0.576933 
P01023 6 5 197.8 0.01596 0.771084 0.845413 
Q96M27 1 1 44.23 0.029133 0.876819 0.704601 
Q13541 1 1 32.69 0.046278 0.986356 0.578398 
216 
 
P19878 1 0 29.07 0.022408 0.832407 0.770655 
Q8TBY9 1 0 30.75 0.005118 0.560698 0.980859 
Q9BT09 1 1 42.93 0.03377 0.884555 0.66522 
X6R700 1 1 17.68 0.011656 0.681657 0.90096 
E9PDQ8 2 2 68.67 0.01839 0.783856 0.815899 
O14828 1 1 52.16 0.005617 0.560698 0.975967 
Q5M9N0 1 1 23.33 0.02849 0.876819 0.710428 
P30084 6 6 337.3 0.011195 0.681657 0.907049 
O14745 2 2 65.39 0.006103 0.560698 0.970865 
Q6S8J3 8 1 933.15 0.002964 0.435709 0.996153 
Q9UMX5 2 2 65.68 0.031468 0.884555 0.684195 
P60709 25 6 1970.86 0.017487 0.783856 0.826683 
Q562R1 11 0 648.57 0.031221 0.884555 0.686294 
P14735 1 0 33.56 0.04945 0.990711 0.559949 
P52907 3 3 145.93 0.031976 0.884555 0.679919 
P680325 16 2 1077.46 0.013613 0.733919 0.875298 
B4DSN5 1 0 20.24 0.010977 0.681657 0.909941 
A8K7Q2 16 1 967.97 0.045152 0.986356 0.585248 
C9JIZ6 3 3 161.02 0.011252 0.681657 0.906299 
O43923 1 1 17.68 0.023468 0.83462 0.759472 
C9J8T6 1 1 76.51 0.04159 0.963765 0.608071 
P10253 3 3 172.06 0.011708 0.681657 0.900277 
 

































































































































































































































































































































































Proteins of the mitochondrial matrix and intermembrane space increased by 















A0A024R3B9 1 1 45.77 0.014208 0.534926 0.867613 
Q15554 1 0 15.16 0.021296 0.534926 0.782729 
A8MYB8 2 1 75.11 0.040235 0.534926 0.617241 
P13647 5 1 193.05 0.017519 0.534926 0.826295 
A0A1B0GVP8 1 1 14.26 0.030219 0.534926 0.694959 
Q14151 5 1 260.52 0.027561 0.534926 0.719028 
H0YBL3 1 1 22.05 0.047876 0.534926 0.568951 
Q9NWZ3 1 1 24.12 0.001036 0.219198 0.99997 
Q9NZT1 3 3 187.05 0.033451 0.534926 0.667784 
P31944 1 1 53.7 0.046429 0.534926 0.577492 
220 
 
G3V1V0 12 12 591.82 0.046139 0.534926 0.579235 
P46778 14 14 645.28 0.038272 0.534926 0.631044 
G5E9G0 28 1 1846.28 0.044079 0.534926 0.591934 
H3BMM9 3 3 92.96 0.026893 0.534926 0.72534 
P39023 34 7 2199.3 0.046159 0.534926 0.579115 
P00441 4 4 303.09 0.004101 0.286345 0.989408 
 
Proteins of the mitochondrial matrix and intermembrane space decreased by 
















Q99733 6 4 412.84 0.048063 0.534926 0.567868 
Q06124 5 5 268.71 0.0475 0.534926 0.571146 
F8VQZ7 5 5 271.96 0.044498 0.534926 0.589306 
P43487 6 6 305.33 0.039535 0.534926 0.622089 
A0A087WY61 23 0 1139.19 0.046536 0.534926 0.576852 
H0YIV4 11 1 659.78 0.001329 0.219198 0.999876 
Q92688 10 5 586 0.032059 0.534926 0.679222 
F8VV59 12 2 692.61 0.002455 0.286345 0.998046 
Q14980 23 0 1130.12 0.025733 0.534926 0.736559 
Q9GZL7 4 4 210.8 0.032495 0.534926 0.675599 
Q13257 3 3 112.59 0.019125 0.534926 0.80728 
A0A087WTB8 4 4 176.81 0.033558 0.534926 0.666919 
Q6Y7W6 7 7 362.26 0.003798 0.286345 0.991528 
M0R0Y2 3 3 110.61 0.032731 0.534926 0.673654 
I3L397 6 6 585.41 0.027384 0.534926 0.720692 
P50990 19 19 981.06 0.044299 0.534926 0.590555 
O75792 1 1 36.31 0.042804 0.534926 0.600089 
G3V1C3 6 6 358.31 0.034647 0.534926 0.658267 
Q13564 9 9 423.51 0.045065 0.534926 0.585785 
221 
 
P18615 6 6 292.56 0.03632 0.534926 0.645412 
Q9UJA5 3 3 260.16 0.048015 0.534926 0.568143 
P13797 18 18 802.69 0.042826 0.534926 0.599949 
M0R389 5 5 262.71 0.011189 0.534189 0.907129 
C9JA08 4 4 189.02 0.025224 0.534926 0.741595 
P22059 3 3 82.5 0.021998 0.534926 0.775073 
P24666 2 2 109.09 0.045547 0.534926 0.582824 
J3KTF8 5 5 187.34 0.018952 0.534926 0.809291 
P17480 12 12 518.42 0.014855 0.534926 0.859338 
P49770 5 5 273.66 0.018462 0.534926 0.815038 
P78362 5 2 185.3 0.047497 0.534926 0.571159 
A0A087WTP3 7 7 295.78 0.029125 0.534926 0.704666 
B2WTI3 2 2 131.16 0.045533 0.534926 0.582912 
P02647 21 19 1340.62 0.012107 0.534926 0.895007 
Q92922 7 7 257.55 0.026187 0.534926 0.732134 
Q9Y224 7 7 388.53 0.017384 0.534926 0.827926 
Q5VYK3 13 13 576.35 0.043381 0.534926 0.596371 
A0A0A0MTN3 5 4 200.64 0.01639 0.534926 0.840074 
H0Y9N5 1 1 28.67 0.024053 0.534926 0.753428 
I3L2B0 13 1 592.33 0.033703 0.534926 0.665757 
G3V2E7 7 6 362.46 0.049555 0.546813 0.559359 
Q96CT7 9 8 578.41 0.043907 0.534926 0.593022 
Q86WV7 4 3 209.07 0.006893 0.403383 0.96196 
P08670; 31 28 1670.35 0.003964 0.286345 0.990398 
O14776;G3V220 5 5 235.93 0.037546 0.534926 0.636311 
A0A087WY55 4 4 167.8 0.043234 0.534926 0.597313 
Q96GX9 2 2 93.14 0.020118 0.534926 0.795881 
Q8WU90 6 6 289.31 0.041648 0.534926 0.607682 
Q99543;C9IZ83 11 11 588.25 0.009312 0.485137 0.931807 
J3KPM9 3 3 148.47 0.018246 0.534926 0.817603 
E7EVX8; 4 4 210.73 0.04496 0.534926 0.586436 
O75153 14 1 637.43 0.045126 0.534926 0.585409 
F5GZY1 2 2 100.36 0.021924 0.534926 0.77587 
Q96KP4 3 2 118.69 0.022946 0.534926 0.764943 
Q6P2E9 2 2 62.16 0.037817 0.534926 0.634329 
222 
 
Q15527 1 1 42.19 0.038537 0.534926 0.629141 
Q9Y5X3 6 6 213.26 0.013097 0.534926 0.882024 
F5H6C2 1 1 15.28 0.004262 0.286345 0.988201 
C9JJP5 2 2 82.93 0.046455 0.534926 0.577335 
F6TLX2 4 4 168.89 0.014995 0.534926 0.857556 
Q96GX2 1 1 20.62 0.039038 0.534926 0.625579 
A0A087X060 1 1 16.83 0.027509 0.534926 0.719515 
Q16513 4 4 95.49 0.004224 0.286345 0.988489 
Q14247 8 8 333.19 0.000741 0.219198 0.999997 
O00178 7 7 424.16 0.032239 0.534926 0.677721 
P0DN79 5 5 368.07 0.000806 0.219198 0.999994 
Q5T4U8 1 1 34.28 0.011124 0.534189 0.907994 
I3L2H7 1 1 69.84 0.006178 0.386467 0.970049 
Q16762 3 3 155.3 0.027684 0.534926 0.717878 
Q9BV57; 5 5 289.76 0.043424 0.534926 0.596096 
Q8WUM0 2 2 56.83 0.045267 0.534926 0.584543 
E7ER27 2 2 101.28 0.011639 0.534926 0.901182 
F5H5U2 2 1 53.43 0.024065 0.534926 0.753305 
A6NIR2 1 1 32.56 0.001646 0.229715 0.99964 
Q14691 4 4 204.57 0.003288 0.286345 0.994577 
Q9BRS2 3 3 112.52 0.032826 0.534926 0.672875 
P15924 2 2 48.38 0.045152 0.534926 0.585249 
P48147 3 3 147.44 0.035 0.534926 0.655508 
A0A0C4DG62 1 1 49.25 0.028576 0.534926 0.709646 
B4E1Z4 3 3 88.17 0.002541 0.286345 0.997775 




























M0R0F0 2 2 191.72 0.08375 0.990182 0.43408 
H0YIQ2 1 1 15.81 0.023877 0.828711 0.813109 
H0YK64 1 1 16.46 0.033551 0.828711 0.717568 
O15399 1 1 19.79 0.102047 0.990182 0.378051 
D6RD47 1 1 58.93 0.153646 0.990182 0.275228 
P02808 1 1 97.78 0.133391 0.990182 0.308579 
O15303 1 1 21.59 0.017938 0.828711 0.879573 
C9JW96 9 9 790.31 0.148825 0.990182 0.282543 
Q6NVU6 1 1 16.74 0.087667 0.990182 0.420794 
